U.S. patent application number 14/615383 was filed with the patent office on 2015-08-20 for hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents.
The applicant listed for this patent is Intezyne Technologies, Inc.. Invention is credited to Kurt Breitenkamp, Kevin N. Sill, Habib Skaff.
Application Number | 20150232616 14/615383 |
Document ID | / |
Family ID | 39586942 |
Filed Date | 2015-08-20 |
United States Patent
Application |
20150232616 |
Kind Code |
A1 |
Sill; Kevin N. ; et
al. |
August 20, 2015 |
HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR
ENCAPSULATION OF HYDROPHOBIC AGENTS
Abstract
The present invention relates to the field of polymer chemistry
and more particularly to multiblock copolymers and micelles
comprising the same.
Inventors: |
Sill; Kevin N.; (Tampa,
FL) ; Skaff; Habib; (Tampa, FL) ; Breitenkamp;
Kurt; (San Francisco, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Intezyne Technologies, Inc. |
Tampa |
FL |
US |
|
|
Family ID: |
39586942 |
Appl. No.: |
14/615383 |
Filed: |
February 5, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12873642 |
Sep 1, 2010 |
8980326 |
|
|
14615383 |
|
|
|
|
12112825 |
Apr 30, 2008 |
7799339 |
|
|
12873642 |
|
|
|
|
60914958 |
Apr 30, 2007 |
|
|
|
Current U.S.
Class: |
525/432 |
Current CPC
Class: |
A61K 47/34 20130101;
Y10S 977/906 20130101; C08G 65/325 20130101; C08J 3/03 20130101;
A61P 35/00 20180101; Y10S 977/773 20130101; C08L 2203/02 20130101;
A61K 9/1075 20130101; C08G 73/028 20130101; Y10S 930/29 20130101;
C08G 65/33341 20130101; C08G 2261/126 20130101; C08G 65/2627
20130101; C08J 2377/04 20130101; C08G 69/08 20130101 |
International
Class: |
C08G 69/08 20060101
C08G069/08 |
Claims
1.-28. (canceled)
29. A multiblock copolymer of formula I: ##STR01788## wherein: n is
275+10; m is 0; m' is 5-50; R.sup.x is a glutamic acid side-chain
or an aspartic acid side-chain; R.sup.y consists of a mixture of D-
and L-amino acid side-chain groups selected from: D-benzylglutamate
and L-benzylglutamate, D-benzylaspartate and L-benzylaspartate,
D-leucine and L-tyrosine, or D-phenylalanine and L-tyrosine,
wherein the R.sup.y block is not in the form of an .alpha.-helix;
R.sup.1 is --N.sub.3 or --OCH.sub.3; Q is a valence bond; and
R.sup.2a is hydrogen or --NHC(O)CH.sub.3.
30. The multiblock copolymer according to claim 29, wherein R.sup.y
consists of a mixture of R.sup.y consists of a mixture of D-leucine
and L-tyrosine amino acid side-chain groups.
31. The multiblock copolymer according to claim 29, wherein R.sup.y
consists of a mixture of D- and L-amino acid side-chain groups
selected from: D-benzylglutamate and L-benzylglutamate, or
D-benzylaspartate and L-benzylaspartate.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a Continuation of U.S. patent
application Ser. No. 12/873,642, filed Sep. 1, 2010, which is a
Continuation of U.S. patent application Ser. No. 12/112,825, filed
Apr. 30, 2008, which claims priority to U.S. provisional patent
application Ser. No. 60/914,958, filed Apr. 30, 2007, the entirety
of each of which is hereby incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to the field of polymer
chemistry and more particularly to multiblock copolymers and uses
thereof.
BACKGROUND OF THE INVENTION
[0003] The development of new therapeutic agents has dramatically
improved the quality of life and survival rate of patients
suffering from a variety of disorders. However, drug delivery
innovations are needed to improve the success rate of these
treatments. Specifically, delivery systems are still needed which
effectively minimize premature excretion and/or metabolism of
therapeutic agents and deliver these agents specifically to
diseased cells thereby reducing their toxicity to healthy
cells.
[0004] Rationally-designed, nanoscopic drug carriers, or
"nanovectors," offer a promising approach to achieving these goals
due to their inherent ability to overcome many biological barriers.
Moreover, their multi-functionality permits the incorporation of
cell-targeting groups, diagnostic agents, and a multitude of drugs
in a single delivery system. Polymer micelles, formed by the
molecular assembly of functional, amphiphilic block copolymers,
represent one notable type of multifunctional nanovector.
[0005] Polymer micelles are particularly attractive due to their
ability to deliver large payloads of a variety of drugs (e.g. small
molecule, proteins, and DNA/RNA therapeutics), their improved in
vivo stability as compared to other colloidal carriers (e.g.
liposomes), and their nanoscopic size which allows for passive
accumulation in diseased tissues, such as solid tumors, by the
enhanced permeation and retention (EPR) effect. Using appropriate
surface functionality, polymer micelles are further decorated with
cell-targeting groups and permeation enhancers that can actively
target diseased cells and aid in cellular entry, resulting in
improved cell-specific delivery.
[0006] While self assembly represents a convenient method for the
bottom-up design of nanovectors, the forces that drive and sustain
the assembly of polymer micelles are concentration dependent and
inherently reversible. In clinical applications, where polymer
micelles are rapidly diluted following administration, this
reversibility, along with high concentrations of
micelle-destabilizing blood components (e.g. proteins, lipids, and
phospholipids), often leads to premature dissociation of the
drug-loaded micelle before active or passive targeting is
effectively achieved. For polymer micelles to fully reach their
cell-targeting potential and exploit their envisioned
multi-functionality, in vivo circulation time must be improved.
Drug delivery vehicles are needed, which are infinitely stable to
post-administration dilution, can avoid biological barriers (e.g.
reticuloendothelial system (RES) uptake), and deliver drugs in
response to the physiological environment encountered in diseased
tissues, such as solid tumors.
BRIEF DESCRIPTION OF THE DRAWINGS
[0007] FIG. 1 depicts the results of dynamic light scattering of
Fe.sub.2O.sub.3 encapsulated micelles.
[0008] FIG. 2 depicts the results of dynamic light scattering of
Fe.sub.2O.sub.3 encapsulated micelles.
[0009] FIG. 3 depicts the results of dynamic light scattering of
Docetaxel encapsulated micelles.
[0010] FIG. 4 depicts the results of dynamic light scattering of
Letrozole encapsulated micelles.
[0011] FIG. 5 depicts the results of a cytotoxicity assay on a
micelle of the present invention.
[0012] FIG. 6 depicts the CMC curves of
N.sub.3-PEG12K-b-Poly(Asp).sub.10-b-Poly(L-Leu.sub.13-co-L-Tyr.sub.17)-Ac
(Example 21) and
N.sub.3-PEG12K-b-Poly(Asp).sub.10-b-Poly(D-Leu.sub.13-co-L-Tyr.sub.17)-Ac
(Example 22).
[0013] FIG. 7 depicts the CMC curves of
N.sub.3-PEG12K-b-P(L-Glu(Bzl).sub.30)-Ac (Example 17) and
N.sub.3-PEG12K-b-Poly(L-Glu(Bzl).sub.15-co-D-Glu(Bzl).sub.15)-Ac
(Example 18).
[0014] FIG. 8 depicts the solution .sup.1H NMR of
N.sub.3-PEG12K-b-P(L-Glu(Bzl).sub.30)-Ac (Example 17) in
DMSO-d.sub.6.
[0015] FIG. 9 depicts the solution .sup.1H NMR of
N.sub.3-PEG12K-b-Poly(L-Glu(Bzl).sub.15-co-D-Glu(Bzl).sub.15)-Ac
(Example 18) in DMSO-d.sub.6.
[0016] FIG. 10 depicts the solution .sup.1H NMR of
N.sub.3-PEG12K-b-Poly(Asp).sub.10-b-Poly(L-Leu.sub.13-co-L-Tyr.sub.17)-Ac
(Example 21) in DMSO-d.sub.6.
[0017] FIG. 11 depicts the solution .sup.1H NMR of
N.sub.3-PEG12K-b-Poly(Asp).sub.10-b-Poly(D-Leu.sub.13-co-L-Tyr.sub.17)-Ac
(Example 22) in DMSO-d.sub.6.
[0018] FIG. 12 depicts the circular dichroism spectra of
N.sub.3-PEG12K-b-P(L-Glu(Bzl).sub.30)-Ac (Example 17) and
N.sub.3-PEG12K-b-Poly(L-Glu(Bzl).sub.15-co-D-Glu(Bzl).sub.15)-Ac
(Example 18).
[0019] FIG. 13 depicts the circular dichroism spectra of
N.sub.3-PEG12K-b-Poly(Asp).sub.10-b-Poly(L-Leu.sub.13-co-L-Tyr.sub.17)-Ac
(Example 21) and
N.sub.3-PEG12K-b-Poly(Asp).sub.10-b-Poly(D-Leu.sub.13-co-L-Tyr.sub.17)-Ac
(Example 22).
DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION
1. General Description
[0020] According to one embodiment, the present invention provides
a micelle comprising a multiblock copolymer which comprises a
polymeric hydrophilic block, optionally a crosslinkable or
crosslinked poly(amino acid block), and a hydrophobic D,L-mixed
poly(amino acid) block, characterized in that said micelle has an
inner core, optionally a crosslinkable or crosslinked outer core,
and a hydrophilic shell. It will be appreciated that the polymeric
hydrophilic block corresponds to the hydrophilic shell, the
optionally crosslinkable or crosslinked poly(amino acid block)
corresponds to the optionally crosslinked outer core, and the
hydrophobic D,L-mixed poly(amino acid) block corresponds to the
inner core.
[0021] The "hydrophobic D,L-mixed poly(amino acid)" block, as
described herein, consists of a mixture of D and L enantiomers to
facilitate the encapsulation of hydrophobic moieties. It is well
established that homopolymers and copolymers of amino acids,
consisting of a single stereoisomer, may exbibit secondary
structures such as the .alpha.-helix or .beta.-sheet. See
.alpha.-Aminoacid-N-Caroboxy-Anhydrides and Related Heterocycles,
H. R. Kricheldorf, Springer-Verlag, 1987. For example,
poly(L-benzyl glutatmate) typically exhibits an .alpha.-helical
conformation; however this secondary structure can be disrupted by
a change of solvent or temperature (see Advances in Protein
Chemistry XVI, P. Urnes and P. Doty, Academic Press, New York
1961). The secondary structure can also be disrupted by the
incorporation of structurally dissimilar amino acids such as
.beta.-sheet forming amino acids (e.g. proline) or through the
incorporation of amino acids with dissimilar stereochemistry (e.g.
mixture of D and L stereoisomers), which results in poly(amino
acids) with a random coil conformation. See Sakai, R.; Ikeda; S.;
Isemura, T. Bull Chem. Soc. Japan 1969, 42, 1332-1336, Paolillo,
L.; Temussi, P. A.; Bradbury, E. M.; Crane-Robinson, C. Biopolymers
1972, 11, 2043-2052, and Cho, I.; Kim, J. B.; Jung, H. J. Polymer
2003, 44, 5497-5500.
[0022] While the methods to influence secondary structure of
poly(amino acids) have been known for some time, it has been
suprisingly discovered that block copolymers possessing a random
coil conformation are particularly useful for the encapsulation of
hydrophobic molecules and nanoparticles when compared to similar
block copolymers possessing a helical segment. Without wishing to
be bound to any particular theory, it is believed that provided
block copolymers having a coil-coil conformation allow for
efficient packing and loading of hydrophobic moieties within the
micelle core, while the steric demands of a rod-coil conformation
for a helix-containing block copolymer results in less effective
encapsulation.
2. Definitions
[0023] Compounds of this invention include those described
generally above, and are further illustrated by the embodiments,
sub-embodiments, and species disclosed herein. As used herein, the
following definitions shall apply unless otherwise indicated. For
purposes of this invention, the chemical elements are identified in
accordance with the Periodic Table of the Elements, CAS version,
Handbook of Chemistry and Physics, 75.sup.th Ed. Additionally,
general principles of organic chemistry are described in "Organic
Chemistry", Thomas Sorrell, University Science Books, Sausalito:
1999, and "March's Advanced Organic Chemistry", 5.sup.th Ed., Ed.:
Smith, M. B. and March, J., John Wiley & Sons, New York: 2001,
the entire contents of which are hereby incorporated by
reference.
[0024] As used herein, the term "sequential polymerization", and
variations thereof, refers to the method wherein, after a first
monomer (e.g. NCA, lactam, or imide) is incorporated into the
polymer, thus forming an amino acid "block", a second monomer (e.g.
NCA, lactam, or imide) is added to the reaction to form a second
amino acid block, which process may be continued in a similar
fashion to introduce additional amino acid blocks into the
resulting multi-block copolymers.
[0025] As used herein, the term "multiblock copolymer" refers to a
polymer comprising one synthetic polymer portion and two or more
poly(amino acid) portions. Such multi-block copolymers include
those having the format W-X'-X'', wherein W is a synthetic polymer
portion and X and X' are poly(amino acid) chains or "amino acid
blocks". In certain embodiments, the multiblock copolymers of the
present invention are triblock copolymers. As described herein, one
or more of the amino acid blocks may be "mixed blocks", meaning
that these blocks can contain a mixture of amino acid monomers
thereby creating multiblock copolymers of the present invention. In
some embodiments, the multiblock copolymers of the present
invention comprise a mixed amino acid block and are tetrablock
copolymers.
[0026] As used herein, the term "triblock copolymer" refers to a
polymer comprising one synthetic polymer portion and two poly(amino
acid) portions.
[0027] As used herein, the term "tetrablock copolymer" refers to a
polymer comprising one synthetic polymer portion and either two
poly(amino acid) portions, wherein 1 poly(amino acid) portion is a
mixed block or a polymer comprising one synthetic polymer portion
and three poly(amino acid) portions.
[0028] As used herein, the term "inner core" as it applies to a
micelle of the present invention refers to the center of the
micelle formed by the hydrophobic D,L-mixed poly(amino acid) block.
In accordance with the present invention, the inner core is not
crosslinked. By way of illustration, in a triblock polymer of the
format W-X'-X'', as described above, the inner core corresponds to
the X'' block.
[0029] As used herein, the term "outer core" as it applies to a
micelle of the present invention refers to the layer formed by the
first poly(amino acid) block. The outer core lies between the inner
core and the hydrophilic shell. In accordance with the present
invention, the outer core is either crosslinkable or is
cross-linked. By way of illustration, in a triblock polymer of the
format W-X'-X'', as described above, the outer core corresponds to
the X' block. It is contemplated that the X' block can be a mixed
block.
[0030] As used herein, the terms "drug-loaded" and "encapsulated",
and derivatives thereof, are used interchangeably. In accordance
with the present invention, a "drug-loaded" micelle refers to a
micelle having a drug, or therapeutic agent, situated within the
core of the micelle. This is also referred to as a drug, or
therapeutic agent, being "encapsulated" within the micelle.
[0031] As used herein, the term "polymeric hydrophilic block"
refers to a polymer that is not a poly(amino acid) and is
hydrophilic in nature. Such hydrophilic polymers are well known in
the art and include polyethyleneoxide (also referred to as
polyethylene glycol or PEG), and derivatives thereof,
poly(N-vinyl-2-pyrolidone), and derivatives thereof,
poly(N-isopropylacrylamide), and derivatives thereof,
poly(hydroxyethyl acrylate), and derivatives thereof,
poly(hydroxylethyl methacrylate), and derivatives thereof, and
polymers of N-(2-hydroxypropoyl)methacrylamide (HMPA) and
derivatives thereof.
[0032] As used herein, the term "poly(amino acid)" or "amino acid
block" refers to a covalently linked amino acid chain wherein each
monomer is an amino acid unit. Such amino acid units include
natural and unnatural amino acids. In certain embodiments, each
amino acid unit of the optionally a crosslinkable or crosslinked
poly(amino acid block) is in the L-configuration. Such poly(amino
acids) include those having suitably protected functional groups.
For example, amino acid monomers may have hydroxyl or amino
moieties which are optionally protected by a suitable hydroxyl
protecting group or a suitable amine protecting group, as
appropriate. Such suitable hydroxyl protecting groups and suitable
amine protecting groups are described in more detail herein, infra.
As used herein, an amino acid block comprises one or more monomers
or a set of two or more monomers. In certain embodiments, an amino
acid block comprises one or more monomers such that the overall
block is hydrophilic. In still other embodiments, amino acid blocks
of the present invention include random amino acid blocks, ie
blocks comprising a mixture of amino acid residues.
[0033] As used herein, the term "D,L-mixed poly(amino acid) block"
refers to a poly(amino acid) block wherein the poly(amino acid)
consists of a mixture of amino acids in both the D- and
L-configurations. In certain embodiments, the D,L-mixed poly(amino
acid) block is hydrophobic. In other embodiments, the D,L-mixed
poly(amino acid) block consists of a mixture of D-configured
hydrophobic amino acids and L-configured hydrophilic amino acid
side-chain groups such that the overall poly(amino acid) block
comprising is hydrophobic.
[0034] Exemplary poly(amino acids) include poly(benzyl glutamate),
poly(benzyl aspartate), poly(L-leucine-co-tyrosine),
poly(D-leucine-co-tyrosine), poly(L-phenylalanine-co-tyrosine),
poly(D-phenylalanine-co-tyrosine), poly(L-leucine-coaspartic acid),
poly(D-leucine-co-aspartic acid), poly(L-phenylalanine-co-aspartic
acid), poly(D-phenylalanine-co-aspartic acid), poly(L-benzyl
aspartate-co-aspartic acid), poly(D-benzyl aspartate-co-aspartic
acid), poly(L-benzyl aspartate-co-tyrosine), poly(D-benzyl
aspartate-co-tyrosine).
[0035] As used herein, the phrase "natural amino acid side-chain
group" refers to the side-chain group of any of the 20 amino acids
naturally occuring in proteins. Such natural amino acids include
the nonpolar, or hydrophobic amino acids, glycine, alanine, valine,
leucine isoleucine, methionine, phenylalanine, tryptophan, and
proline. Cysteine is sometimes classified as nonpolar or
hydrophobic and other times as polar. Natural amino acids also
include polar, or hydrophilic amino acids, such as tyrosine,
serine, threonine, aspartic acid (also known as aspartate, when
charged), glutamic acid (also known as glutamate, when charged),
asparagine, and glutamine. Certain polar, or hydrophilic, amino
acids have charged side-chains. Such charged amino acids include
lysine, arginine, and histidine. One of ordinary skill in the art
would recognize that protection of a polar or hydrophilic amino
acid side-chain can render that amino acid nonpolar. For example, a
suitably protected tyrosine hydroxyl group can render that tyroine
nonpolar and hydrophobic by virtue of protecting the hydroxyl
group.
[0036] As used herein, the phrase "unnatural amino acid side-chain
group" refers to amino acids not included in the list of 20 amino
acids naturally occuring in proteins, as described above. Such
amino acids include the D-isomer of any of the 20 naturally
occuring amino acids. Unnatural amino acids also include
homoserine, DOPA (also referred to as levodopa or 3,4-dihydroxy
phenyl alanine), ornithine, and thyroxine. Other unnatural amino
acids side-chains are well know to one of ordinary skill in the art
and include unnatural aliphatic side chains. Other unnatural amino
acids include modified amino acids, including those that are
N-alkylated, cyclized, phosphorylated, acetylated, amidated,
azidylated, labelled, and the like.
[0037] As used herein, the term "tacticity" refers to the
stereochemistry of the poly(amino acid) hydrophobic block. A
poly(amino acid) block consisting of a single stereoisomer (e.g.
all L isomer) is referred to as "isotactic". A poly(amino acid)
consisting of a random incorporation of D and L amino acid monomers
is referred to as an "atactic" polymer. A poly(amino acid) with
alternating stereochemistry (e.g. . . . DLDLDL . . . ) is referred
to as a "syndiotactic" polymer. Polymer tacticity is described in
more detail in "Principles of Polymerization", 3rd Ed., G. Odian,
John Wiley & Sons, New York: 1991, the entire contents of which
are hereby incorporated by reference.
[0038] As used herein, the phrase "living polymer chain-end" refers
to the terminus resulting from a polymerization reaction which
maintains the ability to react further with additional monomer or
with a polymerization terminator.
[0039] As used herein, the term "termination" refers to attaching a
terminal group to a polymer chain-end by the reaction of a living
polymer with an appropriate compound. Alternatively, the term
"termination" may refer to attaching a terminal group to an amine
or hydroxyl end, or derivative thereof, of the polymer chain.
[0040] As used herein, the term "polymerization terminator" is used
interchangeably with the term "polymerization terminating agent"
and refers to a compound that reacts with a living polymer
chain-end to afford a polymer with a terminal group. Alternatively,
the term "polymerization terminator" may refer to a compound that
reacts with an amine or hydroxyl end, or derivative thereof, of the
polymer chain, to afford a polymer with a terminal group.
[0041] As used herein, the term "polymerization initiator" refers
to a compound, which reacts with, or whose anion or free base form
reacts with, the desired monomer in a manner which results in
polymerization of that monomer. In certain embodiments, the
polymerization initiator is the compound that reacts with an
alkylene oxide to afford a polyalkylene oxide block. In other
embodiments, the polymerization initiator is an amine salt as
described herein. In certain embodiments, the polymerization
initiator is a trifluoroacetic acid amine salt.
[0042] The term "aliphatic" or "aliphatic group", as used herein,
denotes a hydrocarbon moiety that may be straight-chain (i.e.,
unbranched), branched, or cyclic (including fused, bridging, and
spiro-fused polycyclic) and may be completely saturated or may
contain one or more units of unsaturation, but which is not
aromatic. Unless otherwise specified, aliphatic groups contain 1-20
carbon atoms. In some embodiments, aliphatic groups contain 1-10
carbon atoms. In other embodiments, aliphatic groups contain 1-8
carbon atoms. In still other embodiments, aliphatic groups contain
1-6 carbon atoms, and in yet other embodiments aliphatic groups
contain 1-4 carbon atoms. Suitable aliphatic groups include, but
are not limited to, linear or branched, alkyl, alkenyl, and alkynyl
groups, and hybrids thereof such as (cycloalkyl)alkyl,
(cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
[0043] The term "heteroatom" means one or more of oxygen, sulfur,
nitrogen, phosphorus, or silicon. This includes any oxidized form
of nitrogen, sulfur, phosphorus, or silicon; the quaternized form
of any basic nitrogen, or; a substitutable nitrogen of a
heterocyclic ring including .dbd.N-- as in 3,4-dihydro-2H-pyrrolyl,
--NH-- as in pyrrolidinyl, or .dbd.N(R.sup..dagger.)-- as in
N-substituted pyrrolidinyl.
[0044] The term "unsaturated", as used herein, means that a moiety
has one or more units of unsaturation.
[0045] As used herein, the term "bivalent, saturated or
unsaturated, straight or branched C.sub.1-12 hydrocarbon chain",
refers to bivalent alkylene, alkenylene, and alkynylene chains that
are straight or branched as defined herein.
[0046] The term "aryl" used alone or as part of a larger moiety as
in "aralkyl", "aralkoxy", or "aryloxyalkyl", refers to monocyclic,
bicyclic, and tricyclic ring systems having a total of five to
fourteen ring members, wherein at least one ring in the system is
aromatic and wherein each ring in the system contains three to
seven ring members. The term "aryl" may be used interchangeably
with the term "aryl ring".
[0047] As described herein, compounds of the invention may contain
"optionally substituted" moieties. In general, the term
"substituted", whether preceded by the term "optionally" or not,
means that one or more hydrogens of the designated moiety are
replaced with a suitable substituent. Unless otherwise indicated,
an "optionally substituted" group may have a suitable substituent
at each substitutable position of the group, and when more than one
position in any given structure may be substituted with more than
one substituent selected from a specified group, the substituent
may be either the same or different at every position. Combinations
of substituents envisioned by this invention are preferably those
that result in the formation of stable or chemically feasible
compounds. The term "stable", as used herein, refers to compounds
that are not substantially altered when subjected to conditions to
allow for their production, detection, and, in certain embodiments,
their recovery, purification, and use for one or more of the
purposes disclosed herein.
[0048] Suitable monovalent substituents on a substitutable carbon
atom of an "optionally substituted" group are independently
halogen; --(CH.sub.2).sub.0-4.sup..smallcircle.;
--(CH.sub.2).sub.0-4OR.sup..smallcircle.;
--O--(CH.sub.2).sub.0-4C(O)OR.sup..smallcircle.;
--(CH.sub.2).sub.0-4CH(OR.sup..smallcircle..sub.2;
--(CH.sub.2).sub.0-4SR.sup..smallcircle.; --(CH.sub.2).sub.0-4Ph,
which may be substituted with R.sup..smallcircle.;
--(CH.sub.2).sub.0-4 O(CH.sub.2).sub.0-1Ph which may be substituted
with R.sup..smallcircle.; --CH.dbd.CHPh, which may be substituted
with R.sup..smallcircle.; --NO.sub.2; --CN; --N.sub.3;
--(CH.sub.2).sub.0-4N(R.sup..smallcircle.).sub.2;
--(CH.sub.2).sub.0-4N(R.sup..smallcircle.)C(O)R.sup..smallcircle.;
--N(R.sup..smallcircle.)C(S)R.sup..smallcircle.;
--(CH.sub.2).sub.0-4
N(R.sup..smallcircle.)C(O)NR.sup..smallcircle..sub.2;
--N(R.sup..smallcircle.)C(S)NR.sup..smallcircle.).sub.2;
--(CH.sub.2).sub.0-4N(R.sup..smallcircle.)C(O)OR.sup..smallcircle.;
--N(R.sup..smallcircle.)N(R.sup..smallcircle.)C(O)R.sup..smallcircle.;
--N(R.sup..smallcircle.)N(R.sup..smallcircle.)C(O)NR.sup..smallcircle..su-
b.2;
--N(R.sup..smallcircle.)N(R.sup..smallcircle.)C(O)OR.sup..smallcircle-
.; --(CH.sub.2).sub.0-4C(O)R.sup..smallcircle.;
--C(S)R.sup..smallcircle.;
--(CH.sub.2).sub.0-4C(O)OR.sup..smallcircle.;
--(CH.sub.2).sub.0-4C(O)SR.sup..smallcircle.;
--(CH.sub.2).sub.0-4C(O)OSiR.sup..smallcircle..sub.3;
--(CH.sub.2).sub.0-4OC(O)R.sup..smallcircle.;
--OC(O)(CH.sub.2).sub.0-4SR--, SC(S)SR.sup..smallcircle.;
--(CH.sub.2).sub.0-4SC(O)R.sup..smallcircle.;
--(CH.sub.2).sub.0-4C(O)NR.sup..smallcircle..sub.2;
--C(S)NR.sup..smallcircle..sub.2; --C(S)SR.sup..smallcircle.;
--SC(S)SR.sup..smallcircle., --(CH.sub.2).sub.0-4
OC(O)NR.sup..smallcircle..sub.2;
--C(O)N(OR.sup..smallcircle.)R.sup..smallcircle.;
--C(O)C(O)R.sup..smallcircle.;
--C(O)CH.sub.2C(O)R.sup..smallcircle.;
--C(NOR.sup..smallcircle.)R.sup..smallcircle.;
--(CH.sub.2).sub.0-4SSR.sup..smallcircle.;
--(CH.sub.2).sub.0-4S(O).sub.2R.sup..smallcircle.;
--(CH.sub.2).sub.0-4S(O).sub.2OR.sup..smallcircle.;
--(CH.sub.2).sub.0-4OS(O).sub.2R.sup..smallcircle.;
--S(O).sub.2NR.sup..smallcircle..sub.2;
--(CH.sub.2).sub.0-4S(O)R.sup..smallcircle.;
--N(R.sup..smallcircle.)S(O).sub.2NR.sup..smallcircle..sub.2;
--N(R.sup..smallcircle.)S(O).sub.2R.sup..smallcircle.;
--N(OR.sup..smallcircle.)R.sup..smallcircle.;
--C(NH)NR.sup..smallcircle..sub.2; --P(O).sub.2R.sup..smallcircle.;
--P(O)R.sup..smallcircle..sub.2; --OP(O)R.sup..smallcircle..sub.2;
--OP(O)(OR.sup..smallcircle.).sub.2; SiR.sup..smallcircle..sub.3;
--(C.sub.1-4 straight or
branched)alkylene)O--N(R.sup..smallcircle.).sub.2; or --(C.sub.1-4
straight or branched)alkylene)C(O)O--N(R.sup..smallcircle.).sub.2,
wherein each R.sup..smallcircle. may be substituted as defined
below and is independently hydrogen, C.sub.1-6 aliphatic,
--CH.sub.2Ph, --O(CH.sub.2).sub.0-1Ph, or a 5-6-membered saturated,
partially unsaturated, or aryl ring having 0-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, or,
notwithstanding the definition above, two independent occurrences
of R.sup..smallcircle., taken together with their intervening
atom(s), form a 3-12-membered saturated, partially unsaturated, or
aryl mono- or bicyclic ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, which may be substituted
as defined below.
[0049] Suitable monovalent substituents on R.sup..smallcircle. (or
the ring formed by taking two independent occurrences of
R.sup..smallcircle. together with their intervening atoms), are
independently halogen, --(CH.sub.2).sub.0-2R.sup..cndot.,
-(haloR.sup..cndot.), --(CH.sub.2).sub.0-2OH,
--(CH.sub.2).sub.0-2OR.sup..cndot.,
--(CH.sub.2).sub.0-2CH(OR.sup..cndot.).sub.2;
--O(haloR.sup..cndot.), --CN, --N.sub.3,
--(CH.sub.2).sub.0-2C(O)R.sup..cndot., --(CH.sub.2).sub.0-2C(O)OH,
--(CH.sub.2).sub.0-2C(O)OR.sup..cndot.,
--(CH.sub.2).sub.0-2SR.sup..cndot., --(CH.sub.2).sub.0-2SH,
--(CH.sub.2).sub.0-2NH.sub.2, --(CH.sub.2).sub.0-2NHR.sup..cndot.,
--(CH.sub.2).sub.0-2NR.sup..cndot..sub.2, --NO.sub.2,
--SiR.sup..cndot..sub.3, --OSiR.sup..cndot..sub.3,
--C(O)SR.sup..cndot., --(C.sub.1-4 straight or branched
alkylene)C(O)OR.sup..cndot., or --SSR.sup..cndot. wherein each
R.sup..cndot. is unsubstituted or where preceded by "halo" is
substituted only with one or more halogens, and is independently
selected from C.sub.1-4 aliphatic, --CH.sub.2Ph,
--O(CH.sub.2).sub.0-1Ph, or a 5-6-membered saturated, partially
unsaturated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur. Suitable divalent
substituents on a saturated carbon atom of R.sup..smallcircle.
include .dbd.O and .dbd.S.
[0050] Suitable divalent substituents on a saturated carbon atom of
an "optionally substituted" group include the following: .dbd.O,
.dbd.S, .dbd.NNR*.sub.2, .dbd.NNHC(O)R*, .dbd.NNHC(O)OR*,
.dbd.NNHS(O).sub.2R*, .dbd.NR*, .dbd.NOR*,
--O(C(R*.sub.2)).sub.2-3O--, or --S(C(R*.sub.2)).sub.2-3S--,
wherein each independent occurrence of R* is selected from
hydrogen, C.sub.1-6 aliphatic which may be substituted as defined
below, or an unsubstituted 5-6-membered saturated, partially
unsaturated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur. Suitable divalent
substituents that are bound to vicinal substitutable carbons of an
"optionally substituted" group include: --O(CR*.sub.2).sub.2-3O --,
wherein each independent occurrence of R* is selected from
hydrogen, C.sub.1-6 aliphatic which may be substituted as defined
below, or an unsubstituted 5-6-membered saturated, partially
unsaturated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur. A suitable tetravalent
substituent that is bound to vicinal substitutable methylene
carbons of an "optionally substituted" group is the dicobalt
hexacarbonyl cluster represented by
##STR00001##
when depicted with the methylenes which bear it.
[0051] Suitable substituents on the aliphatic group of R* include
halogen, --R.sup..cndot., -(haloR.sup..cndot.), --OH,
--OR.sup..cndot., --O(haloR.sup..cndot.), --CN, --C(O)OH,
--C(O)OR.sup..cndot., --NH.sub.2, --NHR.sup..cndot.,
--NR.sup..cndot..sub.2, or --NO.sub.2, wherein each R.sup..cndot.
is unsubstituted or where preceded by "halo" is substituted only
with one or more halogens, and is independently C.sub.1-4
aliphatic, --CH.sub.2Ph, --O(CH.sub.2).sub.0-1Ph, or a 5-6-membered
saturated, partially unsaturated, or aryl ring having 0-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur.
[0052] Suitable substituents on a substitutable nitrogen of an
"optionally substituted" group include --R.sup..dagger.,
--NR.sup..dagger..sub.2, --C(O)R.sup..dagger.,
--C(O)OR.sup..dagger., --C(O)C(O)R.sup..dagger.,
--C(O)CH.sub.2C(O)R.sup..dagger., --S(O).sub.2R.sup..dagger.,
--S(O).sub.2NR.sup..dagger..sub.2, --C(S)NR.sup..dagger..sub.2,
--C(NH)NR.sup..dagger..sub.2, or
--N(R.sup..dagger.)S(O).sub.2R.sup..dagger.; wherein each
R.sup..dagger. is independently hydrogen, C.sub.1-6 aliphatic which
may be substituted as defined below, unsubstituted --OPh, or an
unsubstituted 5-6-membered saturated, partially unsaturated, or
aryl ring having 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, or, notwithstanding the definition
above, two independent occurrences of R.sup..dagger., taken
together with their intervening atom(s) form an unsubstituted
3-12-membered saturated, partially unsaturated, or aryl mono- or
bicyclic ring having 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur.
[0053] Suitable substituents on the aliphatic group of
R.sup..dagger. are independently halogen, --R.sup..cndot.,
-(haloR.sup..cndot.), --OH, --OR.sup..cndot.,
--O(haloR.sup..cndot.), --CN, --C(O)OH, --C(O)OR.sup..cndot.,
--NH.sub.2, --NHR.sup..cndot., --NR.sup..cndot..sub.2, or
--NO.sub.2, wherein each R.sup..cndot. is unsubstituted or where
preceded by "halo" is substituted only with one or more halogens,
and is independently C.sub.1-4 aliphatic, --CH.sub.2Ph,
--O(CH.sub.2).sub.0-1Ph, or a 5-6-membered saturated, partially
unsaturated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur.
[0054] Protected hydroxyl groups are well known in the art and
include those described in detail in Protecting Groups in Organic
Synthesis, T. W. Greene and P. G. M. Wuts, 3.sup.rd edition, John
Wiley & Sons, 1999, the entirety of which is incorporated
herein by reference. Examples of suitably protected hydroxyl groups
further include, but are not limited to, esters, carbonates,
sulfonates allyl ethers, ethers, silyl ethers, alkyl ethers,
arylalkyl ethers, and alkoxyalkyl ethers. Examples of suitable
esters include formates, acetates, proprionates, pentanoates,
crotonates, and benzoates. Specific examples of suitable esters
include formate, benzoyl formate, chloroacetate, trifluoroacetate,
methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate,
3-phenylpropionate, 4-oxopentanoate,
4,4-(ethylenedithio)pentanoate, pivaloate (trimethylacetate),
crotonate, 4-methoxy-crotonate, benzoate, p-benylbenzoate,
2,4,6-trimethylbenzoate. Examples of suitable carbonates include
9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl,
2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and
p-nitrobenzyl carbonate. Examples of suitable silyl ethers include
trimethylsilyl, triethylsilyl, t-butyldimethylsilyl,
t-butyldiphenylsilyl, triisopropylsilyl ether, and other
trialkylsilyl ethers. Examples of suitable alkyl ethers include
methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl,
t-butyl, and allyl ether, or derivatives thereof. Alkoxyalkyl
ethers include acetals such as methoxymethyl, methylthiomethyl,
(2-methoxyethoxy)methyl, benzyloxymethyl,
beta-(trimethylsilyl)ethoxymethyl, and tetrahydropyran-2-yl ether.
Examples of suitable arylalkyl ethers include benzyl,
p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, O-nitrobenzyl,
p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2-
and 4-picolyl ethers.
[0055] Protected amines are well known in the art and include those
described in detail in Greene (1999). Suitable mono-protected
amines further include, but are not limited to, aralkylamines,
carbamates, allyl amines, amides, and the like. Examples of
suitable mono-protected amino moieties include
t-butyloxycarbonylamino (--NHBOC), ethyloxycarbonylamino,
methyloxycarbonylamino, trichloroethyloxycarbonylamino,
allyloxycarbonylamino (--NHAlloc), benzyloxocarbonylamino
(--NHCBZ), allylamino, benzylamino (--NHBn),
fluorenylmethylcarbonyl (--NHFmoc), formamido, acetamido,
chloroacetamido, dichloroacetamido, trichloroacetamido,
phenylacetamido, trifluoroacetamido, benzamido,
t-butyldiphenylsilyl, and the like. Suitable di-protected amines
include amines that are substituted with two substituents
independently selected from those described above as mono-protected
amines, and further include cyclic imides, such as phthalimide,
maleimide, succinimide, and the like. Suitable di-protected amines
also include pyrroles and the like,
2,2,5,5-tetramethyl-[1,2,5]azadisilolidine and the like, and
azide.
[0056] Protected aldehydes are well known in the art and include
those described in detail in Greene (1999). Suitable protected
aldehydes further include, but are not limited to, acyclic acetals,
cyclic acetals, hydrazones, imines, and the like. Examples of such
groups include dimethyl acetal, diethyl acetal, diisopropyl acetal,
dibenzyl acetal, bis(2-nitrobenzyl) acetal, 1,3-dioxanes,
1,3-dioxolanes, semicarbazones, and derivatives thereof.
[0057] Protected carboxylic acids are well known in the art and
include those described in detail in Greene (1999). Suitable
protected carboxylic acids further include, but are not limited to,
optionally substituted C.sub.1-6 aliphatic esters, optionally
substituted aryl esters, silyl esters, activated esters, amides,
hydrazides, and the like. Examples of such ester groups include
methyl, ethyl, propyl, isopropyl, butyl, isobutyl, benzyl, and
phenyl ester, wherein each group is optionally substituted.
Additional suitable protected carboxylic acids include oxazolines
and ortho esters.
[0058] Protected thiols are well known in the art and include those
described in detail in Greene (1999). Suitable protected thiols
further include, but are not limited to, disulfides, thioethers,
silyl thioethers, thioesters, thiocarbonates, and thiocarbamates,
and the like. Examples of such groups include, but are not limited
to, alkyl thioethers, benzyl and substituted benzyl thioethers,
triphenylmethyl thioethers, and trichloroethoxycarbonyl thioester,
to name but a few.
[0059] A "crown ether moiety" is the radical of a crown ether. A
crown ether is a monocyclic polyether comprised of repeating units
of --CH.sub.2CH.sub.2O--. Examples of crown ethers include
12-crown-4, 15-crown-5, and 18-crown-6.
[0060] Unless otherwise stated, structures depicted herein are also
meant to include all isomeric (e.g., enantiomeric, diastereomeric,
and geometric (or conformational)) forms of the structure; for
example, the R and S configurations for each asymmetric center, Z
and E double bond isomers, and Z and E conformational isomers.
Therefore, single stereochemical isomers as well as enantiomeric,
diastereomeric, and geometric (or conformational) mixtures of the
present compounds are within the scope of the invention. Unless
otherwise stated, all tautomeric forms of the compounds of the
invention are within the scope of the invention. Additionally,
unless otherwise stated, structures depicted herein are also meant
to include compounds that differ only in the presence of one or
more isotopically enriched atoms. For example, compounds having the
present structures except for the replacement of hydrogen by
deuterium or tritium, or the replacement of a carbon by a .sup.13C-
or .sup.14C-enriched carbon are within the scope of this invention.
Such compounds are useful, for example, as in neutron scattering
experiments, as analytical tools or probes in biological
assays.
[0061] As used herein, the term "detectable moiety" is used
interchangeably with the term "label" and relates to any moiety
capable of being detected (e.g., primary labels and secondary
labels). A "detectable moiety" or "label" is the radical of a
detectable compound.
[0062] "Primary" labels include radioisotope-containing moieties
(e.g., moieties that contain .sup.32P, .sup.33P, .sup.35S, or
.sup.14C), mass-tags, and fluorescent labels, and are
signal-generating reporter groups which can be detected without
further modifications.
[0063] Other primary labels include those useful for positron
emission tomography including molecules containing radioisotopes
(e.g. .sup.18F) or ligands with bound radioactive metals (e.g.
.sup.62Cu). In other embodiments, primary labels are contrast
agents for magnetic resonance imaging such as gadolinium,
gadolinium chelates, or iron oxide (e.g Fe.sub.3O.sub.4 and
Fe.sub.2O.sub.3) particles. Similarly, semiconducting nanoparticles
(e.g. cadmium selenide, cadmium sulfide, cadmium telluride) are
useful as fluorescent labels. Other metal nanoparticles (e.g
colloidal gold) also serve as primary labels.
[0064] "Secondary" labels include moieties such as biotin, or
protein antigens, that require the presence of a second compound to
produce a detectable signal. For example, in the case of a biotin
label, the second compound may include streptavidin-enzyme
conjugates. In the case of an antigen label, the second compound
may include an antibody-enzyme conjugate. Additionally, certain
fluorescent groups can act as secondary labels by transferring
energy to another compound or group in a process of nonradiative
fluorescent resonance energy transfer (FRET), causing the second
compound or group to then generate the signal that is detected.
[0065] Unless otherwise indicated, radioisotope-containing moieties
are optionally substituted hydrocarbon groups that contain at least
one radioisotope. Unless otherwise indicated,
radioisotope-containing moieties contain from 1-40 carbon atoms and
one radioisotope. In certain embodiments, radioisotope-containing
moieties contain from 1-20 carbon atoms and one radioisotope.
[0066] The terms "fluorescent label", "fluorescent group",
"fluorescent compound", "fluorescent dye", and "fluorophore", as
used herein, refer to compounds or moieties that absorb light
energy at a defined excitation wavelength and emit light energy at
a different wavelength. Examples of fluorescent compounds include,
but are not limited to: Alexa Fluor dyes (Alexa Fluor 350, Alexa
Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 568, Alexa
Fluor 594, Alexa Fluor 633, Alexa Fluor 660 and Alexa Fluor 680),
AMCA, AMCA-S, BODIPY dyes (BODIPY FL, BODIPY R6G, BODIPY TMR,
BODIPY TR, BODIPY 530/550, BODIPY 558/568, BODIPY 564/570, BODIPY
576/589, BODIPY 581/591, BODIPY 630/650, BODIPY 650/665),
Carboxyrhodamine 6G, carboxy-X-rhodamine (ROX), Cascade Blue,
Cascade Yellow, Coumarin 343, Cyanine dyes (Cy3, Cy5, Cy3.5,
Cy5.5), Dansyl, Dapoxyl, Dialkylaminocoumarin,
4',5'-Dichloro-2',7'-dimethoxy-fluorescein, DM-NERF, Eosin,
Erythrosin, Fluorescein, FAM, Hydroxycoumarin, IRDyes (IRD40, IRD
700, IRD 800), JOE, Lissamine rhodamine B, Marina Blue,
Methoxycoumarin, Naphthofluorescein, Oregon Green 488, Oregon Green
500, Oregon Green 514, Pacific Blue, PyMPO, Pyrene, Rhodamine B,
Rhodamine 6G, Rhodamine Green, Rhodamine Red, Rhodol Green,
2',4',5',7'-Tetra-bromosulfone-fluorescein, Tetramethyl-rhodamine
(TMR), Carboxytetramethylrhodamine (TAMRA), Texas Red, Texas
Red-X.
[0067] The term "mass-tag" as used herein refers to any moiety that
is capable of being uniquely detected by virtue of its mass using
mass spectrometry (MS) detection techniques. Examples of mass-tags
include electrophore release tags such as
N-[3-[4'-[(p-Methoxytetrafluorobenzyl)oxy]phenyl]-3-methylglyceronyl]ison-
ipecotic Acid,
4'42,3,5,6-Tetrafluoro-4-(pentafluorophenoxyl)]methyl acetophenone,
and their derivatives. The synthesis and utility of these mass-tags
is described in U.S. Pat. Nos. 4,650,750, 4,709,016, 5,360,8191,
5,516,931, 5,602,273, 5,604,104, 5,610,020, and 5,650,270. Other
examples of mass-tags include, but are not limited to, nucleotides,
dideoxynucleotides, oligonucleotides of varying length and base
composition, oligopeptides, oligosaccharides, and other synthetic
polymers of varying length and monomer composition. A large variety
of organic molecules, both neutral and charged (biomolecules or
synthetic compounds) of an appropriate mass range (100-2000
Daltons) may also be used as mass-tags.
[0068] The term "substrate", as used herein refers to any material
or macromolecular complex to which a functionalized end-group of a
block copolymer can be attached. Examples of commonly used
substrates include, but are not limited to, glass surfaces, silica
surfaces, plastic surfaces, metal surfaces, surfaces containing a
metalic or chemical coating, membranes (eg., nylon, polysulfone,
silica), micro-beads (eg., latex, polystyrene, or other polymer),
porous polymer matrices (eg., polyacrylamide gel, polysaccharide,
polymethacrylate), macromolecular complexes (eg., protein,
polysaccharide).
3. Description of Exemplary Embodiments
[0069] A. Multiblock Copolymers
[0070] As described generally above, one embodiment of the present
invention provides a micelle comprising a multiblock copolymer
which comprises a polymeric hydrophilic block, optionally a
poly(amino acid block) that may be crosslinked, and a hydrophobic
D,L-mixed poly(amino acid) block, characterized in that said
micelle has an inner core, optionally a crosslinkable outer core,
and a hydrophilic shell.
[0071] Amphiphilic multiblock copolymers, as described herein, can
self-assemble in aqueous solution to form nano- and micron-sized
structures. In water, these amphiphilic multiblock copolymers
assemble by multi-molecular micellization when present in solution
above the critical micelle concentration (CMC). Without wishing to
be bound by any particular theory, it is believed that the
hydrophobic poly(amino acid) portion or "block" of the copolymer
collapses to form the micellar core, while the hydrophilic PEG
block forms a peripheral corona and imparts water solubility. In
certain embodiments, the multiblock copolymers in accordance with
the present invention possess distinct hydrophobic and hydrophilic
segments that form micelles. In addition, these multiblock polymers
optionally comprise a poly(amino acid) block which contains
functionality suitable for crosslinking. It will be appreciated
that this functionality is found on the corresponding amino acid
side-chain.
[0072] In certain embodiments, the PEG block possesses a molecular
weight of approx. 10,000 Da (225 repeat units) and contains at
least one terminal amine hydrochloride salt used to initiate the
synthesis of poly(amino acid) multi-block copolymers. In other
embodiments, the PEG block possesses a molecular weight of approx.
12,000 Da (270 repeat units) and contains at least one terminal
amine difluoroacetic acid ("DFA") salt used to initiate the
synthesis of poly(amino acid) multi-block copolymers. Without
wishing to be bound by theory, it is believed that this particular
PEG chain length imparts adequate water-solubility to the micelles
and provides relatively long in vivo circulation times.
[0073] In certain embodiments, the present invention provides a
micelle comprising a multiblock copolymer of formula I:
##STR00002##
[0074] wherein:
[0075] n is 10-2500;
[0076] m is 0 to 1000;
[0077] m' is 2 to 1000;
[0078] R.sup.x is a natural or unnatural amino acid side-chain
group that is capable of crosslinking;
[0079] R.sup.y forms a hydrophobic D,L-mixed poly(amino acid)
block;
[0080] R.sup.1 is
--Z(CH.sub.2CH.sub.2Y).sub.p(CH.sub.2).sub.tR.sup.3, wherein:
[0081] Z is --O--, --S--, --C.ident.C--, or --CH.sub.2--; [0082]
each Y is independently --O-- or --S--; [0083] p is 0-10; [0084] t
is 0-10; and [0085] R.sup.3 is hydrogen, --N.sub.3, --CN, a
mono-protected amine, a di-protected amine, a protected aldehyde, a
protected hydroxyl, a protected carboxylic acid, a protected thiol,
a 9-30 membered crown ether, or an optionally substituted group
selected from aliphatic, a 5-8 membered saturated, partially
unsaturated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, an 8-10 membered
saturated, partially unsaturated, or aryl bicyclic ring having 0-5
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or a detectable moiety; [0086] Q is a valence bond or a
bivalent, saturated or unsaturated, straight or branched C.sub.1-12
hydrocarbon chain, wherein 0-6 methylene units of Q are
independently replaced by -Cy-, --O--, --NH--, --S--, --OC(O)--,
--C(O)O--, --C(O)--, --SO--, --SO.sub.2--, --NHSO.sub.2--,
--SO.sub.2NH--, --NHC(O)--, --C(O)NH--, --OC(O)NH--, or
--NHC(O)O--, wherein: [0087] -Cy- is an optionally substituted 5-8
membered bivalent, saturated, partially unsaturated, or aryl ring
having 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, or an optionally substituted 8-10 membered
bivalent saturated, partially unsaturated, or aryl bicyclic ring
having 0-5 heteroatoms independently selected from nitrogen,
oxygen, or sulfur; [0088] R.sup.2a is a mono-protected amine, a
di-protected amine, --N(R.sup.4).sub.2, --NR.sup.4C(O)R.sup.4,
--NR.sup.4C(O)N(R.sup.4).sub.2, --NR.sup.4C(O)OR.sup.4, or
--NR.sup.4SO.sub.2R.sup.4; and [0089] each R.sup.4 is independently
hydrogen or an optionally substituted group selected from
aliphatic, a 5-8 membered saturated, partially unsaturated, or aryl
ring having 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, an 8-10 membered saturated, partially
unsaturated, or aryl bicyclic ring having 0-5 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, or a
detectable moiety, or: [0090] two R.sup.4 on the same nitrogen atom
are taken together with said nitrogen atom to form an optionally
substituted 4-7 membered saturated, partially unsaturated, or aryl
ring having 1-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur.
[0091] According to another embodiment, the present invention
provides compounds of formula I, as described above, wherein said
compounds have a polydispersity index ("PDI") of about 1.0 to about
1.2. According to another embodiment, the present invention
provides compounds of formula I, as described above, wherein said
compound has a polydispersity index ("PDI") of about 1.03 to about
1.15. According to yet another embodiment, the present invention
provides compounds of formula I, as described above, wherein said
compound has a polydispersity index ("PDI") of about 1.10 to about
1.20. According to other embodiments, the present invention
provides compounds of formula I having a PDI of less than about
1.10.
[0092] As defined generally above, the n group of formula I is
10-2500. In certain embodiments, the present invention provides
compounds of formula I, as described above, wherein n is about 225.
In other embodiments, n is about 270. In other embodiments, n is
about 350. In other embodiments, n is about 10 to about 40. In
other embodiments, n is about 40 to about 60. In other embodiments,
n is about 60 to about 90. In still other embodiments, n is about
90 to about 150. In other embodiments, n is about 150 to about 200.
In still other embodiments, n is about 200 to about 250. In other
embodiments, n is about 300 to about 375. In other embodiments, n
is about 400 to about 500. In still other embodiments, n is about
650 to about 750. In certain embodiments, n is selected from
50.+-.10. In other embodiments, n is selected from 80.+-.10,
115.+-.10, 180.+-.10, 225.+-.10, 275.+-.10, 315.+-.10, or
340.+-.10.
[0093] In certain embodiments, the m' group of formula I is about 5
to about 500. In certain embodiments, the m' group of formula I is
about 10 to about 250. In other embodiments, m' is about 10 to
about 50. According to yet another embodiment, m' is about 15 to
about 40. In other embodiments, m' is about 20 to about 40.
According to yet another embodiment, m' is about 50 to about 75.
According to other embodiments, m and m' are independently about 10
to about 100.
[0094] In some embodiments, m is 0. In certain embodiments, m is
5-50. In other embodiments, m is 5-25. In certain embodiments, m'
is 5-50. In other embodiments, m' is 5-10. In other embodiments, m'
is 10-20. In certain embodiments, m and m' add up to about 30 to
about 60. In still other embodiments, m is 1-20 repeat units and m'
is 10-50 repeat units.
[0095] In certain embodiments, the R.sup.3 moiety of the R.sup.1
group of formula I is --N.sub.3.
[0096] In other embodiments, the R.sup.3 moiety of the R.sup.1
group of formula I is --CN.
[0097] In some embodiments, the R.sup.3 moiety of the R.sup.1 group
of formula I is hydrogen.
[0098] In still other embodiments, the R.sup.3 moiety of the
R.sup.1 group of formula I is a mono-protected amine or a
di-protected amine.
[0099] In certain embodiments, the R.sup.3 moiety of the R.sup.1
group of formula I is an optionally substituted aliphatic group.
Examples include methyl, t-butyl, 5-norbornene-2-yl, octane-5-yl,
acetylenyl, trimethylsilylacetylenyl, triisopropylsilylacetylenyl,
and t-butyldimethylsilylacetylenyl. In some embodiments, said
R.sup.3 moiety is an optionally substituted alkyl group. In other
embodiments, said R.sup.3 moiety is an optionally substituted
alkynyl or alkenyl group. When said R.sup.3 moiety is a substituted
aliphatic group, suitable substituents on R.sup.3 include CN,
N.sub.3, trimethylsilyl, triisopropylsilyl, t-butyldimethylsilyl,
N-methyl propiolamido, N-methyl-4-acetylenylanilino,
N-methyl-4-acetylenylbenzoamido, bis-(4-ethynyl-benzyl)-amino,
dipropargylamino, di-hex-5-ynyl-amino, di-pent-4-ynyl-amino,
di-but-3-ynyl-amino, propargyloxy, hex-5-ynyloxy, pent-4-ynyloxy,
di-but-3-ynyloxy, N-methyl-propargylamino,
N-methyl-hex-5-ynyl-amino, N-methyl-pent-4-ynyl-amino,
N-methyl-but-3-ynyl-amino, 2-hex-5-ynyldisulfanyl,
2-pent-4-ynyldisulfanyl, 2-but-3-ynyldisulfanyl, and
2-propargyldisulfanyl. In certain embodiments, the R.sup.1 group is
2-(N-methyl-N-(ethynylcarbonyl)amino)ethoxy, 4-ethynylbenzyloxy, or
2-(4-ethynylphenoxyl)ethoxy.
[0100] In certain embodiments, the R.sup.3 moiety of the R.sup.1
group of formula I is an optionally substituted aryl group.
Examples include optionally substituted phenyl and optionally
substituted pyridyl. When said R.sup.3 moiety is a substituted aryl
group, suitable substituents on R.sup.3 include CN, N.sub.3,
NO.sub.2, --CH.sub.3, --CH.sub.2N.sub.3, --CH.dbd.CH.sub.2, --CCH,
Br, I, F, bis-(4-ethynyl-benzyl)-amino, dipropargylamino,
di-hex-5-ynyl-amino, di-pent-4-ynyl-amino, di-but-3-ynyl-amino,
propargyloxy, hex-5-ynyloxy, pent-4-ynyloxy, di-but-3-ynyloxy,
2-hex-5-ynyloxy-ethyldisulfanyl, 2-pent-4-ynyloxy-ethyldisulfanyl,
2-but-3-ynyloxy-ethyldisulfanyl, 2-propargyloxy-ethyldisulfanyl,
bis-benzyloxy-methyl, [1,3]dioxolan-2-yl, and [1,3]dioxan-2-yl.
[0101] In other embodiments, the R.sup.3 moiety is an aryl group
substituted with a suitably protected amino group. According to
another aspect, the R.sup.3 moiety is phenyl substituted with a
suitably protected amino group.
[0102] In other embodiments, the R.sup.3 moiety of the R.sup.1
group of formula I is a protected hydroxyl group. In certain
embodiments the protected hydroxyl of the R.sup.3 moiety is an
ester, carbonate, sulfonate, allyl ether, ether, silyl ether, alkyl
ether, arylalkyl ether, or alkoxyalkyl ether. In certain
embodiments, the ester is a formate, acetate, proprionate,
pentanoate, crotonate, or benzoate. Exemplary esters include
formate, benzoyl formate, chloroacetate, trifluoroacetate,
methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate,
3-phenylpropionate, 4-oxopentanoate,
4,4-(ethylenedithio)pentanoate, pivaloate (trimethylacetate),
crotonate, 4-methoxy-crotonate, benzoate, p-benylbenzoate,
2,4,6-trimethylbenzoate. Exemplary carbonates include
9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl,
2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and
p-nitrobenzyl carbonate. Examples of suitable silyl ethers include
trimethylsilyl, triethylsilyl, t-butyldimethylsilyl,
t-butyldiphenylsilyl, triisopropylsilyl ether, and other
trialkylsilyl ethers. Exemplary alkyl ethers include methyl,
benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, and
allyl ether, or derivatives thereof. Exemplary alkoxyalkyl ethers
include acetals such as methoxymethyl, methylthiomethyl,
(2-methoxyethoxy)methyl, benzyloxymethyl,
beta-(trimethylsilyl)ethoxymethyl, and tetrahydropyran-2-yl ether.
Exemplary arylalkyl ethers include benzyl, p-methoxybenzyl (MPM),
3,4-dimethoxybenzyl, O-nitrobenzyl, p-nitrobenzyl, p-halobenzyl,
2,6-dichlorobenzyl, p-cyanobenzyl, 2- and 4-picolyl ethers.
[0103] In certain embodiments, the R.sup.3 moiety of the R.sup.1
group of formula I is a mono-protected or di-protected amino group.
In certain embodiments R.sup.3 is a mono-protected amine. In
certain embodiments R.sup.3 is a mono-protected amine selected from
aralkylamines, carbamates, allyl amines, or amides. Exemplary
mono-protected amino moieties include t-butyloxycarbonylamino,
ethyloxycarbonylamino, methyloxycarbonylamino,
trichloroethyloxycarbonylamino, allyloxycarbonylamino,
benzyloxocarbonylamino, allylamino, benzylamino,
fluorenylmethylcarbonyl, formamido, acetamido, chloroacetamido,
dichloroacetamido, trichloroacetamido, phenylacetamido,
trifluoroacetamido, benzamido, and t-butyldiphenylsilylamino. In
other embodiments R.sup.3 is a di-protected amine. Exemplary
di-protected amines include di-benzylamine, di-allylamine,
phthalimide, maleimide, succinimide, pyrrole,
2,2,5,5-tetramethyl-[1,2,5]azadisilolidine, and azide. In certain
embodiments, the R.sup.3 moiety is phthalimido. In other
embodiments, the R.sup.3 moiety is mono- or di-benzylamino or mono-
or di-allylamino. In certain embodiments, the R.sup.1 group is
2-dibenzylaminoethoxy.
[0104] In other embodiments, the R.sup.3 moiety of the R.sup.1
group of formula I is a protected aldehyde group. In certain
embodiments the protected aldehydo moiety of R.sup.3 is an acyclic
acetal, a cyclic acetal, a hydrazone, or an imine. Exemplary
R.sup.3 groups include dimethyl acetal, diethyl acetal, diisopropyl
acetal, dibenzyl acetal, bis(2-nitrobenzyl) acetal, 1,3-dioxane,
1,3-dioxolane, and semicarbazone. In certain embodiments, R.sup.3
is an acyclic acetal or a cyclic acetal. In other embodiments,
R.sup.3 is a dibenzyl acetal.
[0105] In yet other embodiments, the R.sup.3 moiety of the R.sup.1
group of formula I is a protected carboxylic acid group. In certain
embodiments, the protected carboxylic acid moiety of R.sup.3 is an
optionally substituted ester selected from C.sub.1-6 aliphatic or
aryl, or a silyl ester, an activated ester, an amide, or a
hydrazide. Examples of such ester groups include methyl, ethyl,
propyl, isopropyl, butyl, isobutyl, benzyl, and phenyl ester. In
other embodiments, the protected carboxylic acid moiety of R.sup.3
is an oxazoline or an ortho ester. Examples of such protected
carboxylic acid moieties include oxazolin-2-yl and
2-methoxy-[1,3]dioxin-2-yl. In certain embodiments, the R.sup.1
group is oxazolin-2-ylmethoxy or 2-oxazolin-2-yl-1-propoxy.
[0106] According to another embodiments, the R.sup.3 moiety of the
R.sup.1 group of formula I is a protected thiol group. In certain
embodiments, the protected thiol of R.sup.3 is a disulfide,
thioether, silyl thioether, thioester, thiocarbonate, or a
thiocarbamate. Examples of such protected thiols include
triisopropylsilyl thioether, t-butyldimethylsilyl thioether,
t-butyl thioether, benzyl thioether, p-methylbenzyl thioether,
triphenylmethyl thioether, and p-methoxyphenyldiphenylmethyl
thioether. In other embodiments, R.sup.3 is an optionally
substituted thioether selected from alkyl, benzyl, or
triphenylmethyl, or trichloroethoxycarbonyl thioester. In certain
embodmients, R.sup.3 is --S--S-pyridin-2-yl, --S--SBn,
--S--SCH.sub.3, or --S--S(p-ethynylbenzyl). In other embodmients,
R.sup.3 is --S--S-pyridin-2-yl. In still other embodiments, the
R.sup.1 group is 2-triphenylmethylsulfanyl-ethoxy.
[0107] In certain embodiments, the R.sup.3 moiety of the R.sup.1
group of formula I is a crown ether. Examples of such crown ethers
include 12-crown-4, 15-crown-5, and 18-crown-6.
[0108] In still other embodiments, the R.sup.3 moiety of the
R.sup.1 group of formula I is a detectable moiety. According to one
aspect of the invention, the R.sup.3 moiety of the R.sup.1 group of
formula I is a fluorescent moiety. Such fluorescent moieties are
well known in the art and include coumarins, quinolones,
benzoisoquinolones, hostasol, and Rhodamine dyes, to name but a
few. Exemplary fluorescent moieties of the R.sup.3 group of R.sup.1
include anthracen-9-yl, pyren-4-yl, 9-H-carbazol-9-yl, the
carboxylate of rhodamine B, and the carboxylate of coumarin 343. In
certain embodiments, the R.sup.3 moiety of the R.sup.1 group of
formula I is a detectable moiety selected from:
##STR00003## ##STR00004##
[0109] In certain embodiments, the R.sup.3 moiety of the R.sup.1
group of formula I is a group suitable for Click chemistry. Click
reactions tend to involve high-energy ("spring-loaded") reagents
with well-defined reaction coordinates, giving rise to selective
bond-forming events of wide scope. Examples include the
nucleophilic trapping of strained-ring electrophiles (epoxide,
aziridines, aziridinium ions, episulfonium ions), certain forms of
carbonyl reactivity (aldehydes and hydrazines or hydroxylamines,
for example), and several types of cycloaddition reactions. The
azide-alkyne 1,3-dipolar cycloaddition is one such reaction. Click
chemistry is known in the art and one of ordinary skill in the art
would recognize that certain R.sup.3 moieties of the present
invention are suitable for Click chemistry.
[0110] Compounds of formula I having R.sup.3 moieties suitable for
Click chemistry are useful for conjugating said compounds to
biological systems or macromolecules such as proteins, viruses, and
cells, to name but a few. The Click reaction is known to proceed
quickly and selectively under physiological conditions. In
contrast, most conjugation reactions are carried out using the
primary amine functionality on proteins (e.g. lysine or protein
end-group). Because most proteins contain a multitude of lysines
and arginines, such conjugation occurs uncontrollably at multiple
sites on the protein. This is particularly problematic when lysines
or arginines are located around the active site of an enzyme or
other biomolecule. Thus, another embodiment of the present
invention provides a method of conjugating the R.sup.1 groups of a
compound of formula I to a macromolecule via Click chemistry. Yet
another embodiment of the present invention provides a
macromolecule conjugated to a compound of formula I via the R.sup.1
group.
[0111] According to one embodiment, the R.sup.3 moiety of the
R.sup.1 group of formula I is an azide-containing group. According
to another embodiment, the R.sup.3 moiety of the R.sup.1 group of
formula I is an alkyne-containing group. In certain embodiments,
the R.sup.3 moiety of the R.sup.1 group of formula I has a terminal
alkyne moiety. In other embodiments, R.sup.3 moiety of the R.sup.1
group of formula I is an alkyne moiety having an electron
withdrawing group. Accordingly, in such embodiments, the R.sup.3
moiety of the R.sup.1 group of formula I is
##STR00005##
wherein E is an electron withdrawing group and y is 0-6. Such
electron withdrawing groups are known to one of ordinary skill in
the art. In certain embodiments, E is an ester. In other
embodiments, the R.sup.3 moiety of the R.sup.1 group of formula I
is
##STR00006##
wherein E is an electron withdrawing group, such as a --C(O)O--
group and y is 0-6.
[0112] As defined generally above, Q is a valence bond or a
bivalent, saturated or unsaturated, straight or branched C.sub.1-12
hydrocarbon chain, wherein 0-6 methylene units of Q are
independently replaced by -Cy-, --O--, --NH--, --S--, --OC(O)--,
--C(O)O--, --C(O)--, --SO--, --SO.sub.2--, --NHSO.sub.2--,
--SO.sub.2NH--, --NHC(O)--, --C(O)NH--, --OC(O)NH--, or
--NHC(O)O--, wherein -Cy- is an optionally substituted 5-8 membered
bivalent, saturated, partially unsaturated, or aryl ring having 0-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or an optionally substituted 8-10 membered bivalent
saturated, partially unsaturated, or aryl bicyclic ring having 0-5
heteroatoms independently selected from nitrogen, oxygen, or
sulfur. In certain embodiments, Q is a valence bond. In other
embodiments, Q is a bivalent, saturated C.sub.1-12 alkylene chain,
wherein 0-6 methylene units of Q are independently replaced by
-Cy-, --O--, --NH--, --S--, --OC(O)--, --C(O)O--, or --C(O)--,
wherein -Cy- is an optionally substituted 5-8 membered bivalent,
saturated, partially unsaturated, or aryl ring having 0-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or an optionally substituted 8-10 membered bivalent
saturated, partially unsaturated, or aryl bicyclic ring having 0-5
heteroatoms independently selected from nitrogen, oxygen, or
sulfur.
[0113] In certain embodiments, Q is -Cy- (i.e. a C.sub.1 alkylene
chain wherein the methylene unit is replaced by -Cy-), wherein -Cy-
is an optionally substituted 5-8 membered bivalent, saturated,
partially unsaturated, or aryl ring having 0-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur. According
to one aspect of the present invention, -Cy- is an optionally
substituted bivalent aryl group. According to another aspect of the
present invention, -Cy- is an optionally substituted bivalent
phenyl group. In other embodiments, -Cy- is an optionally
substituted 5-8 membered bivalent, saturated carbocyclic ring. In
still other embodiments, -Cy- is an optionally substituted 5-8
membered bivalent, saturated heterocyclic ring having 1-2
heteroatoms independently selected from nitrogen, oxygen, or
sulfur. Exemplary -Cy- groups include bivalent rings selected from
phenyl, pyridyl, pyrimidinyl, cyclohexyl, cyclopentyl, or
cyclopropyl.
[0114] In certain embodiments, R.sup.x is a crosslinkable amino
acid side-chain group. Such crosslinkable amino acid side-chain
groups include tyrosine, serine, cysteine, threonine, aspartic acid
(also known as aspartate, when charged), glutamic acid (also known
as glutamate, when charged), asparagine, histidine, lysine,
arginine, glutamine, or a benzimidazole-functionalized amino
acid.
[0115] As defined above, R.sup.x is a natural or unnatural amino
acid side-chain group capable of forming cross-links. It will be
appreciated that a variety of amino acid side-chain functional
groups are capable of such cross-linking, including, but not
limited to, carboxylate, hydroxyl, thiol, and amino groups.
Examples of R.sup.x moieties having functional groups capable of
forming cross-links include a glutamic acid side-chain,
--CH.sub.2C(O)OH, an aspartic acid side-chain,
--CH.sub.2CH.sub.2C(O)OH, a cystein side-chain, --CH.sub.2SH, a
serine side-chain, --CH.sub.2OH, an aldehyde containing side-chain,
--CH.sub.2C(O)H, a lysine side-chain, --(CH.sub.2).sub.4NH.sub.2,
an arginine side-chain, --(CH.sub.2).sub.3NHC(.dbd.NH)NH.sub.2, a
histidine side-chain, --CH.sub.2-imidazol-4-yl.
[0116] As defined above, R.sup.y forms a hydrophobic D,L-mixed
amino acid block. Such hydrophobic amino acid side-chain groups
include a suitably protected tyrosine side-chain, a suitably
protected serine side-chain, a suitably protected threonine
side-chain, phenylalanine, alanine, valine, leucine, tryptophan,
proline, benzyl and alkyl glutamates, or benzyl and alkyl
aspartates or mixtures thereof. One of ordinary skill in the art
would recognize that protection of a polar or hydrophilic amino
acid side-chain can render that amino acid nonpolar. For example, a
suitably protected tyrosine hydroxyl group can render that tyrosine
nonpolar and hydrophobic by virtue of protecting the hydroxyl
group. Suitable protecting groups for the hydroxyl, amino, and
thiol, and carboylate functional groups of R.sup.x and R.sup.y are
as described herein.
[0117] In other embodiments, R.sup.y consists of a mixture of
D-hydrophobic and L-hydrophilic amino acid side-chain groups such
that the overall poly(amino acid) block comprising R.sup.y is
hydrophobic and is a mixture of D- and L-configured amino acids.
Such mixtures of amino acid side-chain groups include L-tyrosine
and D-leucine, L-tyrosine and D-phenylalanine, L-serine and
D-phenylalanine, L-aspartic acid and D-phenylalanine, L-glutamic
acid and D-phenylalanine, L-tyrosine and D-benzyl glutamate,
L-tyrosine and D-benzyl aspartate, L-serine and D-benzyl glutamate,
L-serine and D-benzyl aspartate, L-aspartic acid and D-benzyl
glutamate, L-aspartic acid and D-benzyl aspartate, L-glutamic acid
and D-benzyl glutamate, L-glutamic acid and D-benzyl aspartate,
L-aspartic acid and D-leucine, and L-glutamic acid and D-leucine.
Ratios (D-hydrophobic to L-hydrophilic) of such amino acid
combinations can range between 5-95 mol %.
[0118] In certain embodiments, R.sup.y consists of a mixture of
D-hydrophobic and L-hydrophobic amino acids. Such mixtures include
D-benzyl glutamate and L-benzyl glutamate, D-benzyl aspartate and
L-benzyl aspartate, D-benzyl aspartate and L-benzyl glutamate, or
D-benzyl glutamate and L-benzyl aspartate. Exemplary compounds are
set forth below.
[0119] As defined generally above, the R.sup.2a group of formula I
is a mono-protected amine, a di-protected amine, --NHR.sup.4,
--N(R.sup.4).sub.2, --NHC(O)R.sup.4, --NR.sup.4C(O)R.sup.4,
--NHC(O)NHR.sup.4, --NHC(O)N(R.sup.4).sub.2,
--NR.sup.4C(O)NHR.sup.4, --NR.sup.4C(O)N(R.sup.4).sub.2,
--NHC(O)OR.sup.4, --NR.sup.4C(O)OR.sup.4, --NHSO.sub.2R.sup.4, or
--NR.sup.4SO.sub.2R.sup.4, wherein each R.sup.4 is independently an
optionally substituted group selected from aliphatic, a 5-8
membered saturated, partially unsaturated, or aryl ring having 0-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, an 8-10-membered saturated, partially unsaturated, or aryl
bicyclic ring having 0-5 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, or a detectable moiety, or two R.sup.4
on the same nitrogen atom are taken together with said nitrogen
atom to form an optionally substituted 4-7 membered saturated,
partially unsaturated, or aryl ring having 1-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur.
[0120] In certain embodiments, the R.sup.2a group of formula I is
--NHR.sup.4 or --N(R.sup.4).sub.2 wherein each R.sup.4 is an
optionally substituted aliphatic group. One exemplary R.sup.4 group
is 5-norbomen-2-yl-methyl. According to yet another aspect of the
present invention, the R.sup.2a group of formula I is --NHR.sup.4
wherein R.sup.4 is a C.sub.1-6 aliphatic group substituted with
N.sub.3. Examples include --CH.sub.2N.sub.3. In some embodiments,
R.sup.4 is an optionally substituted C.sub.1-6 alkyl group.
Examples include methyl, ethyl, propyl, butyl, pentyl, hexyl,
2-(tetrahydropyran-2-yloxy)ethyl, pyridin-2-yldisulfanylmethyl,
methyldisulfanylmethyl, (4-acetylenylphenyl)methyl,
3-(methoxycarbonyl)-prop-2-ynyl, methoxycarbonylmethyl,
2-(N-methyl-N-(4-acetylenylphenyl)carbonylamino)-ethyl,
2-phthalimidoethyl, 4-bromobenzyl, 4-chlorobenzyl, 4-fluorobenzyl,
4-iodobenzyl, 4-propargyloxybenzyl, 2-nitrobenzyl,
4-(bis-4-acetylenylbenzyl)aminomethyl-benzyl,
4-propargyloxy-benzyl, 4-dipropargylamino-benzyl,
4-(2-propargyloxy-ethyldisulfanyl)benzyl, 2-propargyloxy-ethyl,
2-propargyldisulfanyl-ethyl, 4-propargyloxy-butyl,
2-(N-methyl-N-propargylamino)ethyl, and
2-(2-dipropargylaminoethoxy)-ethyl. In other embodiments, R.sup.4
is an optionally substituted C.sub.2-6 alkenyl group. Examples
include vinyl, allyl, crotyl, 2-propenyl, and but-3-enyl. When
R.sup.4 group is a substituted aliphatic group, suitable
substituents on R.sup.4 include N.sub.3, CN, and halogen. In
certain embodiments, R.sup.4 is --CH.sub.2CN, --CH.sub.2CH.sub.2CN,
--CH.sub.2CH(OCH.sub.3).sub.2, 4-(bisbenzyloxymethyl)phenylmethyl,
and the like.
[0121] According to another aspect of the present invention, the
R.sup.2a group of formula I is --NHR.sup.4 wherein R.sup.4 is an
optionally substituted C.sub.2-alkynyl group. Examples include
--CC.ident.CH, --CH.sub.2C.ident.CH, --CH.sub.2C.ident.CCH.sub.3,
and --CH.sub.2CH.sub.2C.ident.CH.
[0122] In certain embodiments, the R.sup.2a group of formula I is
--NHR.sup.4 wherein R.sup.4 is an optionally substituted
5-8-membered aryl ring. In certain embodiments, R.sup.4 is
optionally substituted phenyl or optionally substituted pyridyl.
Examples include phenyl, 4-t-butoxycarbonylaminophenyl,
4-azidomethylphenyl, 4-propargyloxyphenyl, 2-pyridyl, 3-pyridyl,
and 4-pyridyl. In certain embodiments, R.sup.2a is
4-t-butoxycarbonylaminophenylamino, 4-azidomethylphenamino, or
4-propargyloxyphenylamino.
[0123] In certain embodiments, the R.sup.2a group of formula I is
--NHR.sup.4 wherein R.sup.4 is an optionally substituted phenyl
ring. Suitable substituents on the R.sup.4 phenyl ring include
halogen; --(CH.sub.2).sub.0-4R.sup..smallcircle.;
--(CH.sub.2).sub.0-4OR;
--(CH.sub.2).sub.0-4CH(OR.sup..smallcircle.).sub.2;
--(CH.sub.2).sub.0-4SR.sup..smallcircle.; --(CH.sub.2).sub.0-4Ph,
which may be substituted with R.sup..smallcircle.;
--(CH.sub.2).sub.0-4O(CH.sub.2).sub.0-1Ph which may be substituted
with R.sup..smallcircle.; --CH.dbd.CHPh, which may be substituted
with R.sup..smallcircle.; --NO.sub.2; --CN; --N.sub.3;
--(CH.sub.2).sub.0-4N(R.sup..smallcircle.).sub.2;
--(CH.sub.2).sub.0-4N(R.sup..smallcircle.)C(O)R.sup..smallcircle.;
--N(R.sup..smallcircle.)C(S)R.sup..smallcircle.;
--(CH.sub.2).sub.0-4N(R.sup..smallcircle.)C(O)NR.sup..smallcircle..sub.2;
--N(R.sup..smallcircle.)C(S)NR.sup..smallcircle..sub.2;
--(CH.sub.2).sub.0-4N(R.sup..smallcircle.)C(O)OR.sup..smallcircle.;
--N(R.sup..smallcircle.)N(R.sup..smallcircle.)C(O)R.sup..smallcircle.;
--N(R.sup..smallcircle.)N(R.sup..smallcircle.)C(O)NR.sup..smallcircle..su-
b.2;
--N(R.sup..smallcircle.)N(R.sup..smallcircle.)C(O)OR.sup..smallcircle-
.; --(CH.sub.2).sub.0-4C(O)R.sup..smallcircle.;
--C(S)R.sup..smallcircle.;
--(CH.sub.2).sub.0-4C(O)OR.sup..smallcircle.;
--(CH.sub.2).sub.0-4C(O)SR.sup..smallcircle.;
--(CH.sub.2).sub.0-4C(O)OSiR.sup..smallcircle..sub.3;
--(CH.sub.2).sub.0-4OC(O)R.sup..smallcircle.;
--(CH.sub.2).sub.0-4SC(O)R.sup..smallcircle.;
--(CH.sub.2).sub.0-4C(O)NR.sup..smallcircle..sub.2;
--C(S)NR.sup..smallcircle..sub.2;
--(CH.sub.2).sub.0-4OC(O)NR.sup..smallcircle..sub.2;
--C(O)N(OR.sup..smallcircle.)R.sup..smallcircle.;
--C(O)C(O)R.sup..smallcircle.; --C(O)CH.sub.2C(O)R;
--C(NOR.sup..smallcircle.)R.sup..smallcircle.;
--(CH.sub.2).sub.0-4SSR.sup..smallcircle.;
--(CH.sub.2).sub.0-4S(O).sub.2R.sup..smallcircle.;
--(CH.sub.2).sub.0-4S(O).sub.2OR;
--(CH.sub.2).sub.0-4OS(O).sub.2R.sup..smallcircle.;
--S(O).sub.2NR.sup..smallcircle..sub.2;
--(CH.sub.2).sub.0-4S(O)R.sup..smallcircle.;
--N(R.sup..smallcircle.)S(O).sub.2NR.sup..smallcircle..sub.2;
--N(R.sup..smallcircle.)S(O).sub.2R.sup..smallcircle.;
--N(OR.sup..smallcircle.)R.sup..smallcircle.;
--C(NH)NR.sup..smallcircle..sub.2; --P(O).sub.2R.sup..smallcircle.;
--P(O)R.sup..smallcircle..sub.2; --OP(O)R.sup..smallcircle..sub.2;
SiR.sup..smallcircle..sub.3; wherein each independent occurrence of
R.sup..smallcircle. is as defined herein supra. In other
embodiments, the R.sup.2a group of formula I is --NHR.sup.4 wherein
R.sup.4 is phenyl substituted with one or more optionally
substituted C.sub.1-6 aliphatic groups. In still other embodiments,
R.sup.4 is phenyl substituted with vinyl, allyl, acetylenyl,
--CH.sub.2N.sub.3, --CH.sub.2CH.sub.2N.sub.3,
--CH.sub.2C.ident.CCH.sub.3, or --CH.sub.2C.ident.CH.
[0124] In certain embodiments, the R.sup.2a group of formula I is
--NHR.sup.4 wherein R.sup.4 is phenyl substituted with N.sub.3,
N(R.sup..smallcircle.).sub.2, CO.sub.2R.sup..smallcircle., or
C(O)R.sup..smallcircle. wherein each R.sup..smallcircle. is
independently as defined herein supra.
[0125] In certain embodiments, the R.sup.2a group of formula I is
--N(R.sup.4).sub.2 wherein each R.sup.4 is independently an
optionally substituted group selected from aliphatic, phenyl,
naphthyl, a 5-6 membered aryl ring having 1-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, or a 8-10
membered bicyclic aryl ring having 1-5 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, or a detectable
moiety.
[0126] In other embodiments, the R.sup.2a group of formula I is
--N(R.sup.4).sub.2 wherein the two R.sup.4 groups are taken
together with said nitrogen atom to form an optionally substituted
4-7 membered saturated, partially unsaturated, or aryl ring having
1-4 heteroatoms independently selected from nitrogen, oxygen, or
sulfur. According to another embodiment, the two R.sup.4 groups are
taken together to form a 5-6-membered saturated or partially
unsaturated ring having one nitrogen wherein said ring is
substituted with one or two oxo groups. Such R.sup.2a groups
include, but are not limited to, phthalimide, maleimide and
succinimide.
[0127] In certain embodiments, the R.sup.2a group of formula I is a
mono-protected or di-protected amino group. In certain embodiments
R.sup.2a is a mono-protected amine. In certain embodiments R.sup.2a
is a mono-protected amine selected from aralkylamines, carbamates,
allyl amines, or amides. Exemplary mono-protected amino moieties
include t-butyloxycarbonylamino, ethyloxycarbonylamino,
methyloxycarbonylamino, trichloroethyloxycarbonylamino,
allyloxycarbonylamino, benzyloxocarbonylamino, allylamino,
benzylamino, fluorenylmethylcarbonyl, formamido, acetamido,
chloroacetamido, dichloroacetamido, trichloroacetamido,
phenylacetamido, trifluoroacetamido, benzamido, and
t-butyldiphenylsilylamino. In other embodiments R.sup.2a is a
di-protected amine. Exemplary di-protected amino moieties include
di-benzylamino, di-allylamino, phthalimide, maleimido, succinimido,
pyrrolo, 2,2,5,5-tetramethyl-[1,2,5]azadisilolidino, and azido. In
certain embodiments, the R.sup.2a moiety is phthalimido. In other
embodiments, the R.sup.2a moiety is mono- or di-benzylamino or
mono- or di-allylamino.
[0128] In certain embodiments, the R.sup.2a group of formula I
comprises a group suitable for Click chemistry. One of ordinary
skill in the art would recognize that certain R.sup.2a groups of
the present invention are suitable for Click chemistry.
[0129] Compounds of formula I having R.sup.2a groups comprising
groups suitable for Click chemistry are useful for conjugating said
compounds to biological systems such as proteins, viruses, and
cells, to name but a few. After conjugation to a biomolecule, drug,
cell, substrate, or the like, the other end-group functionality,
corresponding to the R.sup.1 moiety of formula I, can be used to
attach targeting groups for cell specific delivery including, but
not limited to, fluorescent dyes, covalent attachment to surfaces,
and incorporation into hydrogels. Thus, another embodiment of the
present invention provides a method of conjugating the R.sup.2a
group of a compound of formula I to a fluorescent dye, small
molecule drug, or macromolecule via Click chemistry. Yet another
embodiment of the present invention provides a macromolecule
conjugated to a compound of formula I via the R.sup.2a group.
[0130] According to one embodiment, the R.sup.2a group of formula I
is an azide-containing group. According to another embodiment, the
R.sup.2a group of formula I is an alkyne-containing group.
[0131] In certain embodiments, the R.sup.2a group of formula I has
a terminal alkyne moiety. In other embodiments, the R.sup.2a group
of formula I is an alkyne-containing moiety having an electron
withdrawing group. Accordingly, in such embodiments, the R.sup.2a
group of formula I is
##STR00007##
wherein E is an electron withdrawing group and y is 0-6. Such
electron withdrawing groups are known to one of ordinary skill in
the art. In certain embodiments, E is an ester. In other
embodiments, the R.sup.2a group of formula I is
##STR00008##
wherein E is an electron withdrawing group, such as a --C(O)O--
group and y is 0-6.
[0132] Table 1 sets forth exemplary compounds of the present
invention having the formula:
##STR00009##
wherein w is 50 to 400, x is 0-30, y is 1-50, z is 1-50, and p is
the sum of y and z.
TABLE-US-00001 TABLE 1 Compound A.sup.1 A.sup.2 E.sup.1 1
##STR00010## ##STR00011## ##STR00012## 2 ##STR00013## ##STR00014##
##STR00015## 3 ##STR00016## ##STR00017## ##STR00018## 4
##STR00019## ##STR00020## ##STR00021## 5 ##STR00022## ##STR00023##
##STR00024## 6 ##STR00025## ##STR00026## ##STR00027## 7
##STR00028## ##STR00029## ##STR00030## 8 ##STR00031## ##STR00032##
##STR00033## 9 ##STR00034## ##STR00035## ##STR00036## 10
##STR00037## ##STR00038## ##STR00039## 11 ##STR00040## ##STR00041##
##STR00042## 12 ##STR00043## ##STR00044## ##STR00045## 13
##STR00046## ##STR00047## ##STR00048## 14 ##STR00049## ##STR00050##
##STR00051## 15 ##STR00052## ##STR00053## ##STR00054## 16
##STR00055## ##STR00056## ##STR00057## 17 ##STR00058## ##STR00059##
##STR00060## 18 ##STR00061## ##STR00062## ##STR00063## 19
##STR00064## ##STR00065## ##STR00066## 20 ##STR00067## ##STR00068##
##STR00069## 21 ##STR00070## ##STR00071## ##STR00072## 22
##STR00073## ##STR00074## ##STR00075## 23 ##STR00076## ##STR00077##
##STR00078## 24 ##STR00079## ##STR00080## ##STR00081## 25
##STR00082## ##STR00083## ##STR00084## 26 ##STR00085## ##STR00086##
##STR00087## 27 ##STR00088## ##STR00089## ##STR00090## 28
##STR00091## ##STR00092## ##STR00093## 29 ##STR00094## ##STR00095##
##STR00096## 30 ##STR00097## ##STR00098## ##STR00099## 31
##STR00100## ##STR00101## ##STR00102## 32 ##STR00103## ##STR00104##
##STR00105## 33 ##STR00106## ##STR00107## ##STR00108## 34
##STR00109## ##STR00110## ##STR00111## 35 ##STR00112## ##STR00113##
##STR00114## 36 ##STR00115## ##STR00116## ##STR00117## 37
##STR00118## ##STR00119## ##STR00120## 38 ##STR00121## ##STR00122##
##STR00123## 39 ##STR00124## ##STR00125## ##STR00126## 40
##STR00127## ##STR00128## ##STR00129## 41 ##STR00130## ##STR00131##
##STR00132## 42 ##STR00133## ##STR00134## ##STR00135## 43
##STR00136## ##STR00137## ##STR00138## 44 ##STR00139## ##STR00140##
##STR00141## 45 ##STR00142## ##STR00143## ##STR00144## 46
##STR00145## ##STR00146## ##STR00147## 47 ##STR00148## ##STR00149##
##STR00150## 48 ##STR00151## ##STR00152## ##STR00153## 49
##STR00154## ##STR00155## ##STR00156## 50 ##STR00157## ##STR00158##
##STR00159## 51 ##STR00160## ##STR00161## ##STR00162## 52
##STR00163## ##STR00164## ##STR00165## 53 ##STR00166## ##STR00167##
##STR00168## 54 ##STR00169## ##STR00170## ##STR00171## 55
##STR00172## ##STR00173## ##STR00174## 56 ##STR00175## ##STR00176##
##STR00177## 57 ##STR00178## ##STR00179## ##STR00180## 58
##STR00181## ##STR00182## ##STR00183## 59 ##STR00184## ##STR00185##
##STR00186## 60 ##STR00187## ##STR00188## ##STR00189##
[0133] Table 2 sets forth exemplary compounds of the present
invention having the formula:
##STR00190##
wherein w is 50 to 400, x is 0-30, y is 1-50, z is 1-50, and p is
the sum of y and z.
TABLE-US-00002 TABLE 2 Compound A.sup.1 A.sup.2 E.sup.1 61
##STR00191## ##STR00192## ##STR00193## 62 ##STR00194## ##STR00195##
##STR00196## 63 ##STR00197## ##STR00198## ##STR00199## 64
##STR00200## ##STR00201## ##STR00202## 65 ##STR00203## ##STR00204##
##STR00205## 66 ##STR00206## ##STR00207## ##STR00208## 67
##STR00209## ##STR00210## ##STR00211## 68 ##STR00212## ##STR00213##
##STR00214## 69 ##STR00215## ##STR00216## ##STR00217## 70
##STR00218## ##STR00219## ##STR00220## 71 ##STR00221## ##STR00222##
##STR00223## 72 ##STR00224## ##STR00225## ##STR00226## 73
##STR00227## ##STR00228## ##STR00229## 74 ##STR00230## ##STR00231##
##STR00232## 75 ##STR00233## ##STR00234## ##STR00235## 76
##STR00236## ##STR00237## ##STR00238## 77 ##STR00239## ##STR00240##
##STR00241## 78 ##STR00242## ##STR00243## ##STR00244## 79
##STR00245## ##STR00246## ##STR00247## 80 ##STR00248## ##STR00249##
##STR00250## 81 ##STR00251## ##STR00252## ##STR00253## 82
##STR00254## ##STR00255## ##STR00256## 83 ##STR00257## ##STR00258##
##STR00259## 84 ##STR00260## ##STR00261## ##STR00262## 85
##STR00263## ##STR00264## ##STR00265## 86 ##STR00266## ##STR00267##
##STR00268## 87 ##STR00269## ##STR00270## ##STR00271## 88
##STR00272## ##STR00273## ##STR00274## 89 ##STR00275## ##STR00276##
##STR00277## 90 ##STR00278## ##STR00279## ##STR00280## 91
##STR00281## ##STR00282## ##STR00283## 92 ##STR00284## ##STR00285##
##STR00286## 93 ##STR00287## ##STR00288## ##STR00289## 94
##STR00290## ##STR00291## ##STR00292## 95 ##STR00293## ##STR00294##
##STR00295## 96 ##STR00296## ##STR00297## ##STR00298## 97
##STR00299## ##STR00300## ##STR00301## 98 ##STR00302## ##STR00303##
##STR00304## 99 ##STR00305## ##STR00306## ##STR00307## 100
##STR00308## ##STR00309## ##STR00310## 101 ##STR00311##
##STR00312## ##STR00313## 102 ##STR00314## ##STR00315##
##STR00316## 103 ##STR00317## ##STR00318## ##STR00319## 104
##STR00320## ##STR00321## ##STR00322## 105 ##STR00323##
##STR00324## ##STR00325## 106 ##STR00326## ##STR00327##
##STR00328## 107 ##STR00329## ##STR00330## ##STR00331## 108
##STR00332## ##STR00333## ##STR00334## 109 ##STR00335##
##STR00336## ##STR00337## 110 ##STR00338## ##STR00339##
##STR00340## 111 ##STR00341## ##STR00342## ##STR00343## 112
##STR00344## ##STR00345## ##STR00346## 113 ##STR00347##
##STR00348## ##STR00349## 114 ##STR00350## ##STR00351##
##STR00352## 115 ##STR00353## ##STR00354## ##STR00355## 116
##STR00356## ##STR00357## ##STR00358## 117 ##STR00359##
##STR00360## ##STR00361## 118 ##STR00362## ##STR00363##
##STR00364## 119 ##STR00365## ##STR00366## ##STR00367## 120
##STR00368## ##STR00369## ##STR00370##
[0134] Table 3 sets forth exemplary compounds of the present
invention having the formula:
##STR00371##
wherein w is 50 to 400, x is 0-30, y is 1-50, z is 1-50, and p is
the sum of y and z.
TABLE-US-00003 TABLE 3 Compound A.sup.1 A.sup.2 E.sup.1 121
##STR00372## ##STR00373## ##STR00374## 122 ##STR00375##
##STR00376## ##STR00377## 123 ##STR00378## ##STR00379##
##STR00380## 124 ##STR00381## ##STR00382## ##STR00383## 125
##STR00384## ##STR00385## ##STR00386## 126 ##STR00387##
##STR00388## ##STR00389## 127 ##STR00390## ##STR00391##
##STR00392## 128 ##STR00393## ##STR00394## ##STR00395## 129
##STR00396## ##STR00397## ##STR00398## 130 ##STR00399##
##STR00400## ##STR00401## 131 ##STR00402## ##STR00403##
##STR00404## 132 ##STR00405## ##STR00406## ##STR00407## 133
##STR00408## ##STR00409## ##STR00410## 134 ##STR00411##
##STR00412## ##STR00413## 135 ##STR00414## ##STR00415##
##STR00416## 136 ##STR00417## ##STR00418## ##STR00419## 137
##STR00420## ##STR00421## ##STR00422## 138 ##STR00423##
##STR00424## ##STR00425## 139 ##STR00426## ##STR00427##
##STR00428## 140 ##STR00429## ##STR00430## ##STR00431## 141
##STR00432## ##STR00433## ##STR00434## 142 ##STR00435##
##STR00436## ##STR00437## 143 ##STR00438## ##STR00439##
##STR00440## 144 ##STR00441## ##STR00442## ##STR00443## 145
##STR00444## ##STR00445## ##STR00446## 146 ##STR00447##
##STR00448## ##STR00449## 147 ##STR00450## ##STR00451##
##STR00452## 148 ##STR00453## ##STR00454## ##STR00455## 149
##STR00456## ##STR00457## ##STR00458## 150 ##STR00459##
##STR00460## ##STR00461## 151 ##STR00462## ##STR00463##
##STR00464## 152 ##STR00465## ##STR00466## ##STR00467## 153
##STR00468## ##STR00469## ##STR00470## 154 ##STR00471##
##STR00472## ##STR00473## 155 ##STR00474## ##STR00475##
##STR00476## 156 ##STR00477## ##STR00478## ##STR00479## 157
##STR00480## ##STR00481## ##STR00482## 158 ##STR00483##
##STR00484## ##STR00485## 159 ##STR00486## ##STR00487##
##STR00488## 160 ##STR00489## ##STR00490## ##STR00491## 161
##STR00492## ##STR00493## ##STR00494## 162 ##STR00495##
##STR00496## ##STR00497## 163 ##STR00498## ##STR00499##
##STR00500## 164 ##STR00501## ##STR00502## ##STR00503## 165
##STR00504## ##STR00505## ##STR00506## 166 ##STR00507##
##STR00508## ##STR00509## 167 ##STR00510## ##STR00511##
##STR00512## 168 ##STR00513## ##STR00514## ##STR00515## 169
##STR00516## ##STR00517## ##STR00518## 170 ##STR00519##
##STR00520## ##STR00521## 171 ##STR00522## ##STR00523##
##STR00524## 172 ##STR00525## ##STR00526## ##STR00527## 173
##STR00528## ##STR00529## ##STR00530## 174 ##STR00531##
##STR00532## ##STR00533## 175 ##STR00534## ##STR00535##
##STR00536## 176 ##STR00537## ##STR00538## ##STR00539## 177
##STR00540## ##STR00541## ##STR00542## 178 ##STR00543##
##STR00544## ##STR00545## 179 ##STR00546## ##STR00547##
##STR00548## 180 ##STR00549## ##STR00550## ##STR00551##
[0135] Table 4 sets forth exemplary compounds of the present
invention having the formula:
##STR00552##
wherein w is 50 to 400, x is 0-30, y is 1-50, z is 1-50, and p is
the sum of y and z.
TABLE-US-00004 TABLE 4 Compound A.sup.1 A.sup.2 E.sup.1 181
##STR00553## ##STR00554## ##STR00555## 182 ##STR00556##
##STR00557## ##STR00558## 183 ##STR00559## ##STR00560##
##STR00561## 184 ##STR00562## ##STR00563## ##STR00564## 185
##STR00565## ##STR00566## ##STR00567## 186 ##STR00568##
##STR00569## ##STR00570## 187 ##STR00571## ##STR00572##
##STR00573## 188 ##STR00574## ##STR00575## ##STR00576## 189
##STR00577## ##STR00578## ##STR00579## 190 ##STR00580##
##STR00581## ##STR00582## 191 ##STR00583## ##STR00584##
##STR00585## 192 ##STR00586## ##STR00587## ##STR00588## 193
##STR00589## ##STR00590## ##STR00591## 194 ##STR00592##
##STR00593## ##STR00594## 195 ##STR00595## ##STR00596##
##STR00597## 196 ##STR00598## ##STR00599## ##STR00600## 197
##STR00601## ##STR00602## ##STR00603## 198 ##STR00604##
##STR00605## ##STR00606## 199 ##STR00607## ##STR00608##
##STR00609## 200 ##STR00610## ##STR00611## ##STR00612## 201
##STR00613## ##STR00614## ##STR00615## 202 ##STR00616##
##STR00617## ##STR00618## 203 ##STR00619## ##STR00620##
##STR00621## 204 ##STR00622## ##STR00623## ##STR00624## 205
##STR00625## ##STR00626## ##STR00627## 206 ##STR00628##
##STR00629## ##STR00630## 207 ##STR00631## ##STR00632##
##STR00633## 208 ##STR00634## ##STR00635## ##STR00636## 209
##STR00637## ##STR00638## ##STR00639## 210 ##STR00640##
##STR00641## ##STR00642## 211 ##STR00643## ##STR00644##
##STR00645## 212 ##STR00646## ##STR00647## ##STR00648## 213
##STR00649## ##STR00650## ##STR00651## 214 ##STR00652##
##STR00653## ##STR00654## 215 ##STR00655## ##STR00656##
##STR00657## 216 ##STR00658## ##STR00659## ##STR00660## 217
##STR00661## ##STR00662## ##STR00663## 218 ##STR00664##
##STR00665## ##STR00666## 219 ##STR00667## ##STR00668##
##STR00669## 220 ##STR00670## ##STR00671## ##STR00672## 221
##STR00673## ##STR00674## ##STR00675## 222 ##STR00676##
##STR00677## ##STR00678## 223 ##STR00679## ##STR00680##
##STR00681## 224 ##STR00682## ##STR00683## ##STR00684## 225
##STR00685## ##STR00686## ##STR00687## 226 ##STR00688##
##STR00689## ##STR00690## 227 ##STR00691## ##STR00692##
##STR00693## 228 ##STR00694## ##STR00695## ##STR00696## 229
##STR00697## ##STR00698## ##STR00699## 230 ##STR00700##
##STR00701## ##STR00702## 231 ##STR00703## ##STR00704##
##STR00705## 232 ##STR00706## ##STR00707## ##STR00708## 233
##STR00709## ##STR00710## ##STR00711## 234 ##STR00712##
##STR00713## ##STR00714## 235 ##STR00715## ##STR00716##
##STR00717## 236 ##STR00718## ##STR00719## ##STR00720## 237
##STR00721## ##STR00722## ##STR00723## 238 ##STR00724##
##STR00725## ##STR00726## 239 ##STR00727## ##STR00728##
##STR00729## 240 ##STR00730## ##STR00731## ##STR00732##
[0136] Table 5 sets forth exemplary compounds of the present
invention having the formula:
##STR00733##
wherein w is 50 to 400, x is 0-30, y is 1-50, z is 1-50, and p is
the sum of y and z.
TABLE-US-00005 TABLE 5 Compound A.sup.1 A.sup.2 E.sup.1 241
##STR00734## ##STR00735## ##STR00736## 242 ##STR00737##
##STR00738## ##STR00739## 243 ##STR00740## ##STR00741##
##STR00742## 244 ##STR00743## ##STR00744## ##STR00745## 245
##STR00746## ##STR00747## ##STR00748## 246 ##STR00749##
##STR00750## ##STR00751## 247 ##STR00752## ##STR00753##
##STR00754## 248 ##STR00755## ##STR00756## ##STR00757## 249
##STR00758## ##STR00759## ##STR00760## 250 ##STR00761##
##STR00762## ##STR00763## 251 ##STR00764## ##STR00765##
##STR00766## 252 ##STR00767## ##STR00768## ##STR00769## 253
##STR00770## ##STR00771## ##STR00772## 254 ##STR00773##
##STR00774## ##STR00775## 255 ##STR00776## ##STR00777##
##STR00778## 256 ##STR00779## ##STR00780## ##STR00781## 257
##STR00782## ##STR00783## ##STR00784## 258 ##STR00785##
##STR00786## ##STR00787## 259 ##STR00788## ##STR00789##
##STR00790## 260 ##STR00791## ##STR00792## ##STR00793## 261
##STR00794## ##STR00795## ##STR00796## 262 ##STR00797##
##STR00798## ##STR00799## 263 ##STR00800## ##STR00801##
##STR00802## 264 ##STR00803## ##STR00804## ##STR00805## 265
##STR00806## ##STR00807## ##STR00808## 266 ##STR00809##
##STR00810## ##STR00811## 267 ##STR00812## ##STR00813##
##STR00814## 268 ##STR00815## ##STR00816## ##STR00817## 269
##STR00818## ##STR00819## ##STR00820## 270 ##STR00821##
##STR00822## ##STR00823## 271 ##STR00824## ##STR00825##
##STR00826## 272 ##STR00827## ##STR00828## ##STR00829## 273
##STR00830## ##STR00831## ##STR00832## 274 ##STR00833##
##STR00834## ##STR00835## 275 ##STR00836## ##STR00837##
##STR00838## 276 ##STR00839## ##STR00840## ##STR00841## 277
##STR00842## ##STR00843## ##STR00844## 278 ##STR00845##
##STR00846## ##STR00847## 279 ##STR00848## ##STR00849##
##STR00850## 280 ##STR00851## ##STR00852## ##STR00853## 281
##STR00854## ##STR00855## ##STR00856## 282 ##STR00857##
##STR00858## ##STR00859## 283 ##STR00860## ##STR00861##
##STR00862## 284 ##STR00863## ##STR00864## ##STR00865## 285
##STR00866## ##STR00867## ##STR00868## 286 ##STR00869##
##STR00870## ##STR00871## 287 ##STR00872## ##STR00873##
##STR00874## 288 ##STR00875## ##STR00876## ##STR00877## 289
##STR00878## ##STR00879## ##STR00880## 290 ##STR00881##
##STR00882## ##STR00883## 291 ##STR00884## ##STR00885##
##STR00886## 292 ##STR00887## ##STR00888## ##STR00889## 293
##STR00890## ##STR00891## ##STR00892## 294 ##STR00893##
##STR00894## ##STR00895## 295 ##STR00896## ##STR00897##
##STR00898## 296 ##STR00899## ##STR00900## ##STR00901## 297
##STR00902## ##STR00903## ##STR00904## 298 ##STR00905##
##STR00906## ##STR00907## 299 ##STR00908## ##STR00909##
##STR00910## 300 ##STR00911## ##STR00912## ##STR00913##
[0137] Table 6 sets forth exemplary compounds of the present
invention having the formula:
##STR00914##
wherein w is 50 to 400, x is 0-30, y is 1-50, z is 1-50, and p is
the sum of y and z.
TABLE-US-00006 TABLE 6 Compound A.sup.1 A.sup.2 A.sup.3 301
##STR00915## ##STR00916## ##STR00917## 302 ##STR00918##
##STR00919## ##STR00920## 303 ##STR00921## ##STR00922##
##STR00923## 304 ##STR00924## ##STR00925## ##STR00926## 305
##STR00927## ##STR00928## ##STR00929## 306 ##STR00930##
##STR00931## ##STR00932## 307 ##STR00933## ##STR00934##
##STR00935## 308 ##STR00936## ##STR00937## ##STR00938## 309
##STR00939## ##STR00940## ##STR00941## 310 ##STR00942##
##STR00943## ##STR00944## 311 ##STR00945## ##STR00946##
##STR00947## 312 ##STR00948## ##STR00949## ##STR00950## 313
##STR00951## ##STR00952## ##STR00953## 314 ##STR00954##
##STR00955## ##STR00956## 315 ##STR00957## ##STR00958##
##STR00959## 316 ##STR00960## ##STR00961## ##STR00962## 317
##STR00963## ##STR00964## ##STR00965## 318 ##STR00966##
##STR00967## ##STR00968## 319 ##STR00969## ##STR00970##
##STR00971## 320 ##STR00972## ##STR00973## ##STR00974## 321
##STR00975## ##STR00976## ##STR00977## 322 ##STR00978##
##STR00979## ##STR00980## 323 ##STR00981## ##STR00982##
##STR00983## 324 ##STR00984## ##STR00985## ##STR00986## 325
##STR00987## ##STR00988## ##STR00989## 326 ##STR00990##
##STR00991## ##STR00992## 327 ##STR00993## ##STR00994##
##STR00995## 328 ##STR00996## ##STR00997## ##STR00998## 329
##STR00999## ##STR01000## ##STR01001## 330 ##STR01002##
##STR01003## ##STR01004## 331 ##STR01005## ##STR01006##
##STR01007## 332 ##STR01008## ##STR01009## ##STR01010## 333
##STR01011## ##STR01012## ##STR01013## 334 ##STR01014##
##STR01015## ##STR01016## 335 ##STR01017## ##STR01018##
##STR01019## 336 ##STR01020## ##STR01021## ##STR01022## 337
##STR01023## ##STR01024## ##STR01025## 338 ##STR01026##
##STR01027## ##STR01028## 339 ##STR01029## ##STR01030##
##STR01031## 340 ##STR01032## ##STR01033## ##STR01034## 341
##STR01035## ##STR01036## ##STR01037## 342 ##STR01038##
##STR01039## ##STR01040## 343 ##STR01041## ##STR01042##
##STR01043## 344 ##STR01044## ##STR01045## ##STR01046## 345
##STR01047## ##STR01048## ##STR01049## 346 ##STR01050##
##STR01051## ##STR01052## 347 ##STR01053## ##STR01054##
##STR01055## 348 ##STR01056## ##STR01057## ##STR01058## 349
##STR01059## ##STR01060## ##STR01061## 350 ##STR01062##
##STR01063## ##STR01064## 351 ##STR01065## ##STR01066##
##STR01067## 352 ##STR01068## ##STR01069## ##STR01070## 353
##STR01071## ##STR01072## ##STR01073## 354 ##STR01074##
##STR01075## ##STR01076## 355 ##STR01077## ##STR01078##
##STR01079## 356 ##STR01080## ##STR01081## ##STR01082## 357
##STR01083## ##STR01084## ##STR01085## 358 ##STR01086##
##STR01087## ##STR01088## 359 ##STR01089## ##STR01090##
##STR01091## 360 ##STR01092## ##STR01093## ##STR01094## 361
##STR01095## ##STR01096## ##STR01097## 362 ##STR01098##
##STR01099## ##STR01100## 363 ##STR01101## ##STR01102##
##STR01103## 364 ##STR01104## ##STR01105## ##STR01106## 365
##STR01107## ##STR01108## ##STR01109## 366 ##STR01110##
##STR01111## ##STR01112## 367 ##STR01113## ##STR01114##
##STR01115## 368 ##STR01116## ##STR01117## ##STR01118## 369
##STR01119## ##STR01120## ##STR01121## 370 ##STR01122##
##STR01123## ##STR01124## 371 ##STR01125## ##STR01126##
##STR01127## 372 ##STR01128## ##STR01129## ##STR01130## 373
##STR01131## ##STR01132## ##STR01133## 374 ##STR01134##
##STR01135## ##STR01136## 375 ##STR01137## ##STR01138##
##STR01139## 376 ##STR01140## ##STR01141## ##STR01142## 377
##STR01143## ##STR01144## ##STR01145## 378 ##STR01146##
##STR01147## ##STR01148## 379 ##STR01149## ##STR01150##
##STR01151## 380 ##STR01152## ##STR01153## ##STR01154##
[0138] In certain embodiments, the present invention provides a
micelle comprising a multiblock copolymer of formula I, wherein m
is 0 thus forming a compound of formula I-a:
##STR01155##
wherein: [0139] n is 10-2500; [0140] m' is 2 to 1000; [0141]
R.sup.y forms a hydrophobic D,L-mixed poly(amino acid) block;
[0142] R.sup.1 is
--Z(CH.sub.2CH.sub.2Y).sub.p(CH.sub.2).sub.tR.sup.3, wherein:
[0143] Z is --O--, --S--, --C.ident.C--, or --CH.sub.2--; [0144]
each Y is independently --O-- or --S--; [0145] p is 0-10; [0146] t
is 0-10; and [0147] R.sup.3 is hydrogen, --N.sub.3, --CN, a
mono-protected amine, a di-protected amine, a protected aldehyde, a
protected hydroxyl, a protected carboxylic acid, a protected thiol,
a 9-30 membered crown ether, or an optionally substituted group
selected from aliphatic, a 5-8 membered saturated, partially
unsaturated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, an 8-10 membered
saturated, partially unsaturated, or aryl bicyclic ring having 0-5
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or a detectable moiety; [0148] Q is a valence bond or a
bivalent, saturated or unsaturated, straight or branched C.sub.1-12
hydrocarbon chain, wherein 0-6 methylene units of Q are
independently replaced by -Cy-, --O--, --NH--, --S--, --OC(O)--,
--C(O)O--, --C(O)--, --SO--, --SO.sub.2--, --NHSO.sub.2--,
--SO.sub.2NH--, --NHC(O)--, --C(O)NH--, --OC(O)NH--, or
--NHC(O)O--, wherein: [0149] -Cy- is an optionally substituted 5-8
membered bivalent, saturated, partially unsaturated, or aryl ring
having 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, or an optionally substituted 8-10 membered
bivalent saturated, partially unsaturated, or aryl bicyclic ring
having 0-5 heteroatoms independently selected from nitrogen,
oxygen, or sulfur; [0150] R.sup.2a is a mono-protected amine, a
di-protected amine, --N(R.sup.4).sub.2, --NR.sup.4C(O)R.sup.4,
--NR.sup.4C(O)N(R.sup.4).sub.2, --NR.sup.4C(O)OR.sup.4, or
--NR.sup.4SO.sub.2R.sup.4; and [0151] each R.sup.4 is independently
hydrogen or an optionally substituted group selected from
aliphatic, a 5-8 membered saturated, partially unsaturated, or aryl
ring having 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, an 8-10 membered saturated, partially
unsaturated, or aryl bicyclic ring having 0-5 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, or a
detectable moiety, or: [0152] two R.sup.4 on the same nitrogen atom
are taken together with said nitrogen atom to form an optionally
substituted 4-7 membered saturated, partially unsaturated, or aryl
ring having 1-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, wherein each of R.sup.1, n, m', R.sup.y, and
R.sup.2a, is as described herein singly and in combination.
[0153] According to another embodiment, the present invention
provides compounds of formula I-a, as described above, wherein said
compounds have a polydispersity index ("PDI") of about 1.0 to about
1.2. According to another embodiment, the present invention
provides compounds of formula I-a, as described above, wherein said
compound has a polydispersity index ("PDI") of about 1.03 to about
1.15. According to yet another embodiment, the present invention
provides compounds of formula I-a, as described above, wherein said
compound has a polydispersity index ("PDI") of about 1.10 to about
1.20. According to other embodiments, the present invention
provides compounds of formula I-a having a PDI of less than about
1.10.
[0154] Table 7 sets forth exemplary compounds of the present
invention having the formula:
##STR01156##
wherein w is 50 to 400, y is 1-50, z is 1-50, and p is the sum of y
and z.
TABLE-US-00007 TABLE 7 Com- pound E.sup.1 A.sup.1 A.sup.2 381
##STR01157## ##STR01158## ##STR01159## 382 ##STR01160##
##STR01161## ##STR01162## 383 ##STR01163## ##STR01164##
##STR01165## 384 ##STR01166## ##STR01167## ##STR01168## 385
##STR01169## ##STR01170## ##STR01171## 386 ##STR01172##
##STR01173## ##STR01174## 387 ##STR01175## ##STR01176##
##STR01177## 388 ##STR01178## ##STR01179## ##STR01180## 381
##STR01181## ##STR01182## ##STR01183## 382 ##STR01184##
##STR01185## ##STR01186## 383 ##STR01187## ##STR01188##
##STR01189## 384 ##STR01190## ##STR01191## ##STR01192## 385
##STR01193## ##STR01194## ##STR01195## 386 ##STR01196##
##STR01197## ##STR01198## 387 ##STR01199## ##STR01200##
##STR01201## 388 ##STR01202## ##STR01203## ##STR01204## 389
##STR01205## ##STR01206## ##STR01207## 390 ##STR01208##
##STR01209## ##STR01210## 391 ##STR01211## ##STR01212##
##STR01213## 392 ##STR01214## ##STR01215## ##STR01216## 393
##STR01217## ##STR01218## ##STR01219## 394 ##STR01220##
##STR01221## ##STR01222## 395 ##STR01223## ##STR01224##
##STR01225## 396 ##STR01226## ##STR01227## ##STR01228## 397
##STR01229## ##STR01230## ##STR01231## 398 ##STR01232##
##STR01233## ##STR01234## 399 ##STR01235## ##STR01236##
##STR01237## 400 ##STR01238## ##STR01239## ##STR01240## 401
##STR01241## ##STR01242## ##STR01243## 402 ##STR01244##
##STR01245## ##STR01246## 403 ##STR01247## ##STR01248##
##STR01249## 404 ##STR01250## ##STR01251## ##STR01252## 405
##STR01253## ##STR01254## ##STR01255## 406 ##STR01256##
##STR01257## ##STR01258## 407 ##STR01259## ##STR01260##
##STR01261## 408 ##STR01262## ##STR01263## ##STR01264## 409
##STR01265## ##STR01266## ##STR01267## 410 ##STR01268##
##STR01269## ##STR01270## 411 ##STR01271## ##STR01272##
##STR01273## 412 ##STR01274## ##STR01275## ##STR01276## 413
##STR01277## ##STR01278## ##STR01279## 414 ##STR01280##
##STR01281## ##STR01282## 415 ##STR01283## ##STR01284##
##STR01285## 416 ##STR01286## ##STR01287## ##STR01288## 417
##STR01289## ##STR01290## ##STR01291## 418 ##STR01292##
##STR01293## ##STR01294## 419 ##STR01295## ##STR01296##
##STR01297## 420 ##STR01298## ##STR01299## ##STR01300## 421
##STR01301## ##STR01302## ##STR01303## 422 ##STR01304##
##STR01305## ##STR01306## 423 ##STR01307## ##STR01308##
##STR01309## 424 ##STR01310## ##STR01311## ##STR01312## 425
##STR01313## ##STR01314## ##STR01315## 426 ##STR01316##
##STR01317## ##STR01318## 427 ##STR01319## ##STR01320##
##STR01321## 428 ##STR01322## ##STR01323## ##STR01324## 429
##STR01325## ##STR01326## ##STR01327## 430 ##STR01328##
##STR01329## ##STR01330## 431 ##STR01331## ##STR01332##
##STR01333## 432 ##STR01334## ##STR01335## ##STR01336## 433
##STR01337## ##STR01338## ##STR01339## 434 ##STR01340##
##STR01341## ##STR01342## 435 ##STR01343## ##STR01344##
##STR01345## 436 ##STR01346## ##STR01347## ##STR01348## 437
##STR01349## ##STR01350## ##STR01351## 438 ##STR01352##
##STR01353## ##STR01354## 439 ##STR01355## ##STR01356##
##STR01357## 440 ##STR01358## ##STR01359## ##STR01360## 441
##STR01361## ##STR01362## ##STR01363## 442 ##STR01364##
##STR01365## ##STR01366## 443 ##STR01367## ##STR01368##
##STR01369## 444 ##STR01370## ##STR01371## ##STR01372## 445
##STR01373## ##STR01374## ##STR01375## 446 ##STR01376##
##STR01377## ##STR01378## 447 ##STR01379## ##STR01380##
##STR01381## 448 ##STR01382## ##STR01383## ##STR01384## 449
##STR01385## ##STR01386## ##STR01387## 450 ##STR01388##
##STR01389## ##STR01390## 451 ##STR01391## ##STR01392##
##STR01393## 452 ##STR01394## ##STR01395## ##STR01396## 453
##STR01397## ##STR01398## ##STR01399## 454 ##STR01400##
##STR01401## ##STR01402## 455 ##STR01403## ##STR01404##
##STR01405## 456 ##STR01406## ##STR01407## ##STR01408## 457
##STR01409## ##STR01410## ##STR01411## 458 ##STR01412##
##STR01413## ##STR01414## 459 ##STR01415## ##STR01416##
##STR01417## 460 ##STR01418## ##STR01419## ##STR01420## 461
##STR01421## ##STR01422## ##STR01423## 462 ##STR01424##
##STR01425## ##STR01426## 463 ##STR01427## ##STR01428##
##STR01429## 464 ##STR01430## ##STR01431## ##STR01432## 465
##STR01433## ##STR01434## ##STR01435## 466 ##STR01436##
##STR01437## ##STR01438## 467 ##STR01439## ##STR01440##
##STR01441## 468 ##STR01442## ##STR01443## ##STR01444## 469
##STR01445## ##STR01446## ##STR01447## 470 ##STR01448##
##STR01449## ##STR01450## 471 ##STR01451## ##STR01452##
##STR01453## 472 ##STR01454## ##STR01455## ##STR01456## 473
##STR01457## ##STR01458## ##STR01459## 474 ##STR01460##
##STR01461## ##STR01462## 475 ##STR01463## ##STR01464##
##STR01465## 476 ##STR01466## ##STR01467## ##STR01468## 477
##STR01469## ##STR01470## ##STR01471## 478 ##STR01472##
##STR01473## ##STR01474## 479 ##STR01475## ##STR01476##
##STR01477## 480 ##STR01478## ##STR01479## ##STR01480## 481
##STR01481## ##STR01482## ##STR01483## 482 ##STR01484##
##STR01485## ##STR01486## 483 ##STR01487## ##STR01488##
##STR01489## 484 ##STR01490## ##STR01491## ##STR01492##
[0155] In other embodiments, the present invention provides a
micelle comprising a multiblock copolymer of formula II:
##STR01493##
wherein: [0156] n is 10-2500; [0157] m is 1 to 1000; [0158] m' is 2
to 1000; [0159] R.sup.x is a crosslinked natural or unnatural amino
acid side-chain group; [0160] R.sup.y forms a hydrophobic D,L-mixed
poly(amino acid) block; [0161] R.sup.1 is
--Z(CH.sub.2CH.sub.2Y).sub.p(CH.sub.2).sub.tR.sup.3, wherein:
[0162] Z is --O--, --S--, --C.ident.C--, or --CH.sub.2--; [0163]
each Y is independently --O-- or --S--; [0164] p is 0-10; [0165] t
is 0-10; and [0166] R.sup.3 is --N.sub.3, --CN, a mono-protected
amine, a di-protected amine, a protected aldehyde, a protected
hydroxyl, a protected carboxylic acid, a protected thiol, a 9-30
membered crown ether, or an optionally substituted group selected
from aliphatic, a 5-8 membered saturated, partially unsaturated, or
aryl ring having 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, an 8-10 membered saturated, partially
unsaturated, or aryl bicyclic ring having 0-5 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, or a
detectable moiety; [0167] Q is a valence bond or a bivalent,
saturated or unsaturated, straight or branched C.sub.1-12
hydrocarbon chain, wherein 0-6 methylene units of Q are
independently replaced by -Cy-, --O--, --NH--, --S--, --OC(O)--,
--C(O)O--, --C(O)--, --SO--, --SO.sub.2--, --NHSO.sub.2--,
--SO.sub.2NH--, --NHC(O)--, --C(O)NH--, --OC(O)NH--, or
--NHC(O)O--, wherein: [0168] -Cy- is an optionally substituted 5-8
membered bivalent, saturated, partially unsaturated, or aryl ring
having 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, or an optionally substituted 8-10 membered
bivalent saturated, partially unsaturated, or aryl bicyclic ring
having 0-5 heteroatoms independently selected from nitrogen,
oxygen, or sulfur; [0169] R.sup.2a is a mono-protected amine, a
di-protected amine, --N(R.sup.4).sub.2, --NR.sup.4C(O)R.sup.4,
--NR.sup.4C(O)N(R.sup.4).sub.2, --NR.sup.4C(O)OR.sup.4, or
--NR.sup.4SO.sub.2R.sup.4; and [0170] each R.sup.4 is independently
an optionally substituted group selected from hydrogen, aliphatic,
a 5-8 membered saturated, partially unsaturated, or aryl ring
having 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, an 8-10 membered saturated, partially
unsaturated, or aryl bicyclic ring having 0-5 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, or a
detectable moiety, or: [0171] two R.sup.4 on the same nitrogen atom
are taken together with said nitrogen atom to form an optionally
substituted 4-7 membered saturated, partially unsaturated, or aryl
ring having 1-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, wherein each of R.sup.1, n, m, m', R.sup.x,
R.sup.y, and R.sup.2a, is as described herein singly and in
combination.
[0172] According to another embodiment, the present invention
provides compounds of formula II, as described above, wherein said
compounds have a polydispersity index ("PDI") of about 1.0 to about
1.2. According to another embodiment, the present invention
provides compounds of formula II, as described above, wherein said
compound has a polydispersity index ("PDI") of about 1.03 to about
1.15. According to yet another embodiment, the present invention
provides compounds of formula II, as described above, wherein said
compound has a polydispersity index ("PDI") of about 1.10 to about
1.20. According to other embodiments, the present invention
provides compounds of formula II having a PDI of less than about
1.10.
[0173] In certain embodiments, the present invention provides a
compound selected from:
##STR01494##
wherein each w is independently, 50 to 400, each x is
independently, 0-30, each y is independently 1-50, each z is
independently 1-50, and each p is the sum of y and z.
[0174] In certain embodiments, the present invention provides a
compound selected from:
##STR01495## ##STR01496##
wherein each w is independently, 50 to 400, each y is independently
1-50, each z is independently 1-50, and each p is the sum of y and
z.
[0175] B. Crosslinking Chemistries
[0176] In certain embodiments, the present invention provides
crosslinked micelles which effectively encapsulate hydrophobic or
ionic therapeutic agents at pH 7.4 (blood) but dissociate and
release the drug at targeted, acidic pH values ranging from 5.0
(endosomal pH) to 6.8 (extracellular tumor pH). In yet other
embodiements, the pH value can be adjusted between 4.0 and 7.4.
These pH-targeted nanovectors will dramatically improve the
cancer-specific delivery of chemotherapeutic agents and minimize
the harmful side effects commonly encountered with potent
chemotherapy drugs. In addition, the utilization of chemistries
which can be tailored to dissociate across a range of pH values
make these drug-loaded micelles applicable in treating solid tumors
and malignancies that have become drug resistant.
[0177] In certain embodiments, micelles of the present invention
comprise a crosslinked multiblock polymer of formula III:
##STR01497##
wherein: [0178] n is 10-2500; [0179] m is 1 to 1000; [0180] m' is 2
to 1000; [0181] L is a bivalent, saturated or unsaturated, straight
or branched C.sub.1-12 hydrocarbon chain, wherein 0-6 methylene
units of L are independently replaced by -M-, -Cy-, --O--, --NH--,
--S--, --OC(O)--, --C(O)O--, --C(O)--, --SO--, --SO.sub.2--,
--NHSO.sub.2--, --SO.sub.2NH--, --NHC(O)--, --C(O)NH--,
--OC(O)NH--, or --NHC(O)O--, wherein: [0182] -M- is a suitable
bivalent metal; [0183] -Cy- is an optionally substituted 5-8
membered bivalent, saturated, partially unsaturated, or aryl ring
having 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, or an optionally substituted 8-10 membered
bivalent saturated, partially unsaturated, or aryl bicyclic ring
having 0-5 heteroatoms independently selected from nitrogen,
oxygen, or sulfur; [0184] R.sup.y forms a hydrophobic D,L-mixed
poly(amino acid) block; [0185] R.sup.1 is
--Z(CH.sub.2CH.sub.2Y).sub.p(CH.sub.2).sub.tR.sup.3, wherein:
[0186] Z is --O--, --S--, --C.ident.C--, or --CH.sub.2--; [0187]
each Y is independently --O-- or --S--; [0188] p is 0-10; [0189] t
is 0-10; and [0190] R.sup.3 is --N.sub.3, --CN, a mono-protected
amine, a di-protected amine, a protected aldehyde, a protected
hydroxyl, a protected carboxylic acid, a protected thiol, a 9-30
membered crown ether, or an optionally substituted group selected
from aliphatic, a 5-8 membered saturated, partially unsaturated, or
aryl ring having 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, an 8-10 membered saturated, partially
unsaturated, or aryl bicyclic ring having 0-5 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, or a
detectable moiety; [0191] Q is a valence bond or a bivalent,
saturated or unsaturated, straight or branched C.sub.1-12 alkylene
chain, wherein 0-6 methylene units of Q are independently replaced
by -Cy-, --O--, --NH--, --S--, --OC(O)--, --C(O)O--, --C(O)--,
--SO--, --SO.sub.2--, --NHSO.sub.2--, --SO.sub.2NH--, --NHC(O)--,
--C(O)NH--, --OC(O)NH--, or --NHC(O)O--, wherein: [0192] -Cy- is an
optionally substituted 5-8 membered bivalent, saturated, partially
unsaturated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, or an optionally
substituted 8-10 membered bivalent saturated, partially
unsaturated, or aryl bicyclic ring having 0-5 heteroatoms
independently selected from nitrogen, oxygen, or sulfur; [0193]
R.sup.2a is a mono-protected amine, a di-protected amine,
--N(R.sup.4).sub.2, --NR.sup.4C(O)R.sup.4,
--NR.sup.4C(O)N(R.sup.4).sub.2, --NR.sup.4C(O)OR.sup.4, or
--NR.sup.4SO.sub.2R.sup.4; and [0194] each R.sup.4 is independently
an optionally substituted group selected from hydrogen, aliphatic,
a 5-8 membered saturated, partially unsaturated, or aryl ring
having 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, an 8-10 membered saturated, partially
unsaturated, or aryl bicyclic ring having 0-5 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, or a
detectable moiety, or: [0195] two R.sup.4 on the same nitrogen atom
are taken together with said nitrogen atom to form an optionally
substituted 4-7 membered saturated, partially unsaturated, or aryl
ring having 1-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, wherein each of R.sup.1, n, m, m', R.sup.y, and
R.sup.2a, is as described in classes and subclasses herein singly
and in combination.
[0196] According to another embodiment, the present invention
provides compounds of formula III, as described above, wherein said
compounds have a polydispersity index ("PDI") of about 1.0 to about
1.2. According to another embodiment, the present invention
provides compounds of formula III, as described above, wherein said
compound has a polydispersity index ("PDI") of about 1.03 to about
1.15. According to yet another embodiment, the present invention
provides compounds of formula I, as described above, wherein said
compound has a polydispersity index ("PDI") of about 1.10 to about
1.20. According to other embodiments, the present invention
provides compounds of formula III having a PDI of less than about
1.10.
[0197] As defined generally above, the L group of formula III is a
bivalent, saturated or unsaturated, straight or branched C.sub.1-12
hydrocarbon chain, wherein 0-6 methylene units of L are
independently replaced by -M-, Cy, --O--, NH--, --S--, --C(O)--,
--SO--, --SO2-, NHC(O)--, C(O)NH--, OC(O)NH--, or --NHC(O)O--,
wherein -M- is a suitable bivalent metal, and -Cy- is an optionally
substituted 5-8 membered bivalent, saturated, partially
unsaturated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, or an optionally
substituted 8-10 membered bivalent saturated, partially
unsaturated, or aryl bicyclic ring having 0-5 heteroatoms
independently selected from nitrogen, oxygen, or sulfur. It will be
appreciated that the L group of formula III represents crosslinked
amino acid side-chain groups. In certain embodiments, the
crosslinked amino acid side-chain groups correspond to the R.sup.x
moiety of compounds of formulae I and II as described herein. In
certain embodiments, the L group of formula III represents a metal
crosslinked amino acid side-chain group, a hydrazone crosslinked
amino acid side-chain group, an ester crosslinked amino acid
side-chain group, an amide crosslinked side-chain group, an imine
(e.g. Schiff base) crosslinked side-chain group, or a disulfide
crosslinked side-chain group.
[0198] In certain embodiments, the L group of formula III comprises
-M-. In other embodiments, -M- is zinc, calcium, iron or aluminum.
In yet other embodiments, -M- is strontium, manganese, palladium,
silver, gold, cadmium, chromium, indium, or lead.
[0199] In other embodiments, the L group of formula III is a
bivalent, saturated or unsaturated, straight or branched C.sub.1-12
hydrocarbon chain wherein 2 methylene units of L are independently
replaced by --C(O)--, --C(O)NH--, --NHC(O)--, --S--, --C(O)O--,
--OC(O)--, --C(O)NHN--, -.dbd.NNHC(O)--, -.dbd.N--, --N.dbd.-,
-M-OC(O)--, or --C(O)O-M-. According to another embodiment, the L
group of formula III is a bivalent, saturated or unsaturated,
straight or branched C.sub.1-6 hydrocarbon chain, wherein two
methylene units of L are replaced by --C(O)-- or --C(O)NH--. In
other embodiments, the L group of formula III is a bivalent,
saturated or unsaturated, straight or branched C.sub.1-12
hydrocarbon chain having at least 2 units of unsaturation.
According to yet another embodiment, the L group of formula III is
a bivalent, saturated or unsaturated, straight or branched
C.sub.1-12 alkylene chain wherein two methylene units of L are
replaced by --NH--. According to yet another embodiment, the L
group of formula III is a bivalent, saturated or unsaturated,
straight or branched C.sub.1-12 alkylene chain wherein two
methylene units of L are replaced by --C(O)NHN.
[0200] In certain embodiments, the -M- moiety of the L group of
formula III is zinc. In other embodiments, L forms a
zinc-dicarboxylate crosslinking moiety. In certain embodiments, the
crosslinking utilizes zinc-mediated coupling of carboxylic acids, a
highly selective and pH-sensitive reaction that is performed in
water. This reaction, which is widely used in cough lozenge
applications, involves the association of zinc ions with carboxylic
acids at basic pH. See Bakar, N. K. A.; Taylor, D. M.; Williams, D.
R. Chem. Spec. Bioavail. 1999, 11, 95-101; and Eby, G. A. J.
Antimicrob. Chemo. 1997, 40, 483-493. These zinc-carboxylate bonds
readily dissociate in the presence of acid.
##STR01498##
[0201] Scheme 1 above illustrates the reaction of an aqueous zinc
ion (e.g. from zinc chloride) with two equivalents of an
appropriate carboxylic acid to form the zinc dicarboxylate. This
reaction occurs rapidly and irreversibly in a slightly basic pH
environment but upon acidification, is reversible within a tunable
range of pH 4.0-6.8 to reform ZnX.sub.2, where X is the conjugate
base. One of ordinary skill in the art will recognize that a
variety of natural and unnatural amino acid side-chains have a
carboxylic acid moeity that can be crosslinked by zinc or another
suitable metal.
[0202] In certain embodiments, L represents aspartic acid
side-chains crosslinked with zinc. Without wishing to be bound by
theory, it is believed that the zinc aspartate crosslinks are
stable in the blood compartment (pH 7.4), allowing for effective
accumulation of the drug-loaded micelles in solid tumors by passive
and active targeting mechanisms. In the presence of lactic acid
concentrations commonly encountered in solid tumors or in acidic
organelles of cancer cells, rapid degradation of the metal
crosslinks leading to micelle dissociation and release of the drug
at the tumor site. Preliminary, qualitative studies have shown that
crosslinked zinc aspartate segments are reversible in the presence
of .alpha.-hydroxyacids.
[0203] In certain embodiments, the -M- moiety of the L group of
formula III is zinc. In some embodiments, L forms a zinc-imidazole
crosslinking moiety. In certain embodiments, the crosslinking
utilizes zinc-mediated coupling of imidazoles.
##STR01499##
[0204] Scheme 2 above illustrates the reaction of an aqueous zinc
(II) ion (e.g. from zinc chloride or zinc acetate) with two
equivalents of an appropriate imidazole (e.g. histidine) to form a
zinc-histidine complex. This reaction occurs rapidly in a slightly
basic pH environment and is reversible upon acidification to pH
less than 6. (Tezcan, et. al. J. Am. Chem. Soc. 2007, 129,
13347-13375.)
[0205] In certain embodiments, R.sup.x is a histidine side-chain
crosslinked with zinc. Without wishing to be bound by any
particular theory, it is believed that zinc-histidine crosslinks
are stable in the blood compartment (pH 7.4), allowing for
effective accumulation of therapeutic loaded micelles in solid
tumors by passive and/or active targeting mechanisms. In the
presence of lactic acid concentrations commonly encountered in
solid tumors or hydrochloric acid in acidic organelles of cancer
cells, rapid degradation of the metal crosslinks occurs which leads
to micelle dissociation and release of the polynucleotide at the
tumor site.
##STR01500##
[0206] Scheme 3 above illustrates the reaction of an aqueous zinc
(II) ion (e.g. from zinc chloride or zinc acetate) with two
equivalents of an appropriate imidazole (e.g. benzimidazole) to
form a zinc-benzimidazole complex.
[0207] In certain embodiments, R.sup.x is a benzimidazole
side-chain crosslinked with zinc. Without wishing to be bound by
any particular theory, it is believed that zinc-benzimidazole
crosslinks are stable in the blood compartment (pH 7.4), allowing
for effective accumulation of therapeutic loaded micelles in solid
tumors by passive and/or active targeting mechanisms. In the
presence of lactic acid concentrations commonly encountered in
solid tumors or hydrochloric acid in acidic organelles of cancer
cells, rapid degradation of the metal crosslinks occurs which leads
to micelle dissociation and release of the polynucleotide at the
tumor site.
[0208] It will be appreciated that such imidazole- and
benzimidazole-containing side-chains can be incorporated into a
provided multiblock copolymer during preparation of a compound of
formula I by virtue of incorporation of the R.sup.x group.
Alternatively, such imidazole- and benzimidazole-containing
side-chains can be incorporated into said compound of formula I
after polymerization, i.e. post-polymerization. Such
post-polymerization incorporation of imidazole- and
benzimidazole-containing side-chains is depicted in Schemes 4 and
5, below. Other methods of post-polymerization modification will be
apparent to one of ordinary skill in the art.
##STR01501##
##STR01502##
[0209] The choice of zinc as a crosslinking metal is advantageous
for effective micelle crosslinking. Zinc chloride and the zinc
lactate by-product are generally recognized as non-toxic, and other
safety concerns are not anticipated. Pharmaceutical grade zinc
chloride is commonly used in mouthwash and as a chlorophyll
stabilizer in vegetables while zinc lactate is used as an additive
in toothpaste and drug preparation. The reaction is reversible
within a tunable pH range, selective toward carboxylic acids, and
should not alter the encapsulated chemotherapy agents. While zinc
has been chosen as an exemplary metal for micelle crosslinking, it
should be noted that many other metals undergo acid sensitive
coupling with carboxylic acids. These metals include calcium, iron
and aluminum, to name but a few. One or more of these metals can be
substituted for zinc.
[0210] The ultimate goal of metal-mediated crosslinking is to
ensure micelle stability when diluted in the blood (pH 7.4)
followed by rapid dissolution and drug release in response to a
finite pH change such as those found in cancer cells. Previous
reports suggest a widely variable and tunable dissociation pH for
zinc-acid bonds (from approximately 2.0 to 7.0) depending on the
carboxylic acid used and number of bonds formed. See Cannan, R. K.;
Kibrick, A. J. Am. Chem. Soc. 1938, 60, 2314-2320. Without wishing
to be bound by theory, it is believed that the concentration of
zinc chloride and the number of aspartic acid, or other carboxylic
acid-containing amino acid, repeat units in the crosslinking block
will ultimately control the pH at which complete micelle
disassembly occurs. The synthetic versatility of the block
copolymer design is advantageous since one or more variables are
tuned to achieve the desired pH reversibility. By simple adjustment
of zinc chloride/polymer stoichiometry, pH-reversible crosslinking
is finely tuned across the pH range of interest. For example,
higher zinc concentrations yield more zinc crosslinks which require
higher acid concentrations (i.e. lower pH) to dissociate.
Adjustments in zinc/polymer stoichiometry will yield the desired pH
reversibility, however other variables such as increasing the
poly(aspartic acid) block length (i.e. 15-25 repeat units) further
tune the reversible crosslinking reaction if necessary.
[0211] In other embodiments, L comprises a mixture of crosslinked
hydrophilic amino acid side-chain groups. Such mixtures of amino
acid side-chain groups include those having a carboxylic acid
functionality, a hydroxyl functionality, a thiol functionality,
and/or amine functionality. It will be appreciated that when L
comprises a mixture of crosslinked hydrophilic amino acid
side-chain functionalities, then multiple crosslinking can occur.
For example, when L comprises a carboxylic acid-containing
side-chain (e.g., aspartic acid or glutamic acid) and a
thiol-containing side-chain (e.g., cysteine), then the amino acid
block can have both zinc crosslinking and cysteine crosslinking
(dithiol). This sort of mixed crosslinked block is advantageous for
the delivery of therapeutic drugs to the cytosol of diseased cells
because a second stimuli must be present to allow for drug release.
For example, micelles possessing both carboxylic acid-zinc
crosslinking and cysteine dithiol crosslinking would be required to
enter an acidic environment (e.g. a tumor) and enter an environment
with a high concentration of glutathione (e.g. in the cell
cytoplasm). When L comprises an amine-containing side-chain (e.g.,
lysine or arginine) and a thiol-containing side-chain (e.g.,
cysteine), then the amino acid block can have both imine (e.g.
Schiff base) crosslinking and cysteine crosslinking (dithiol). The
zinc and ester crosslinked carboxylic acid functionality and the
imine (e.g. Schiff base) crosslinked amine functionality are
reversible in acidic organelles (i.e. endosomes, lysosome) while
disulfides are reduced in the cytosol by glutathione or other
reducing agents resulting in drug release exclusively in the
cytoplasm.
[0212] Exemplary R.sup.1 groups of any of formulae I, I-a, II, and
III are set forth in Table 8, below.
TABLE-US-00008 TABLE 8 Representative R.sup.1 Groups ##STR01503## a
##STR01504## b ##STR01505## c ##STR01506## d ##STR01507## e
##STR01508## f ##STR01509## g ##STR01510## h ##STR01511## i
##STR01512## j ##STR01513## k ##STR01514## l ##STR01515## m
##STR01516## n ##STR01517## o ##STR01518## p ##STR01519## q
##STR01520## r ##STR01521## s ##STR01522## t ##STR01523## u
##STR01524## v ##STR01525## w ##STR01526## x ##STR01527## y
##STR01528## z ##STR01529## aa ##STR01530## bb ##STR01531## cc
##STR01532## dd ##STR01533## ee ##STR01534## ff ##STR01535## gg
##STR01536## hh ##STR01537## ii ##STR01538## jj ##STR01539## kk
##STR01540## ll ##STR01541## mm ##STR01542## nn ##STR01543## oo
##STR01544## pp ##STR01545## qq ##STR01546## rr ##STR01547## ss
##STR01548## tt ##STR01549## uu ##STR01550## vv ##STR01551## ww
##STR01552## xx ##STR01553## yy ##STR01554## zz ##STR01555## aaa
##STR01556## bbb ##STR01557## ccc ##STR01558## ddd ##STR01559## eee
##STR01560## fff ##STR01561## ggg ##STR01562## hhh ##STR01563## iii
##STR01564## jjj ##STR01565## kkk ##STR01566## lll ##STR01567## mmm
##STR01568## nnn ##STR01569## ooo ##STR01570## ppp ##STR01571## qqq
##STR01572## rrr ##STR01573## sss ##STR01574## ttt ##STR01575## uuu
##STR01576## vvv ##STR01577## www ##STR01578## xxx ##STR01579## yyy
##STR01580## zzz
[0213] One of ordinary skill in the art would recognize that
certain R.sup.1 groups depicted in Tables 1-8 are protected groups,
e.g. protected amine, protected hydroxyl, protected thiol,
protected carboxylic acid, or protected alkyne groups. Each of
these protected groups is readily deprotected (see, for example,
Green). Accordingly, the deprotected groups corresponding to the
protected groups set forth in Table 8 are also contemplated.
According to another embodiment, the R.sup.1 group of any of
formulae I, I-a, II, and III is selected from a deprotected group
of Table 8.
[0214] Additional exemplary R.sup.1 groups of any of formulae I,
I-a, II, and III are set forth in Table 8a, below.
TABLE-US-00009 TABLE 8a Representative R.sup.1 Groups ##STR01581##
a ##STR01582## b ##STR01583## c ##STR01584## d ##STR01585## e
##STR01586## f ##STR01587## g ##STR01588## h ##STR01589## i
##STR01590## j ##STR01591## k ##STR01592## l ##STR01593## m
##STR01594## n ##STR01595## o ##STR01596## p ##STR01597## q
##STR01598## r ##STR01599## s ##STR01600## t ##STR01601## u
##STR01602## v ##STR01603## w ##STR01604## x ##STR01605## y
##STR01606## z ##STR01607## aa ##STR01608## bb ##STR01609## cc
##STR01610## dd ##STR01611## ee ##STR01612## ff ##STR01613## gg
##STR01614## hh ##STR01615## ii ##STR01616## jj ##STR01617## kk
##STR01618## ll ##STR01619## mm ##STR01620## nn ##STR01621## oo
##STR01622## pp ##STR01623## qq ##STR01624## rr ##STR01625## ss
##STR01626## tt ##STR01627## uu ##STR01628## vv ##STR01629## ww
##STR01630## xx ##STR01631## yy ##STR01632## zz ##STR01633## aaa
##STR01634## bbb ##STR01635## ccc ##STR01636## ddd ##STR01637## eee
##STR01638## fff ##STR01639## ggg ##STR01640## hhh ##STR01641## iii
##STR01642## jjj ##STR01643## kkk ##STR01644## lll ##STR01645## mmm
##STR01646## nnn ##STR01647## ooo ##STR01648## ppp ##STR01649## qqq
##STR01650## rrr ##STR01651## sss ##STR01652## ttt
[0215] In certain embodiments, the R.sup.1 group of any of formulae
I, I-a, II, and III is selected from any of those R.sup.1 groups
depicted in Table 8, supra. In other embodiments, the R.sup.1 group
of any of formulae I, I-a, II, and III is group k or l. In yet
other embodiments, the R.sup.1 group of any of formulae I, I-a, II,
and III is n, o, cc, dd, ee, ff, hh, h, ii, jj, ll, or uu. In still
other embodiments, the R.sup.1 group of any of formulae I, I-a, II,
and III is h, aa, yy, zz, or aaa.
[0216] According to another aspect of the present invention, the
R.sup.1 group of any of formulae I, I-a, II, and III is q, r, s, t,
www, xxx, or yyy.
[0217] Exemplary R.sup.2a groups of any of formulae I, I-a, II, and
III are set forth in Table 9, below.
TABLE-US-00010 TABLE 9 Representative R.sup.2a Groups ##STR01653##
i ##STR01654## ii ##STR01655## iii ##STR01656## iv ##STR01657## v
##STR01658## vi ##STR01659## vii ##STR01660## viii ##STR01661## ix
##STR01662## x ##STR01663## x ##STR01664## xi ##STR01665## xii
##STR01666## xiii ##STR01667## xiv ##STR01668## xv ##STR01669## xvi
##STR01670## xvii ##STR01671## xviii ##STR01672## xix ##STR01673##
xx ##STR01674## xxi ##STR01675## xxii ##STR01676## xxiii
##STR01677## xxiv ##STR01678## xxv ##STR01679## xxvi ##STR01680##
xxvii ##STR01681## xxviii ##STR01682## xxix ##STR01683## xxx
##STR01684## xxxi ##STR01685## xxxii ##STR01686## xxxiii
##STR01687## xxxiv ##STR01688## xxxv ##STR01689## xxxvi
##STR01690## xxxvii ##STR01691## xxxviii ##STR01692## xxxix
##STR01693## xl ##STR01694## xli ##STR01695## xlii ##STR01696##
xliii ##STR01697## xliv ##STR01698## xlv ##STR01699## xlvi
##STR01700## xlvii
[0218] In certain embodiments, the R.sup.2a group of any of
formulae I, I-a, II, and III is selected from any of those R.sup.2a
groups depicted in Table 9, supra. In other embodiments, the
R.sup.2a group of any of formulae I, I-a, II, and III is group v,
viii, xvi, xix, xxii, xxx, xxxi, xxxii, xxxiii, xxxiv, xxxv, xxxvi,
xxxvii, or xlii. In yet other embodiments, the R.sup.2a group of
any of formulae I, I-a, II, and III is xv, xviii, xx, xxi, xxxviii,
or xxxix. In certain embodiments, the R.sup.2a group of any of
formulae I, I-a, II, and III is xxxiv.
[0219] One of ordinary skill in the art would recognize that
certain R.sup.2a groups depicted in Table 9 are protected groups,
e.g. protected amine, protected hydroxyl, protected thiol,
protected carboxylic acid, or protected alkyne groups. Each of
these protected groups is readily deprotected (see, for example,
Green). Accordingly, the deprotected groups corresponding to the
protected groups set forth in Table 9 are also contemplated.
According to another embodiment, the R.sup.2a group of any of
formulae I, I-a, II, and III is selected from a deprotected group
of Table 9.
[0220] In certain embodiments, the present invention provides a
compound of any of formulae I, I-a, II, and III wherein each
variable is as defined herein or described in classes and
subclasses both singly and in combination.
[0221] C. Drug Loading
[0222] According to another aspect, the present invention provides
a drug-loaded micelle comprising a multiblock copolymer which
comprises a polymeric hydrophilic block, optionally a crosslinkable
or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed
poly(amino acid block), characterized in that said micelle has a
drug-loaded inner core, optionally a crosslinked outer core, and a
hydrophilic shell. As described herein, micelles of the present
invention are especially useful for encapsulating hydrophobic
therapeutic agents.
[0223] According to another embodiment, the present invention
provides a drug-loaded micelle comprising a multiblock copolymer of
formula I:
##STR01701##
wherein: [0224] n is 10-2500; [0225] m is 0 to 1000; [0226] m' is 2
to 1000; [0227] R.sup.x is a natural or unnatural amino acid
side-chain group that is capable of crosslinking; [0228] R.sup.y
forms a hydrophobic D,L-mixed poly(amino acid) block; [0229]
R.sup.1 is --Z(CH.sub.2CH.sub.2Y).sub.p(CH.sub.2).sub.tR.sup.3,
wherein: [0230] Z is --O--, --S--, --C.ident.C--, or --CH.sub.2--;
[0231] each Y is independently --O-- or --S--; [0232] p is 0-10;
[0233] t is 0-10; and [0234] R.sup.3 is hydrogen, --N.sub.3, --CN,
a mono-protected amine, a di-protected amine, a protected aldehyde,
a protected hydroxyl, a protected carboxylic acid, a protected
thiol, a 9-30 membered crown ether, or an optionally substituted
group selected from aliphatic, a 5-8 membered saturated, partially
unsaturated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, an 8-10 membered
saturated, partially unsaturated, or aryl bicyclic ring having 0-5
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or a detectable moiety; [0235] Q is a valence bond or a
bivalent, saturated or unsaturated, straight or branched
C.sub.1-1.sub.2 hydrocarbon chain, wherein 0-6 methylene units of Q
are independently replaced by -Cy-, --O--, --NH--, --S--,
--OC(O)--, --C(O)O--, --C(O)--, --SO--, --SO.sub.2--,
--NHSO.sub.2--, --SO.sub.2NH--, --NHC(O)--, --C(O)NH--,
--OC(O)NH--, or --NHC(O)O--, wherein: [0236] -Cy- is an optionally
substituted 5-8 membered bivalent, saturated, partially
unsaturated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, or an optionally
substituted 8-10 membered bivalent saturated, partially
unsaturated, or aryl bicyclic ring having 0-5 heteroatoms
independently selected from nitrogen, oxygen, or sulfur; [0237]
R.sup.2a is a mono-protected amine, a di-protected amine,
--N(R.sup.4).sub.2, --NR.sup.4C(O)R.sup.4,
--NR.sup.4C(O)N(R.sup.4).sub.2, --NR.sup.4C(O)OR.sup.4, or
--NR.sup.4SO.sub.2R.sup.4; and [0238] each R.sup.4 is independently
an optionally substituted group selected from hydrogen, aliphatic,
a 5-8 membered saturated, partially unsaturated, or aryl ring
having 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, an 8-10 membered saturated, partially
unsaturated, or aryl bicyclic ring having 0-5 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, or a
detectable moiety, or: [0239] two R.sup.4 on the same nitrogen atom
are taken together with said nitrogen atom to form an optionally
substituted 4-7 membered saturated, partially unsaturated, or aryl
ring having 1-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur.
[0240] Embodiments with respect to each of the R.sup.1, R.sup.2a,
Q, R.sup.x, R.sup.y, n, m, and m' groups of formula I, are as
described in various classes and subclasses, both singly and in
combination, herein.
[0241] In certain embodiments, the present invention provides a
drug-loaded micelle, as described herein, wherein the drug is
docetaxel or taxol.
[0242] In certain embodiments, the present invention provides a
drug-loaded micelle, as described herein, wherein the drug is
SN-38.
[0243] In certain embodiments, the present invention provides a
drug-loaded micelle, as described herein, wherein the drug is
irinotecan.
[0244] In certain embodiments, the present invention provides a
drug-loaded micelle, as described herein, wherein the drug is
letrozole.
[0245] In certain embodiments, the present invention provides a
drug-loaded micelle, as described herein, wherein the drug is
doxorubicin.
[0246] One of ordinary skill in the art will recognize that the
R.sup.2a moiety can interact with the encapsulated drug. In certain
embodiments, the R.sup.2a moiety is hydrophobic when the
encapsulated drug is hydrophobic. Such hydrophobic R.sup.2a groups
include linear and branched alkanes.
[0247] Without wishing to be bound by any particular theory, it is
believed that the accomodation of structurally diverse therapeutic
agents within a micelle of the present invention is effected by
adjusting the hydrophobic D,L-mixed poly(amino acid) block, i.e.,
the block comprising R.sup.y. As discussed above, the hydrophobic
mixture of D and L stereoisomers affords a poly(amino acid) block
with a random coil conformation thereby enhancing the encapsulation
of hydrophobic drugs.
[0248] In certain embodiments, micelles of the present invention
are loaded with a hydrophobic drug. In accordance with such
embodiments, R.sup.y forms a hydrophobic D,L-mixed amino acid
block. Such hydrophobic amino acid side-chain groups include a
suitably protected tyrosine side-chain, a suitably protected serine
side-chain, a suitably protected threonine side-chain,
phenylalanine, alanine, valine, leucine, tryptophan, proline,
benzyl and alkyl glutamates, or benzyl and alkyl aspartates, or
mixtures thereof. One of ordinary skill in the art would recognize
that protection of a polar or hydrophilic amino acid side-chain can
render that amino acid nonpolar. For example, a suitably protected
tyrosine hydroxyl group can render that tyrosine nonpolar and
hydrophobic by virtue of protecting the hydroxyl group. Suitable
protecting groups for the hydroxyl, amino, and thiol, and
carboxylate functional groups of R.sup.y are as described
herein.
[0249] In other embodiments, the R.sup.y group of formula I
comprises a mixture of D-hydrophobic and L-hydrophilic amino acid
side-chain groups such that the overall poly(amino acid) block
comprising R.sup.y is hydrophobic. Such mixtures of amino acid
side-chain groups include D-phenylalanine/L-tyrosine,
D-phenalanine/L-serine, D-benzyl glutamate/L-tyrosine, D-benzyl
glutamate/L-aspartic acid and the like. According to another
embodiment, R.sup.y is a hydrophobic amino acid side-chain group
selected from D-leucine, D-phenylalanine, D-alanine, D-benzyl
aspartate, or D-benzyl glutamate, and one or more of L-tyrosine,
L-cysteine, L-aspartic acid, L-glutamic acid, L-DOPA, L-histidine,
L-lysine, or L-omithine.
[0250] Hydrophobic small molecule drugs suitable for loading into
micelles of the present invention are well known in the art. In
certain embodiments, the present invention provides a drug-loaded
micelle as described herein, wherein the drug is a hydrophobic drug
selected from those described herein, infra.
[0251] In certain embodiments, the present invention provides a
drug-loaded micelle comprising a diblock copolymer of formula
I-a:
##STR01702##
wherein each of the R.sup.1, R.sup.2a, Q, R.sup.y, n, and m' groups
of formula I-a, are as described in various classes and subclasses,
both singly and in combination, herein.
[0252] In certain embodiments, the R.sup.y group of formula I-a
comprises a mixture of hydrophobic and hydrophilic amino acid
side-chain groups such that the overall poly(amino acid) block
comprising R.sup.y is hydrophobic. In other embodiments, R.sup.y
comprises a mixture of phenylalanine and tyrosine. In other
embodiments, R.sup.y comprises a mixture of benzyl glutamate and
aspartic acid. In yet other embodiments, R.sup.y comprises a
mixture of benzyl glutamate and glutamic acid. By way of example,
this particular copolymer is used to encapsulate one or more of
docetaxel, CPT, and paclitaxel in the hydrophobic of benzyl
glutamate/aspartic acid inner core. Although only sparingly soluble
in water, these drugs possess polar functionalities (e.g. amine,
alcohol, and phenols), which makes the incorporation of aspartic
acid, a polar amino acid, advantageous for effective encapsulation.
By utilizing this particular core composition, relatively high
docetaxel, CPT, and paclitaxel loadings are achieved.
[0253] In certain embodiments, the present invention provides a
micelle comprising a compound of formula I-a characterized in that
docetaxel, CPT, and paclitaxel are encapsulated in the hydrophobic
benzyl glutamate/aspartic acid inner core. In still other
embodiments, m' is 10-50 repeat units. In certain embodiments, the
phenylalanine/tyrosine ratio of m' is 4:1. In other embodiments the
the phenylalanine/tyrosine ratio of m' is 9:1. In still other
embodiments, the benzyl glutamate/aspartic acid ratio of m' is 3:1.
In other embodiments, R.sup.y comprises 4-8 asapartic acid repeat
units and 20-32 benzyl glutamate. In still other embodiments,
R.sup.y comprises 2-40 tyrosine and 10-100 benzyl glutamate repeat
units.
[0254] In other embodiments, the present invention provides a
drug-loaded micelle comprising a multiblock copolymer of formula
II:
##STR01703##
wherein each of the R.sup.1, R.sup.2a, Q, R.sup.x, R.sup.y, n, m,
and m' groups of formula II, are as described in various classes
and subclasses, both singly and in combination, herein.
[0255] In still other embodiments, the present invention provides a
drug-loaded micelle comprising a multiblock copolymer of formula
III:
##STR01704##
wherein each of the R.sup.1, R.sup.2a, Q, R.sup.x, R.sup.y, n, m,
L, and m' groups of formula III, are as described in various
classes and subclasses, both singly and in combination, herein.
[0256] In other embodiments, the R.sup.y group of formula III
comprises a mixture of D-hydrophobic and L-hydrophilic amino acid
side-chain groups such that the overall poly(amino acid) block
comprising R.sup.y is hydrophobic. Such mixtures of amino acid
side-chain groups include D-phenylalanine/L-tyrosine,
D-phenalanine/L-serine, D-benzyl glutamate/L-tyrosine, D-benzyl
glutamate/L-aspartic acid and the like. According to another
embodiment, R.sup.y is a hydrophobic amino acid side-chain group
selected from D-leucine, D-phenylalanine, D-alanine, D-benzyl
aspartate, or D-benzyl glutamate, and one or more of L-tyrosine,
L-cysteine, L-aspartic acid, L-glutamic acid, L-DOPA, L-histidine,
L-lysine, or L-omithine.
[0257] In certain embodiments, the present invention provides a
micelle comprising a compound of formula III characterized in that
docetaxel, doxorubicin, CPT, and paclitaxel are encapsulated in the
hydrophobic phenylalanine/tyrosine inner core and the poly(aspartic
acid) outer core is crosslinked with zinc. In certain embodiments,
m and m' add up to about 30 to about 60. In still other
embodiments, m is 1-20 repeat units and m' is 10-50 repeat units.
In certain embodiments, the phenylalanine/tyrosine ratio of m' is
4:1. In other embodiments the the phenylalanine/tyrosine ratio of
m' is 9:1. In still other embodiments, the phenylalanine/tyrosine
ratio of m' is 3:1. In other embodiments, R.sup.y comprises 4-8
tyrosine repeat units and 20-32 phenylalanine. In still other
embodiments, R.sup.y comprises 2-40 tyrosine and 10-100
phenylalanine repeat units.
[0258] Hydrophobic small molecule drugs suitable for loading into
micelles of the present invention are well known in the art. In
certain embodiments, the present invention provides a drug-loaded
micelle as described herein, wherein the drug is a hydrophobic drug
selected from analgesics, anti-inflammatory agents,
antihelminthics, anti-arrhythmic agents, anti-bacterial agents,
anti-viral agents, anti-coagulants, anti-depressants,
anti-diabetics, anti-epileptics, anti-fungal agents, anti-gout
agents, anti-hypertensive agents, anti-malarials, anti-migraine
agents, anti-muscarinic agents, anti-neoplastic agents, erectile
dysfunction improvement agents, immunosuppressants, anti-protozoal
agents, anti-thyroid agents, anxiolytic agents, sedatives,
hypnotics, neuroleptics, .beta.-blockers, cardiac inotropic agents,
corticosteroids, diuretics, anti-parkinsonian agents,
gastro-intestinal agents, histamine receptor antagonists,
keratolyptics, lipid regulating agents, anti-anginal agents, Cox-2
inhibitors, leukotriene inhibitors, macrolides, muscle relaxants,
nutritional agents, opiod analgesics, protease inhibitors, sex
hormones, stimulants, muscle relaxants, anti-osteoporosis agents,
anti-obesity agents, cognition enhancers, anti-urinary incontinence
agents, anti-benign prostate hypertrophy agents, essential fatty
acids, non-essential fatty acids, and mixtures thereof.
[0259] In other embodiments, the hydrophobic drug is selected from
one or more analgesics, anti-bacterial agents, anti-viral agents,
anti-inflammatory agents, anti-depressants, anti-diabetics,
anti-epileptics, anti-hypertensive agents, anti-migraine agents,
immunosuppressants, anxiolytic agents, sedatives, hypnotics,
neuroleptics, .beta.-blockers, gastro-intestinal agents, lipid
regulating agents, anti-anginal agents, Cox-2 inhibitors,
leukotriene inhibitors, macrolides, muscle relaxants, opioid
analgesics, protease inhibitors, sex hormones, cognition enhancers,
anti-urinary incontinence agents, and mixtures thereof.
[0260] According to one aspect, the present invention provides a
micelle, as described herein, loaded with a hydrophobic drug
selected from any one or more of a Exemestance (aromasin),
Camptosar (irinotecan), Ellence (epirubicin), Femara (Letrozole),
Gleevac (imatinib mesylate), Lentaron (formestane),
Cytadren/Orimeten (aminoglutethimide), Temodar, Proscar
(finasteride), Viadur (leuprolide), Nexavar (Sorafenib), Kytril
(Granisetron), Taxotere (Docetaxel), Taxol (paclitaxel), Kytril
(Granisetron), Vesanoid (tretinoin) (retin A), XELODA
(Capecitabine), Arimidex (Anastrozole), Casodex/Cosudex
(Bicalutamide), Faslodex (Fulvestrant), Iressa (Gefitinib),
Nolvadex, Istubal, Valodex (tamoxifen citrate), Tomudex
(Raltitrexed), Zoladex (goserelin acetate), Leustatin (Cladribine),
Velcade (bortezomib), Mylotarg (gemtuzumab ozogamicin), Alimta
(pemetrexed), Gemzar (gemcitabine hydrochloride), Rituxan
(rituximab), Revlimid (lenalidomide), Thalomid (thalidomide),
Alkeran (melphalan), and derivatives thereof.
[0261] D. Polymer Conjugation
[0262] In addition to their core-shell morphology, polymer micelles
can be modified to enable passive and active cell-targeting to
maximize the benefits of current and future therapeutic agents.
Because drug-loaded micelles typically possess diameters greater
than 20 nm, they exhibit dramatically increased circulation time
when compared to stand-alone drugs due to minimized renal
clearance. This unique feature of nanovectors and polymeric drugs
leads to selective accumulation in diseased tissue, especially
cancerous tissue due to the enhanced permeation and retention
effect ("EPR"). The EPR effect is a consequence of the disorganized
nature of the tumor vasculature, which results in increased
permeability of polymer therapeutics and drug retention at the
tumor site. In addition to passive cell targeting by the EPR
effect, micelles are designed to actively target tumor cells
through the chemical attachment of targeting groups to the micelle
periphery. The incorporation of such groups is most often
accomplished through end-group functionalization of the hydrophilic
block using chemical conjugation techniques. Like viral particles,
micelles functionalized with targeting groups utilize
receptor-ligand interactions to control the spatial distribution of
the micelles after administration, further enhancing cell-specific
delivery of therapeutics. In cancer therapy, targeting groups are
designed to interact with receptors that are over-expressed in
cancerous tissue relative to normal tissue such as folic acid,
oligopeptides, sugars, and monoclonal antibodies. See Pan, D.;
Turner, J. L.; Wooley, K. L. Chem. Commun. 2003, 2400-2401;
Gabizon, A.; Shmeeda, H.; Horowitz, A. T.; Zalipsky, S. Adv. Drug
Deliv. Rev. 2004, 56, 1177-1202; Reynolds, P. N.; Dmitriev, I.;
Curiel, D. T. Vector. Gene Ther. 1999, 6, 1336-1339; Derycke, A. S.
L.; Kamuhabwa, A.; Gijsens, A.; Roskams, T.; De Vos, D.; Kasran,
A.; Huwyler, J.; Missiaen, L.; de Witte, P. A. M. T J. Nat. Cancer
Inst. 2004, 96, 1620-30; Nasongkla, N., Shuai, X., Ai, H.;
Weinberg, B. D. P., J.; Boothman, D. A.; Gao, J. Angew. Chem. Int.
Ed. 2004, 43, 6323-6327; Jule, E.; Nagasaki, Y.; Kataoka, K.
Bioconj. Chem. 2003, 14, 177-186; Stubenrauch, K.; Gleiter, S.;
Brinkmann, U.; Rudolph, R.; Lilie, H. Biochem. J. 2001, 356,
867-873; Kurschus, F. C.; Kleinschmidt, M.; Fellows, E.; Dornmair,
K.; Rudolph, R.; Lilie, H.; Jenne, D. E. FEBS Lett. 2004, 562,
87-92; and Jones, S. D.; Marasco, W. A. Adv. Drug Del. Rev. 1998,
31, 153-170.
[0263] Compounds of any of formulae I, I-a, II, and III having
R.sup.3 moieties suitable for Click chemistry are useful for
conjugating said compounds to biological systems or macromolecules
such as proteins, viruses, and cells, to name but a few. The Click
reaction is known to proceed quickly and selectively under
physiological conditions. In contrast, most conjugation reactions
are carried out using the primary amine functionality on proteins
(e.g. lysine or protein end-group). Because most proteins contain a
multitude of lysines and arginines, such conjugation occurs
uncontrollably at multiple sites on the protein. This is
particularly problematic when lysines or arginines are located
around the active site of an enzyme or other biomolecule. Thus,
another embodiment of the present invention provides a method of
conjugating the R.sup.1 groups of a compound of any of formulae I,
I-a, II, and III to a macromolecule via Click chemistry. Yet
another embodiment of the present invention provides a
macromolecule conjugated to a compound of any of formulae I, I-a,
II, and III via the R.sup.1 group.
[0264] After incorporating the poly (amino acid) block portions
into the multi-block coploymer of the present invention resulting
in a multi-block copolymer of the form W-X-X, the other end-group
functionality, corresponding to the R.sup.1 moiety of any of
formulae I, I-a, II, and III, can be used to attach targeting
groups for cell specific delivery including, but not limited to,
attach targeting groups for cell specific delivery including, but
not limited to, proteins, oliogopeptides, antibodies,
monosaccarides, oligosaccharides, vitamins, or other small
biomolecules. Such targeting groups include, but or not limited to
monoclonal and polyclonal antibodies (e.g. IgG, IgA, IgM, IgD, IgE
antibodies), sugars (e.g. mannose, mannose-6-phosphate, galactose),
proteins (e.g. Transferrin), oligopeptides (e.g. cyclic and acylic
RGD-containing oligopedptides), and vitamins (e.g. folate).
Alternatively, the R.sup.1 moiety of any of formulae I, I-a, II,
and III is bonded to a biomolecule, drug, cell, or other suitable
substrate.
[0265] In other embodiments, the R.sup.1 moiety of any of formulae
I, I-a, II, and III is bonded to biomolecules which promote cell
entry and/or endosomal escape. Such biomolecules include, but are
not limited to, oligopeptides containing protein transduction
domains such as the HIV Tat peptide sequence (GRKKRRQRRR) or
oligoarginine (RRRRRRRRR). Oligopeptides which undergo
conformational changes in varying pH environments such
oligohistidine (HHHHH) also promote cell entry and endosomal
escape.
[0266] In other embodiments, the R.sup.1 moiety of any of formulae
I, I-a, II, and III is bonded to detectable moieties, such as
fluorescent dyes or labels for positron emission tomography
including molecules containing radioisotopes (e.g. .sup.18F) or
ligands with bound radioactive metals (e.g. .sup.62Cu). In other
embodiments, the R.sup.1 moiety of any of formulae I, I-a, II, and
III is bonded to a contrast agents for magnetic resonance imaging
such as gadolinium, gadolinium chelates, or iron oxide (e.g
Fe.sub.3O.sub.4 and Fe.sub.2O.sub.3) particles. In other
embodiments, the R.sup.1 moiety of any of formulae I, I-a, II, and
III is bonded to a semiconducting nanoparticle such as cadmium
selenide, cadmium sulfide, or cadmium telluride or bonded to other
metal nanoparticles such as colloidal gold. In other embodiments,
the R.sup.1 moiety of any of formulae I, I-a, II, and III is bonded
to natural or synthetic surfaces, cells, viruses, dyes, drugs,
chelating agents, or used for incorporation into hydrogels or other
tissue scaffolds.
[0267] In one embodiment, the R.sup.1 moiety of any of formulae I,
I-a, II, and III is an alkyne or a terminal alkyne derivative which
is capable of undergoing [3+2] cycloaddition reactions with
complementary azide-bearing molecules and biomolecules. In another
embodiment, the R.sup.1 moiety of any of formulae I, I-a, II, and
III is an azide or an azide derivative which is capable of
undergoing [3+2]cycloaddition reactions with complementary
alkyne-bearing molecules and biomolecules (i.e. click
chemistry).
[0268] Click chemistry has become a popular method of
bioconjugation due to its high reactivity and selectivity, even in
biological media. See Kolb, H. C.; Finn, M. G.; Sharpless, K. B.
Angew. Chem. Int. Ed. 2001, 40, 2004-2021; and Wang, Q.; Chan, T.
R.; Hilgraf, R.; Fokin, V. V.; Sharpless, K. B.; Finn, M. G. J. Am.
Chem. Soc. 2003, 125, 3192-3193. In addition, currently available
recombinant techniques permit the introduction of azides and
alkyne-bearing non-canonical amino acids into proteins, cells,
viruses, bacteria, and other biological entities that consist of or
display proteins. See Link, A. J.; Vink, M. K. S.; Tirrell, D. A.
J. Am. Chem. Soc. 2004, 126, 10598-10602; Deiters, A.; Cropp, T.
A.; Mukherji, M.; Chin, J. W.; Anderson, C.; Schultz, P. G. J. Am.
Chem. Soc. 2003, 125, 11782-11783.
[0269] In another embodiment, the [3+2]cycloaddition reaction of
azide or acetylene-bearing nanovectors and complimentary azide or
acetylene-bearing biomolecules are transition metal catalyzed.
Copper-containing molecules which catalyze the "click" reaction
include, but are not limited to, copper bromide (CuBr), copper
chloride (CuCl), copper sulfate (CuSO.sub.4), copper iodide (CuI),
[Cu(MeCN).sub.4](OTf), and [Cu(MeCN).sub.4](PF.sub.6). Organic and
inorganic metal-binding ligands can be used in conjunction with
metal catalysts and include, but are not limited to, sodium
ascorbate, tris(triazolyl)amine ligands,
tris(carboxyethyl)phosphine (TCEP), and sulfonated
bathophenanthroline ligands.
[0270] In another embodiment, the R.sup.1 moiety of any of formulae
I, I-a, II, and III is an hydrazine or hydrazide derivative which
is capable of undergoing reaction with biomolecules containing
aldehydes or ketones to form hydrazone linkages. In another
embodiment, the R.sup.1 moiety of any of formulae I, I-a, II, and
III is an aldehyde or ketone derivative which is capable of
undergoing reaction with biomolecules containing a hydrazine or
hydrazide derivative to form hydrazone linkages.
[0271] In another embodiment, the R.sup.1 moiety of any of formulae
I, I-a, II, and III is a hydroxylamine derivative which is capable
of undergoing reaction with biomolecules containing aldehydes or
ketones. In another embodiment, the R.sup.1 moiety of any of
formulae I, I-a, II, and III is an aldehyde or ketone which is
capable of undergoing reaction with biomolecules containing a
hydroxylamine, or a hydroxylamine derivative.
[0272] In yet another embodiment, the R.sup.1 moiety of any of
formulae I, I-a, II, and III is an aldehyde or ketone derivative
which is capable of undergoing reaction with biomolecules
containing primary or secondary amines to form imine linkages. In
another embodiment, the R.sup.1 moiety of any of formulae I, I-a,
II, and III is a primary or secondary amine which is capable of
undergoing reaction with biomolecules containing an aldehyde or
ketone functionality to form imine linkages. It will be appreciated
that imine linkages can be further converted to stable amine
linkages by treatment with a suitable reducing agent (e.g. lithium
aluminum hydride, sodium borohydride, sodium cyanoborohydride,
etc.)
[0273] In yet another embodiment, the R.sup.1 moiety of any of
formulae I, I-a, II, and III is an amine (primary or secondary) or
alcohol which is capable of undergoing reaction with biomolecules
containing activated esters (e.g. 4-nitrophenol ester,
N-hydroxysuccinimide, pentafluorophenyl ester,
ortho-pyridylthioester), to form amide or ester linkages. In still
other embodiments, the R.sup.1 moiety of any of formulae I, I-a,
II, and III is an activated ester which is capable of undergoing
reaction with biomolecules possessing amine (primary or secondary)
or alcohols to form amide or ester linkages.
[0274] In still other embodiments, the R.sup.1 moiety of any of
formulae I, I-a, II, and III is an amine or alcohol which is bound
to biomolecules with carboxylic acid functionality using a suitable
coupling agent. In still other embodiments, the R.sup.1 moiety of
any of formulae I, I-a, II, and III is a carboxylic acid
functionality which is bound to biomolecules containing amine or
alcohol functionality using a suitable coupling agent. Such
coupling agents include, but are not limited to, carbodiimides
(e.g. 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC),
diisopropyl carbodiimide (DIC), dicyclohexyl carbodiimide (DCC)),
aminium or phosphonium derivatives (e.g. PyBOP, PyAOP, TBTU, HATU,
HBTU), or a combination of 1-hydroxybenzotriazole (HOBt) and a
aminium or phosphonium derivative.
[0275] In another embodiment, the R.sup.1 moiety of any of formulae
I, I-a, II, and III is an electrophile such as maleimide, a
maleimide derivative, or a bromoacetamide derivative, which is
capable of reaction with biomolecules containing thiols or amines.
In another embodiment, the R.sup.1 moiety of any of formulae I,
I-a, II, and III is a nucleophile such as an amine or thiol which
is capable or reaction with biomolecules containing electrophilic
functionality such as maleimide, a maleimide derivative, or a
bromoacetamide derivative.
[0276] In still other embodiments, the R.sup.1 moiety of any of
formulae I, I-a, II, and III is a ortho-pyridyl disulfide moiety
which undergoes disulfide exchange with biomolecules containing
thiol functionality. In still other embodiments, the R.sup.1 moiety
of any of formulae I, I-a, II, and III is a thiol or thiol
derivative which undergoes disulfide exchange with biomolecules
containing ortho-pyridyl disulfide functionality. It will be
appreciated that such exchange reactions result in a disulfide
linkage which is reversible in the presence of a suitable reducing
agent (e.g. glutathione, dithiothreitol (DTT), etc.).
[0277] In certain embodiments, micelles of the present invention
are mixed micelles comprising one or more compounds of formula I,
I-a, II, or III. It will be appreciated that mixed micelles having
different R.sup.1 groups, as described herein, can be conjugated to
multiple other compounds and/or macromolecules. For example, a
mixed micelle of the present invention can have one R.sup.1 group
suitable for Click chemistry and another R.sup.1 group suitable for
covalent attachment via a variety of coupling reacions. Such a
mixed micelle can be conjugated to different compounds and/or
macromolecules via these different R.sup.1 groups. Such conjugation
reactions are well known to one of ordinary skill in the art and
include those described herein.
4. General Methods for Providing Compounds of the Present
Invention
[0278] Multiblock copolymers of the present invention are prepared
by methods known to one of ordinary skill in the art and those
described in detail in U.S. patent application Ser. No. 11/325,020
filed Jan. 4, 2006 and published as US 20060172914 on Aug. 3, 2006,
the entirety of which is hereby incorporated herein by reference.
Generally, such multiblock copolymers are prepared by sequentially
polymerizing one or more cyclic amino acid monomers onto a
hydrophilic polymer having a terminal amine salt wherein said
polymerization is initiated by said amine salt. In certain
embodiments, said polymerization occurs by ring-opening
polymerization of the cyclic amino acid monomers. In other
embodiments, the cyclic amino acid monomer is an amino acid NCA,
lactam, or imide.
##STR01705##
[0279] Scheme 6 above depicts a general method for preparing
multiblock polymers of the present invention. A macroinitiator of
formula A is treated with a first amino acid NCA to form a compound
of formula B having a first amino acid block. The second amino acid
NCA is added to the living polymer of formula B to form a compound
of formula I' having two differing amino acid blocks. Each of the
R.sup.1, A, n, Q, R.sup.x, R.sup.y, m, and m' groups depicted in
Scheme 6 are as defined and described in classes and subclasses,
singly and in combination, herein.
[0280] One step in the preparation of a compound of formula I
comprises terminating the living polymer chain-end of the compound
of formula I' with a suitable polymerization terminator to afford a
compound of formula I. One of ordinary skill in the art would
recognize that the polymerization terminator provides the R.sup.2a
group of formula I. Accordingly, embodiments directed to the
R.sup.2a group of formula I as set forth above and herein, are also
directed to the suitable polymerization terminator itself, and
similarly, embodiments directed to the suitable polymerization
terminator, as set forth above and herein, are also directed to the
R.sup.2a group of formula I.
[0281] As described above, compounds of formula I are prepared from
compounds of formula I' by treatment with a suitable terminating
agent. One of ordinary skill in the art would recognize that
compounds of formula I are also readily prepared directly from
compounds of formula I. In such cases, and in certain embodiments,
the compound of formula I' is treated with a base to form the
freebase compound prior to, or concurrent with, treatment with the
suitable terminating agent. For example, it is contemplated that a
compound of formula I' is treated with a base and suitable
terminating agent in the same reaction to form a freebase of that
compound. In such cases, it is also contemplated that the base may
also serve as the reaction medium.
[0282] One of ordinary skill in the art would also recognize that
the above method for preparing a compound of formula I may be
performed as a "one-pot" synthesis of compounds of formula I that
utilizes the living polymer chain-end to incorporate the R.sup.2
group of formula I. Alternatively, compounds of formula I may also
be prepared in a multi-step fashion. For example, the living
polymer chain-end of a compound of formula I' may be quenched to
afford an amino group which may then be further derivatized,
according to known methods, to afford a compound of formula I.
[0283] One of ordinary skill in the art will recognize that a
variety of polymerization terminating agents are suitable for the
present invention. Such polymerization terminating agents include
any R.sup.2a-containing group capable of reacting with the living
polymer chain-end of a compound of formula I', or the free-based
amino group of formula I', to afford a compound of formula I. Thus,
polymerization terminating agents include anhydrides, and other
acylating agents, and groups that contain a suitable leaving group
LG that is subject to nucleophilic displacement.
[0284] Alternatively, compounds of formula I' may be coupled to
carboxylic acid-containing groups to form an amide thereof. Thus,
it is contemplated that the amine group of formula I' or freease
thereof, may be coupled with a carboxylic acid moiety to afford
compounds of formula I wherein R.sup.2a is --NHC(O)R.sup.4. Such
coupling reactions are well known in the art. In certain
embodiments, the coupling is achieved with a suitable coupling
reagent. Such reagents are well known in the art and include, for
example, DCC and EDC, among others. In other embodiments, the
carboxylic acid moiety is activated for use in the coupling
reaction. Such activation includes formation of an acyl halide, use
of a Mukaiyama reagent, and the like. These methods, and others,
are known to one of ordinary skill in the art, e.g., see, "Advanced
Organic Chemistry," Jerry March, 5.sup.th Ed., pp. 351-357, John
Wiley and Sons, N.Y.
[0285] A "suitable leaving group that is subject to nucleophilic
displacement" is a chemical group that is readily displaced by a
desired incoming chemical moiety. Suitable leaving groups are well
known in the art, e.g., see, March. Such leaving groups include,
but are not limited to, halogen, alkoxy, sulphonyloxy, optionally
substituted alkylsulphonyloxy, optionally substituted
alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, and
diazonium moieties. Examples of suitable leaving groups include
chloro, iodo, bromo, fluoro, methanesulfonyloxy (mesyloxy),
tosyloxy, triflyloxy, nitro-phenylsulfonyloxy (nosyloxy), and
bromo-phenylsulfonyloxy (brosyloxy).
[0286] According to an alternate embodiment, the suitable leaving
group may be generated in situ within the reaction medium. For
example, a leaving group may be generated in situ from a precursor
of that compound wherein said precursor contains a group readily
replaced by said leaving group in situ.
[0287] Alternatively, when the R.sup.2a group of formula I is a
mono- or di-protected amine, the protecting group(s) is removed and
that functional group may be derivatized or protected with a
different protecting group. It will be appreciated that the removal
of any protecting group of the R.sup.2a group of formula I is
performed by methods suitable for that protecting group. Such
methods are described in detail in Green.
[0288] In other embodiments, the R.sup.2a group of formula I is
incorporated by derivatization of the amino group of formula I', or
freebase thereof, via anhydride coupling, optionally in the
presence of base as appropriate. One of ordinary skill in the art
would recognize that anhydride polymerization terminating agents
containing an azide, an aldehyde, a hydroxyl, an alkyne, and other
groups, or protected forms thereof, may be used to incorporate said
azide, said aldehyde, said protected hydroxyl, said alkyne, and
other groups into the R.sup.2a group of compounds of formula I. It
will also be appreciated that such anhydride polymerization
terminating agents are also suitable for terminating the living
polymer chain-end of a compound of formula I', or freebase thereof.
Such anhydride polymerization terminating agents include, but are
not limited to, those set forth in Table 10 below.
TABLE-US-00011 TABLE 10 Representative Anhydride Polymerization
Terminating Agents ##STR01706## A-1 ##STR01707## A-2 ##STR01708##
A-3 ##STR01709## A-4 ##STR01710## A-5 ##STR01711## A-6 ##STR01712##
A-7 ##STR01713## A-8 ##STR01714## A-9 ##STR01715## A-10
##STR01716## A-11 ##STR01717## A-12 ##STR01718## A-13 ##STR01719##
A-14 ##STR01720## A-15 ##STR01721## A-16
[0289] In other embodiments, the R.sup.4 moiety of the R.sup.2a
group of formula III is incorporated by derivatization of the amino
group of formula I', or freebase thereof, via reaction with a
polymerization terminating agent having a suitable leaving group.
It will also be appreciated that such polymerization terminating
agents are also suitable for terminating the living polymer
chain-end of a compound of formula I', or freebase thereof.
Examples of these polymerization terminating agents include, but
are not limited to, those set forth in Table 11, below.
TABLE-US-00012 TABLE 11 Representative Polymerization Terminating
Agents ##STR01722## L-1 ##STR01723## L-2 ##STR01724## L-3
##STR01725## L-4 ##STR01726## L-5 ##STR01727## L-6 ##STR01728## L-7
##STR01729## L-8 ##STR01730## L-9 ##STR01731## L-10 ##STR01732##
L-11 ##STR01733## L-12 ##STR01734## L-13 ##STR01735## L-14
##STR01736## L-15 ##STR01737## L-16 ##STR01738## L-17 ##STR01739##
L-18 ##STR01740## L-19 ##STR01741## L-20 ##STR01742## L-21
##STR01743## L-22 ##STR01744## L-23 ##STR01745## L-24 ##STR01746##
L-25 ##STR01747## L-26 ##STR01748## L-27 ##STR01749## L-28
##STR01750## L-29 ##STR01751## L-30 ##STR01752## L-31 ##STR01753##
L-32 ##STR01754## L-33 ##STR01755## L-34 ##STR01756## L-35
##STR01757## L-36 ##STR01758## L-37 ##STR01759## L-38 ##STR01760##
L-39 ##STR01761## L-40 ##STR01762## L-41 ##STR01763## L-42
wherein each L is a suitable leaving group as defined above and in
classes and subclasses as described above and herein.
[0290] In certain embodiments, the hydrophilic polymer block is
poly(ethylene glycol) (PEG) having a terminal amine salt ("PEG
macroinitiator"). This PEG macroinitiator initiates the
polymerization of NCAs to provide the multiblock copolymers of the
present invention. Such polymers having a terminal amine salt may
be prepared from synthetic polymers having a terminal amine. Such
synthetic polymers having a terminal amine group are known in the
art and include PEG-amines. PEG-amines may be obtained by the
deprotection of a suitably protected PEG-amine. Preparation of such
suitably protected PEG-amines, and methods of deprotecting the
same, is described in detail in U.S. patent application Ser. No.
11/256,735, filed Oct. 24, 2005 and published as US 20060142506 on
Jun. 29, 2006, the entirety of which is hereby incorporated herein
by reference.
[0291] As described in US 20060142506, suitably protected
PEG-amines may be formed by terminating the living polymer chain
end of a PEG with a terminating agent that contains a suitably
protected amine. The suitably protected amine may then be
deprotected to generate a PEG that is terminated with a free amine
that may subsequently be converted into the corresponding PEG-amine
salt macroinitiator. In certain embodiments, the PEG-amine salt
macroinitiator of the present invention is prepared directly from a
suitably protected PEG-amine by deprotecting said protected amine
with an acid. Accordingly, in other embodiments, the terminating
agent has suitably protected amino group wherein the protecting
group is acid-labile.
[0292] Alternatively, suitable synthetic polymers having a terminal
amine salt may be prepared from synthetic polymers that contain
terminal functional groups that may be converted to amine salts by
known synthetic routes. In certain embodiments, the conversion of
the terminal functional groups to the amine salts is conducted in a
single synthetic step. In other embodiments, the conversion of the
terminal functional groups to the amine salts is achieved by way of
a multi-step sequence. Functional group transformations that afford
amines, amine salts, or protected amines are well known in the art
and include those described in Larock, R.C., "Comprehensive Organic
Transformations," John Wiley & Sons, New York, 1999.
##STR01764##
[0293] Scheme 7 above shows one exemplary method for preparing the
bifunctional PEGs used to prepare the multiblock copolymers of the
present invention. At step (a), the polymerization initiator is
treated with a suitable base to form D. A variety of bases are
suitable for the reaction at step (a). Such bases include, but are
not limited to, potassium naphthalenide, diphenylmethyl potassium,
triphenylmethyl potassium, and potassium hydride. At step (b), the
resulting anion is treated with ethylene oxide to form the polymer
E. Polymer E can be transformed at step (d) to a compound of
formula A directly by terminating the living polymer chain-end of E
with a suitable polymerization terminator to afford a compound of
formula A. Alternatively, polymer E may be quenched at step (c) to
form the hydroxyl compound F. Compound F is then derivatized to
afford a compound of formula A by methods known in the art,
including those described herein. Each of the R, A, n, and Q groups
depicted in Scheme 7 are as defined and described in classes and
subclasses, singly and in combination, herein.
[0294] Although certain exemplary embodiments are depicted and
described above and herein, it will be appreciated that compounds
of the invention can be prepared according to the methods described
generally above using appropriate starting materials by methods
generally available to one of ordinary skill in the art. Additional
embodiments are exemplified in more detail herein.
[0295] Methods of preparing micelles are known to one of ordinary
skill in the art. Micelles can be prepared by a number of different
dissolution methods. In the direct dissolution method, the block
copolymer is added directly to an aqueous medium with or without
heating and micelles are spontaneously formed up dissolution. The
dialysis method is often used when micelles are formed from poorly
aqueous soluble copolymes. The copolymer is dissolved in a water
miscible organic solvent such as N-methyl pyrollidinone,
dimethylformamide, dimethylsulfoxide, tetrahydrofuran, or
dimethylacetamide, and this solution is then dialyzed against water
or another aqueous medium. During dialysis, micelle formation is
induced and the organic solvent is removed. Alternatively, the
block copolymer can be dissolved in in a water miscible organic
solvent such as N-methyl pyrollidinone, dimethylformamide,
dimethylsulfoxide, tetrahydrofuran, or dimethylacetamide and added
dropwise to water or another aqueous medium. The micelles can then
be isolated by filtration or lyophilization.
[0296] Emulsification methods can also be employed for micelle
formation. For example, the block copolymer is dissolved in a
water-immiscible, volatile solvent (e.g. dichloromethane) and added
to water with vigorous agitation. As the solvent is removed by
evaporation, micelles spontaneously form. Prepared micelles can
then be filtered and isolated by lyophilization.
[0297] In one embodiment, drug-loaded miclles possessing carboxylic
acid functionality in the outer core are crosslinked by addition of
zinc chloride to the micelle solution along with a small amount of
sodium hydroxide to neutralize any hydrochloric acid by-product. In
this basic pH environment, the reaction of zinc chloride with the
poly(aspartic acid) crosslinking block should be rapid and
irreversible.
[0298] In another embodiment, drug loaded micelles possessing amine
functionality in the outer core are crosslinked by the addition of
a bifunctional, or multi-functional aldehyde-containing molecule
which forms pH-reversible imine crosslinks. In another embodiment,
drug loaded micelles possessing aldehyde functionality in the outer
core are crosslinked by the addition of a bifunctional, or
multi-functional amine-containing molecule which forms
pH-reversible imine crosslinks.
[0299] In another embodiment, drug loaded micelles possessing
alcohol or amine functionality in the outer core are crosslinked by
the addition of a bifunctional, or multi-functional carboxylic
acid-containing molecules and a coupling agent to form amide or
ester crosslinks. In yet another embodiment, drug loaded micelles
possessing carboxylic acid functionality in the outer core are
crosslinked by the addition of a bifunctional, or multi-functional
amine or alcohol-containing molecules and a coupling agent to form
amide or ester crosslinks. Such coupling agents include, but are
not limited to, carbodiimides (e.g.
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), diisopropyl
carbodiimide (DIC), dicyclohexyl carbodiimide (DCC)), aminium or
phosphonium derivatives (e.g. PyBOP, PyAOP, TBTU, HATU, HBTU), or a
combination of 1-hydroxybenzotriazole (HOBt) and a aminium or
phosphonium derivative.
[0300] In another embodiment, drug loaded micelles possessing
aldehyde or ketone functionality in the outer core are crosslinked
by the addition of a bifunctional, or multifunctional hydrazine or
hydrazide-containing molecule to form pH-reversible hydrazone
crosslinks. In still other embodiments, drug loaded micelles
hydrazine or hydrazide-functionality in the outer core are
crosslinked by the addition of a bifunctional, or multifunctional
aldehyde or ketone-containing molecule to form pH-reversible
hydrazone crosslinks.
[0301] In another embodiment, drug loaded micelles possessing thiol
functionality in the outer core are crosslinked by the addition of
an oxidizing agent (e.g. metal oxides, halogens, oxygen, peroxides,
ozone, peroxyacids, etc.) to form disulfide crosslinks. It will be
appreciated that disulfide crosslinks are reversible in the
presence of a suitable reducing agent (e.g. glutathione,
dithiothreitol (DTT), etc.).
[0302] In yet another embodiment, drug loaded micelles possessing
both carboxylic acid and thiol functionality in the outer core can
be dual crosslinked by the addition of an oxidizing agent (e.g.
metal oxides, halogens, oxygen, peroxides, ozone, peroxyacids,
etc.) to form disulfide crosslinks followed by the addition of zinc
chloride to the micelle solution along with a small amount of
sodium bicarbonate to neutralize any hydrochloric acid by-product.
It will be appreciated that such a dual-crosslinked micelle is
reversible only in the presence of acid and a reducing agent (e.g.
glutathione, dithiothreitol (DTT), etc.).
[0303] According to another aspect, the present invention provides
a method for preparing a micelle comprising a multiblock copolymer
which comprises a polymeric hydrophilic block, optionally a
crosslinkable or crosslinked poly(amino acid block), and a
hydrophobic D,L-mixed poly(amino acid) block, characterized in that
said micelle has an inner core, an optionally crosslinkable or
crosslinked outer core, and a hydrophilic shell, said method
comprising the steps of:
(a) providing a multiblock copolymer of formula I:
##STR01765##
wherein each of the R.sup.1, R.sup.2a, Q, R.sup.x, R.sup.y, n, m,
and m' groups of formula I, are as described in various classes and
subclasses, both singly and in combination, herein, (b) combining
said compound of formula I with a therapeutic agent; and (c)
treating the resulting micelle with a crosslinking reagent to
crosslink Rx.
[0304] In one embodiment, drugs are loaded into the micelle inner
core by adding an aliquot of a copolymer solution in water to the
drug to be incorporated. For example, a stock solution of the drug
in a polar organic solvent is made and allowed to evaporate, and
then the copolymer/water solution is added. In another embodiment,
the drug is incorporated using an oil in water emulsion technique.
In this case, the drug is dissolved in an organic solvent and added
dropwise to the micelle solution in water, and the drug is
incorporated into the micelle during solvent evaporation. In
another embodiment, the drug is dissolved with the copolymer in a
common polar organic solvent and dialyzed against water or another
aqueous medium. See Allen, C.; Maysinger, D.; Eisenberg A. Colloid
Surface B 1999, 16, 3-27.
[0305] In still another embodiment, the loading and crosslinking of
drug-filled micelles is carried out by dissolving neutral
doxorubicin, camptothecin, docetaxel, or paclitaxel and the block
copolymer in a polar solvent such as acetone or ethanol, followed
by slow addition to water or buffer solution. Due to the limited
solubility of these agents in water, the drug is forced into the
core of the micelle, effectively encapsulating the drug.
5. Uses, Methods, and Compositions
[0306] As described herein, micelles of the present invention can
encapsulate a wide variety of therpaeutic agents useful for
treating a wide variety of diseases. In certain embodiments, the
present invention provides a drug-loaded micelle, as described
herein, wherein said micelle is useful for treating the disorder
for which the drug is known to treat. According to one embodiment,
the present invention provides a method for treating one or more
disorders selected from pain, inflammation, arrhythmia, arthritis
(rheumatoid or osteoarthritis), atherosclerosis, restenosis,
bacterial infection, viral infection, depression, diabetes,
epilepsy, fungal infection, gout, hypertension, malaria, migraine,
cancer or other proliferative disorder, erectile dysfunction, a
thyroid disorder, neurological disorders and hormone-related
diseases, Parkinson's disease, Huntington's disease, Alzheimer's
disease, a gastro-intestinal disorder, allergy, an autoimmune
disorder, such as asthma or psoriasis, osteoporosis, obesity and
comorbidities, a cognitive disorder, stroke, AIDS-associated
dementia, amyotrophic lateral sclerosis (ALS, Lou Gehrig's
disease), multiple sclerosis (MS), schizophrenia, anxiety, bipolar
disorder, tauopothy, a spinal cord or peripheral nerve injury,
myocardial infarction, cardiomyocyte hypertrophy, glaucoma, an
attention deficit disorder (ADD or ADHD), a sleep disorder,
reperfusion/ischemia, an angiogenic disorder, or urinary
incontinence, comprising adminsitering to a patient a micelle
comprising a multiblock copolymer which comprises a polymeric
hydrophilic block, optionally a crosslinkable or crosslinked
poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid
block), characterized in that said micelle has a drug-loaded inner
core, optionally a crosslinkable or crosslinked outer core, and a
hydrophilic shell, wherein said micelle encapsulates a therapeutic
agent suitable for treating said disorder.
[0307] In other embodiments, the present invention provides a
method for treating one or more disorders selected from autoimmune
disease, an inflammatory disease, a metabolic disorder, a
psychiatric disorder, diabetes, an angiogenic disorder, tauopothy,
a neurological or neurodegenerative disorder, a spinal cord injury,
glaucoma, baldness, or a cardiovascular disease, comprising
adminsitering to a patient a multiblock copolymer which comprises a
polymeric hydrophilic block, optionally a crosslinkable or
crosslinked poly(amino acid block), and a hydrophobic D,L-mixed
poly(amino acid block), characterized in that said micelle has a
drug-loaded inner core, optionally a crosslinkable or crosslinked
outer core, and a hydrophilic shell, wherein said micelle
encapsulates a therapeutic agent suitable for treating said
disorder.
[0308] In certain embodiments, drug-loaded micelles of the present
invention are useful for treating cancer. Accordingly, another
aspect of the present invention provides a method for treating
cancer in a patient comprising adminsitering to a patient a
multiblock copolymer which comprises a polymeric hydrophilic block,
optionally a crosslinkable or crosslinked poly(amino acid block),
and a hydrophobic D,L-mixed poly(amino acid block), characterized
in that said micelle has a drug-loaded inner core, optionally a
crosslinkable or crosslinked outer core, and a hydrophilic shell,
wherein said micelle encapsulates a chemotherapeutic agent.
According to another embodiment, the present invention relates to a
method of treating a cancer selected from breast, ovary, cervix,
prostate, testis, genitourinary tract, esophagus, larynx,
glioblastoma, neuroblastoma, stomach, skin, keratoacanthoma, lung,
epidermoid carcinoma, large cell carcinoma, small cell carcinoma,
lung adenocarcinoma, bone, colon, adenoma, pancreas,
adenocarcinoma, thyroid, follicular carcinoma, undifferentiated
carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma,
bladder carcinoma, liver carcinoma and biliary passages, kidney
carcinoma, myeloid disorders, lymphoid disorders, Hodgkin's, hairy
cells, buccal cavity and pharynx (oral), lip, tongue, mouth,
pharynx, small intestine, colon-rectum, large intestine, rectum,
brain and central nervous system, and leukemia, comprising
administering a micelle in accordance with the present invention
wherein said micelle encapsulates a chemotherapeutic agent suitable
for treating said cancer.
[0309] P-glycoprotein (Pgp, also called multidrug resistance
protein) is found in the plasma membrane of higher eukaryotes where
it is responsible for ATP hydrolysis-driven export of hydrophobic
molecules. In animals, Pgp plays an important role in excretion of
and protection from environmental toxins; when expressed in the
plasma membrane of cancer cells, it can lead to failure of
chemotherapy by preventing the hydrophobic chemotherapeutic drugs
from reaching their targets inside cells. Indeed, Pgp is known to
transport hydrophobic chemotherapeutic drugs out of tumor cells.
According to one aspect, the present invention provides a method
for delivering a hydrophobic chemotherapeutic drug to a cancer cell
while preventing, or lessening, Pgp excretion of that
chemotherapeutic drug, comprising administering a drug-loaded
micelle comprising a multiblock polymer of the present invention
loaded with a hydrophobic chemotherapeutic drug. Such hydrophobic
chemotherapeutic drugs are well known in the art and include those
described herein.
[0310] Compositions
[0311] According to another embodiment, the invention provides a
composition comprising a micelle of this invention or a
pharmaceutically acceptable derivative thereof and a
pharmaceutically acceptable carrier, adjuvant, or vehicle. In
certain embodiments, the composition of this invention is
formulated for administration to a patient in need of such
composition. In other embodiments, the composition of this
invention is formulated for oral administration to a patient.
[0312] The term "patient", as used herein, means an animal,
preferably a mammal, and most preferably a human.
[0313] The term "pharmaceutically acceptable carrier, adjuvant, or
vehicle" refers to a non-toxic carrier, adjuvant, or vehicle that
does not destroy the pharmacological activity of the compound with
which it is formulated. Pharmaceutically acceptable carriers,
adjuvants or vehicles that may be used in the compositions of this
invention include, but are not limited to, ion exchangers, alumina,
aluminum stearate, lecithin, serum proteins, such as human serum
albumin, buffer substances such as phosphates, glycine, sorbic
acid, potassium sorbate, partial glyceride mixtures of saturated
vegetable fatty acids, water, salts or electrolytes, such as
protamine sulfate, disodium hydrogen phosphate, potassium hydrogen
phosphate, sodium chloride, zinc salts, colloidal silica, magnesium
trisilicate, polyvinyl pyrrolidone, cellulose-based substances,
polyethylene glycol, sodium carboxymethylcellulose, polyacrylates,
waxes, polyethylene-polyoxypropylene-block polymers, polyethylene
glycol and wool fat.
[0314] Pharmaceutically acceptable salts of the compounds of this
invention include those derived from pharmaceutically acceptable
inorganic and organic acids and bases. Examples of suitable acid
salts include acetate, adipate, alginate, aspartate, benzoate,
benzenesulfonate, bisulfate, butyrate, citrate, camphorate,
camphorsulfonate, cyclopentanepropionate, digluconate,
dodecylsulfate, ethanesulfonate, formate, fumarate,
glucoheptanoate, glycerophosphate, glycolate, hemisulfate,
heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide,
2-hydroxyethanesulfonate, lactate, maleate, malonate,
methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate,
phosphate, picrate, pivalate, propionate, salicylate, succinate,
sulfate, tartrate, thiocyanate, tosylate and undecanoate. Other
acids, such as oxalic, while not in themselves pharmaceutically
acceptable, may be employed in the preparation of salts useful as
intermediates in obtaining the compounds of the invention and their
pharmaceutically acceptable acid addition salts.
[0315] Salts derived from appropriate bases include alkali metal
(e.g., sodium and potassium), alkaline earth metal (e.g.,
magnesium), ammonium and N+(C1-4 alkyl)4 salts. This invention also
envisions the quaternization of any basic nitrogen-containing
groups of the compounds disclosed herein. Water or oil-soluble or
dispersible products may be obtained by such quaternization.
[0316] The compositions of the present invention may be
administered orally, parenterally, by inhalation spray, topically,
rectally, nasally, buccally, vaginally or via an implanted
reservoir. The term "parenteral" as used herein includes
subcutaneous, intravenous, intramuscular, intra-articular,
intra-synovial, intrastemal, intrathecal, intrahepatic,
intralesional and intracranial injection or infusion techniques.
Preferably, the compositions are administered orally,
intraperitoneally or intravenously. Sterile injectable forms of the
compositions of this invention may be aqueous or oleaginous
suspension. These suspensions may be formulated according to
techniques known in the art using suitable dispersing or wetting
agents and suspending agents. The sterile injectable preparation
may also be a sterile injectable solution or suspension in a
non-toxic parenterally acceptable diluent or solvent, for example
as a solution in 1,3-butanediol. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's solution and
isotonic sodium chloride solution. In addition, sterile, fixed oils
are conventionally employed as a solvent or suspending medium.
[0317] For this purpose, any bland fixed oil may be employed
including synthetic mono- or di-glycerides. Fatty acids, such as
oleic acid and its glyceride derivatives are useful in the
preparation of injectables, as are natural
pharmaceutically-acceptable oils, such as olive oil or castor oil,
especially in their polyoxyethylated versions. These oil solutions
or suspensions may also contain a long-chain alcohol diluent or
dispersant, such as carboxymethyl cellulose or similar dispersing
agents that are commonly used in the formulation of
pharmaceutically acceptable dosage forms including emulsions and
suspensions. Other commonly used surfactants, such as Tweens, Spans
and other emulsifying agents or bioavailability enhancers which are
commonly used in the manufacture of pharmaceutically acceptable
solid, liquid, or other dosage forms may also be used for the
purposes of formulation.
[0318] The pharmaceutically acceptable compositions of this
invention may be orally administered in any orally acceptable
dosage form including, but not limited to, capsules, tablets,
aqueous suspensions or solutions. In the case of tablets for oral
use, carriers commonly used include lactose and corn starch.
Lubricating agents, such as magnesium stearate, are also typically
added. For oral administration in a capsule form, useful diluents
include lactose and dried cornstarch. When aqueous suspensions are
required for oral use, the active ingredient is combined with
emulsifying and suspending agents. If desired, certain sweetening,
flavoring or coloring agents may also be added. In certain
embodiments, pharmaceutically acceptable compositions of the
present invention are enterically coated.
[0319] Alternatively, the pharmaceutically acceptable compositions
of this invention may be administered in the form of suppositories
for rectal administration. These can be prepared by mixing the
agent with a suitable non-irritating excipient that is solid at
room temperature but liquid at rectal temperature and therefore
will melt in the rectum to release the drug. Such materials include
cocoa butter, beeswax and polyethylene glycols.
[0320] The pharmaceutically acceptable compositions of this
invention may also be administered topically, especially when the
target of treatment includes areas or organs readily accessible by
topical application, including diseases of the eye, the skin, or
the lower intestinal tract. Suitable topical formulations are
readily prepared for each of these areas or organs.
[0321] Topical application for the lower intestinal tract can be
effected in a rectal suppository formulation (see above) or in a
suitable enema formulation. Topically-transdermal patches may also
be used.
[0322] For topical applications, the pharmaceutically acceptable
compositions may be formulated in a suitable ointment containing
the active component suspended or dissolved in one or more
carriers. Carriers for topical administration of the compounds of
this invention include, but are not limited to, mineral oil, liquid
petrolatum, white petrolatum, propylene glycol, polyoxyethylene,
polyoxypropylene compound, emulsifying wax and water.
Alternatively, the pharmaceutically acceptable compositions can be
formulated in a suitable lotion or cream containing the active
components suspended or dissolved in one or more pharmaceutically
acceptable carriers. Suitable carriers include, but are not limited
to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl
esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and
water.
[0323] For ophthalmic use, the pharmaceutically acceptable
compositions may be formulated as micronized suspensions in
isotonic, pH adjusted sterile saline, or, preferably, as solutions
in isotonic, pH adjusted sterile saline, either with or without a
preservative such as benzylalkonium chloride. Alternatively, for
ophthalmic uses, the pharmaceutically acceptable compositions may
be formulated in an ointment such as petrolatum.
[0324] The pharmaceutically acceptable compositions of this
invention may also be administered by nasal aerosol or inhalation.
Such compositions are prepared according to techniques well-known
in the art of pharmaceutical formulation and may be prepared as
solutions in saline, employing benzyl alcohol or other suitable
preservatives, absorption promoters to enhance bioavailability,
fluorocarbons, and/or other conventional solubilizing or dispersing
agents.
[0325] In certain embodiments, the pharmaceutically acceptable
compositions of this invention are formulated for oral
administration.
[0326] The amount of the compounds of the present invention that
may be combined with the carrier materials to produce a composition
in a single dosage form will vary depending upon the host treated,
the particular mode of administration. Preferably, the compositions
should be formulated so that a dosage of between 0.01-100 mg/kg
body weight/day of the drug can be administered to a patient
receiving these compositions.
[0327] It will be appreciated that dosages typically employed for
the encapsulated drug are contemplated by the present invention. In
certain embodiments, a patient is administered a drug-loaded
micelle of the present invention wherein the dosage of the drug is
equivalent to what is typically administered for that drug. In
other embodiments, a patient is administered a drug-loaded micelle
of the present invention wherein the dosage of the drug is lower
than is typically administered for that drug.
[0328] It should also be understood that a specific dosage and
treatment regimen for any particular patient will depend upon a
variety of factors, including the activity of the specific compound
employed, the age, body weight, general health, sex, diet, time of
administration, rate of excretion, drug combination, and the
judgment of the treating physician and the severity of the
particular disease being treated. The amount of a compound of the
present invention in the composition will also depend upon the
particular compound in the composition.
[0329] In order that the invention described herein may be more
fully understood, the following examples are set forth. It will be
understood that these examples are for illustrative purposes only
and are not to be construed as limiting this invention in any
manner.
EXEMPLIFICATION
Preparation of Bifunctional PEGs and Multiblock Copolymers of the
Present Invention
[0330] As described generally above, multiblock copolymers of the
present invention are prepared using the heterobifunctional PEGs
described herein and in U.S. patent application Ser. No.
11/256,735, filed Oct. 24, 2005, published as WO2006/047419 on May
4, 2006 and published as US 20060142506 on Jun. 29, 2006, the
entirety of which is hereby incorporated herein by reference. The
preparation of multiblock polymers in accordance with the present
invention is accomplished by methods known in the art, including
those described in detail in U.S. patent application Ser. No.
11/325,020, filed Jan. 4, 2006, published as WO2006/74202 on Jul.
13, 2006 and published as US 20060172914 on Aug. 3, 2006, the
entirety of which is hereby incorporated herein by reference.
[0331] In each of the Examples below, where an amino acid, or
corresponding NCA, is designated "D", then that amino acid, or
corresponding NCA, is of the D-configuration. Where no such
designation is recited, then that amino acid, or corresponding NCA,
is of the L-configuration.
Example 1
##STR01766##
[0333] Synthesis of mPEG-Hydrochloride--
[0334] To a 500 mL 2-neck round bottom flask was added mPEG (40 g,
5 mmol), phthalimide (4.41 g, 30 mmol) and triphenyl phosphine
(6.55 g, 25 mmol). The reagents were dissolved in anhydrous THF
(300 mL) and stirred at room temperature. Once a homogeneous
solution was present, DIAD (4.04 g, 20 mmol) was added and the
solution stirred for 16 h. The solvent was evaporated and the
residue purified by solid phase extraction (3% MeOH in CHCl.sub.3
(1 L) followed by 10% MeOH in CHCl.sub.3 (1 L) which contained the
polymer product). The solvent was removed and the resulting liquid
dissolved in ethanol (200 mL) and hydrazine hydrate (10 mL). The
solution was stirred at reflux for 14 h, allowed to cool, then
concentrated HCl (15 mL) was added dropwise to the solution. The
solution was filtered and the solvent evaporated. The residue was
dissolved in water and the polymer product extracted with
CHCl.sub.3 (4.times.500 mL). The combined organic layers were dried
over MgSO.sub.4, filtered and the solvent evaporated. The resulting
liquid was diluted with a minimal amount of methanol and
precipitated in to diethyl ether. A white powder (28.2 g, 71%) was
isolated following filtration. 1H NMR (400 MHz, DMSO-d.sub.6,
.delta.) 7.79 br-s, 3.7-3.3 br-m, 2.96 t. GPC (DMF, PEG standards)
M.sub.n=7,800; PDI=1.03.
Example 2
##STR01767##
[0336] Synthesis of mPEG-PAsp-(PAsp-co-DBzGlu)-Ac--
[0337] To a 100 mL round bottom flask was added mPEG-hydrochloride
(1.0 g, 0.13 mmol) and t-butyl aspartic acid NCA (0.28 g, 1.3
mmol). The reagents were dried under vacuum for 1 hour, then NMP
(10 mL) added. The solution was degassed under vacuum the
backfilled with N.sub.2, and stirred at 80.degree. C. After 48 h,
D-benzyl glutamate NCA (0.34 g, 1.3 mmol) and and t-butyl aspartic
acid NCA (0.28 g, 1.3 mmol) was dissolved in NMP (5 mL) and added
to the reaction. After an additional 48 h, the solution was allowed
to cool, then DMAP (0.16 g, 1.3 mmol) and acetic anhydride (0.13 g,
1.3 mmol) added to the stirred solution. After 1 hour, the solution
was precipitated into diethyl ether/hexanes (3:2, 300 mL). A white
solid was recovered after filtration, which was dissolved in
TFA/H.sub.2O (95:5, 40 mL) and stirred for 4 hours at room
temperature. The solvent was evaporated and the residue
precipitated into ether (300 mL). A white powder (0.7 g, 52% yield)
was recovered following filtration. .sup.1H NMR (400 MHz,
DMSO-d.sub.6, .delta.) 12.37, 8.23, 7.97, 7.55, 7.34, 6.97, 5.06,
4.51, 4.27, 3.7-3.3, 3.19, 2.67, 2.35, 2.01, 1.83.
Example 3
##STR01768##
[0339] Synthesis of Azide-PEG-TFA Salt--
[0340] Azide-PEG-BOC was dissolved in 1:1 TFA/CH.sub.2Cl.sub.2 (15
mL) and stirred at room temperature for 1 hour. The solvent was
evaporated and the residue precipitated into ether. A white powder
was recovered by filtration, which was redissolved in a minimal
amount of methanol (40 mL) and again precipitated into ether. A
white powder (2.6 g, 87% yield) was recovered after filtration. 1H
NMR (400 MHz, DMSO-d.sub.6, .delta.) 7.72, 3.3-3.7, 2.98. GPC (DMF,
PEG Standards) M.sub.n=4,800; PDI=1.04.
Example 4
##STR01769##
[0342] Synthesis of Azide-PEG-P(D/LBzGlu)-Ac
[0343] To a 100 mL round bottom flask was added Azide-PEG-TFA salt
(1.89 g, 0.83 mmol), D-benzyl glutamate NCA (1 g, 3.8 mmol), and
L-benzyl glutamate NCA (1 g, 3.8 mmol). The reagents were dried
under vacuum for 1 hour, then NMP (40 mL) added. The solution was
degassed under vacuum the backfilled with N.sub.2, and stirred at
60.degree. C. After 24 h, the solution was allowed to cool, then
DMAP (0.16 g, 1.3 mmol), pyridine (1 mL) and acetic anhydride (1
mL) added to the stirred solution. After 1 hour, the solution was
precipitated into diethyl ether/hexanes (3:2, 300 mL). A white
powder (1.9 g, 54% yield) was recovered following filtration. 1H
NMR (400 MHz, DMSO-d.sub.6, .delta.) 9.08, 8.01, 7.35, 5.08, 4.47,
4.23, 3.3-3.7, 2.68, 2.15, 1.81.
Example 5
##STR01770##
[0345] Synthesis of Glu(Bzl) NCA--
[0346] HO-Glu(Bzl)-NH.sub.2 (30.0 g, 126.0 mmol) was suspended in
300 mL of anhydrous THF and heated to 50.degree. C. Phosgene (20%
in toluene) (81.3 mL, 164.6 mmol) was added to the amino acid
suspension by syringe, and the amino acid dissolved over the course
of approx. 30 minutes, forming a clear solution. The solution was
concentrated by rotory evaporation, dissolved in .about.150 mL of
anhydrous THF, and transferred to an Erlenmeyer flask. Hexane was
added and the product was allowed to crystallize overnight. The NCA
was isolated by filtration and dried in vacuo. 29.8 g (90% yield)
of Glu(Bzl) NCA was isolated as a white, crystalline solid. .sup.1H
NMR (CDCl.sub.3) .delta. 7.36 (5H), 6.22 (1H), 5.14 (2H), 4.35
(1H), 2.61 (2H), 2.29 (1H), 2.14 (1H) ppm.
Example 6
##STR01771##
[0348] Synthesis of d-Glu(Bzl) NCA--
[0349] d-Glu(Bzl) NCA was synthesized as described in Example 3
from HO-d-Glu(Bzl)-NH.sub.2 (30.7 g, 129.2 mmol) and 83.1 mL (168.0
mmol) of phosgene (20% in toluene). 31.8 g (94% yield) of product
was isolated as a white, crystalline solid. .sup.1H NMR
(CDCl.sub.3) .delta. 7.36 (5H), 6.22 (1H), 5.14 (2H), 4.35 (1H),
2.61 (2H), 2.29 (1H), 2.14 (1H) ppm.
Example 7
##STR01772##
[0351] Synthesis of Leu NCA--
[0352] HO-Leu-NH.sub.2 (10.0 g, 76.2 mmol) was suspended in 150 mL
of anhydrous THF and heated to 50.degree. C. Phosgene (20% in
toluene) (76.0 mL, 152.4 mmol) was added to the amino acid
suspension. The amino acid dissolved over the course of approx. 1
hr, forming a clear solution. The solution was concentrated on the
rotovap, transferred to a beaker, and hexane was added to
precipitate the product. The white solid was isolated by filtration
and dissolved in toluene. The solution was filtered over a bed of
Celite to remove any insoluble material. An excess of hexane was
added to the filtrate to precipitate the product. The NCA was
isolated by filtration and dried in vacuo. 9.0 g (75% yield) of Leu
NCA was isolated as a white, crystalline solid. .sup.1H NMR
(d.sub.6-DMSO) .delta. 9.13 (1H), 4.44 (1H), 1.74 (1H), 1.55 (2H),
0.90 (6H) ppm.
Example 8
##STR01773##
[0354] Synthesis of d-Leu NCA
[0355] d-Leu NCA was synthesized as described in Example 1 from
HO-d-Leu-NH.sub.2 (20.0 g, 152.5 mmol) and 99.3 mL (198.3 mmol) of
phosgene (20% in toluene). 13.8 g (58% yield) of NCA was isolated
as a white, crystalline solid. .sup.1H NMR (d.sub.6-DMSO) .delta.
9.13 (1H), 4.44 (1H), 1.74 (1H), 1.55 (2H), 0.90 (6H) ppm.
Example 9
##STR01774##
[0357] Synthesis of Asp(But) NCA--
[0358] HO-Asp(But)-NH.sub.2 (20.0 g, 105.7 mmol) was suspended in
300 mL of anhydrous THF and heated to 50.degree. C. Phosgene (20%
in toluene) (105 mL, 211.4 mmol) was added to the amino acid
suspension, and the amino acid dissolved over the course of approx.
1 hr, forming a clear solution. The solution was concentrated on by
rotary evaporation, transferred to a beaker, and hexane was added
to precipitate the product. The white solid was isolated by
filtration and dissolved in anhydrous THF. The solution was
filtered over a bed of Celite to remove any insoluble material. An
excess of hexane was added on the top of the filtrate and the
bilayer solution was left in the freezer overnight. The NCA was
isolated by filtration and dried in vacuo. 15.0 g (66% yield) of
Asp(But) NCA was isolated as a white, crystalline solid. .sup.1H
NMR (d.sub.6-DMSO) .delta. 8.99 (1H), 4.61 (1H), 2.93 (1H), 2.69
(1H), 1.38 (9H) ppm.
Example 10
##STR01775##
[0360] Synthesis of Tyr(Bzl) NCA--
[0361] HO-Tyr(Bzl)-NH.sub.2 (20.0 g, 105.7 mmol) was suspended in
300 mL of anhydrous THF and heated to 50.degree. C. Phosgene (20%
in toluene) (73.7 mL, 147.4 mmol) was added the amino acid
suspension. The amino acid dissolved over the course of approx. 1
hr, forming a pale yellow solution. The solution was concentrated
on the rotovap, transferred to a beaker, and hexane was added to
precipitate the product. The off-white solid was isolated by
filtration and dissolved in anhydrous THF. The solution was stirred
over carbon black and subsequently filtered over a bed of Celite.
An excess of hexane was added to the filtrate to precipitate the
product. The NCA was isolated by filtration and dried in vacuo.
14.3 g (65% yield) of Tyr(Bzl) NCA was isolated as a off-white,
solid. .sup.1H NMR (d.sub.6-DMSO) .delta. 9.07 (1H), 7.49-7.29
(5H), 7.12-7.07 (2H), 6.98-6.94 (2H), 5.06 (2H), 4.74 (1H),
3.05-2.88 (2H) ppm.
Example 11
##STR01776##
[0363] Synthesis of (Dibenzyl)-N-PEG10OK--OH--
[0364] N,N-dibenzyl-2-aminoethanol (4.3 g, 17.6 mmol) was weighed
into an oven-dried 2 L jacketed, round-bottom flask. An oven-dried
jacketed addition funnel was attached to the reaction flask and
three vacuum/argon cycles was applied to the setup. Anhydrous
tetrahydrofuran (THF) (1.2 L) was introduced to the round bottom
flask directly from a solvent purification system under an
overpressure of argon. N,N-dibenzyl-2-aminoethanol was then
converted to N,N-dibenzyl-2-aminoethoxide by titration by potassium
naphthalenide (0.2 M solution into THF) until a dark green color
persisted in solution for a few seconds. Ethylene oxide (184.0 ml,
4.0 mol) was condensed at -30.degree. C. in the jacketed addition
funnel and subsequently added to the alkoxide solution which had
been cooled to -10.degree. C. The reactor was pressurized with
argon and sealed and then warmed to 10.degree. C. and stirred for 4
hours, then warmed to 20.degree. C. and stirred for 12 hours, and
then warmed to 40.degree. C. and stirred for 3 days. An excess of
methanol was used to terminate the polymerization. The solution was
concentrated by rotary evaporation and used as such for
deprotection of the amine end-group (see Example 12). .sup.1H NMR
(d.sub.6-DMSO) .delta. 7.4-7.2 (10H), 4.55 (1H), 3.83-3.21 (910H)
ppm
Example 12
##STR01777##
[0366] Synthesis of H.sub.2N-PEG10K-OH--
[0367] (Bzl).sub.2-N-PEG10K-OH (176.0 g, 17.6 mmol), Pd(OH).sub.2/C
(32.0 g, 45.6 mmol), ammonium formate (80.0 g, 1.3 mol), and
ethanol (1.2 L) were combined in a 2 L round-bottom flask, heated
to 80.degree. C., and stirred overnight. The reaction was cooled to
room temperature and potassium carbonate (5 g) was added and
stirred for 30 min. The solution was filtered through a bed of
Celite and concentrated by rotary evaporation. The white solid was
then dissolved in 800 ml of a 50/50 brine/saturated potassium
carbonate mixture and extracted three times with dichloromethane.
Dichloromethane fractions were combined, dried over MgSO.sub.4,
concentrated to a volume of approximately 800 ml by rotary
evaporation and used as-is for Boc protection (see Example 13).
.sup.1H NMR (d.sub.6-DMSO) 4.55 (1H), 3.83-3.21 (910H), 2.96 (2H)
ppm
[0368] Example 13
##STR01778##
[0369] Reaction of di-tert-butyl dicarbonate with
H.sub.2N-PEG10OK-OH
[0370] Di-tert-butyl dicarbonate (38.4 g, 176.0 mmol) was added to
a solution of H.sub.2N-PEG10OK-OH (.about.175 g, 17.5 mmol) in
dichloromethane (.about.800 mL) and allowed to stir at room
temperature overnight. The resulting product was concentrated by
rotary evaporation and purified via silica gel chromatography
(97/3.fwdarw.85/15 dichloromethane/methanol). The PEG containing
fractions were combined, concentrated by rotary evaporation, and
precipitated into a 10-fold excess of diethyl ether. The product
was isolated by filtration and dried in vacuo to give 104 g (59%
yield) of Boc-HN-PEG10OK-OH as an off-white powder. .sup.1H NMR
(d.sub.6-DMSO) .delta. 6.75 (1H), 4.55 (1H), 3.83-3.21 (910H), 3.06
(2H), 1.37 (9H) ppm
Example 14
##STR01779##
[0372] Synthesis of Boc-HN-PEG10OK-Mesylate
[0373] BocHN-PEG10K-OH (104 g, 10.4 mmol) was dried by azeotropic
distillation from toluene and dissolved in 600 mL of dry
dichloromethane under nitrogen. The solution was cooled to
0.degree. C. using an ice/water bath and methanesulfonyl chloride
(2.4 mL, 31.2 mmol) was added by syringe. Triethylamine (2.9 mL,
20.8 mmol) was subsequently added by syringe and the reaction was
allowed to warm to room temperature and stirred overnight. The
solution was evaporated to dryness by rotary evaporation and used
as-is for sodium azide substitution (see Example 11). .sup.1H NMR
(d.sub.6-DMSO) .delta. 6.75 (1H), 4.36 (2H), 3.83-3.21 (910H), 3.06
(2H), 1.37 (9H) ppm.
Example 15
##STR01780##
[0375] Synthesis of Boc-NH-PEG10OK-N.sub.3
[0376] BocHN-PEG10OK-Mesylate (.about.104 g, 10.4 mmol) and sodium
azide (6.8 g, 104.0 mmol) were dissolved in 800 mL ethanol, heated
to 80.degree. C., and stirred overnight. After cooling to room
temperature, the contents were concentrated to dryness by rotary
evaporation and dissolved in 250 mL of dichloromethane. The product
was subsequently purified by silica gel chromatography
(97/3.fwdarw.85/15 dichloromethane/methanol). The PEG containing
fractions were combined, concentrated by rotary evaporation, and
precipitated into a 10-fold excess of diethyl ether. The polymer
was isolated by filtration as a white powder (90 g, 86% yield).
.sup.1H NMR (d.sub.6-DMSO) .delta. 6.75 (1H), 3.83-3.21 (910H),
3.06 (2H), 1.37 (9H) ppm.
Example 16
##STR01781##
[0378] Synthesis of N.sub.3-PEG12K-NH.sub.3 DFA Salt--
[0379] N.sub.3-PEG12K-NHBoc (15.0 g, 1.3 mmol) was dissolved in 100
mL of a CH.sub.2C12/DFA solution (70/30) and was allowed to stir at
room temperature overnight. The product was precipitated into
diethyl ether, dissolved in dichloromethane, and reprecipitated
into diethyl ether. The product was isolated by filtration and
dried in vacuo to yield 13.5 g (90% yield) of an off-white powder.
.sup.1H NMR (d.sub.6-DMSO) 7.77 (3H), 5.97 (1H), 3.83-3.21 (1050H),
2.98 (2H) ppm
Example 17
##STR01782##
[0381] Synthesis of N.sub.3-PEG12K-b-P(L-Glu(Bzl).sub.30)-Ac--
[0382] N.sub.3-PEG-NH.sub.3 DFA salt, 12 kDa (5.0 g, 0.42 mmol) was
weighed into an oven-dried, round-bottom flask, dissolved in
toluene, and dried by azeotropic distillation. Excess toluene was
removed under vacuum. L-Glu(Bzl) NCA (3.3 g, 12.5 mmol) was added
to the flask, the flask was evacuated under reduced pressure, and
subsequently backfilled with nitrogen gas. Dry N-methylpyrrolidone
(NMP) (42.0 mL) was introduced by syringe and the solution was
heated to 60.degree. C. The reaction mixture was allowed to stir
for 96 hours at 60.degree. C. under nitrogen gas. The solution was
cooled to room temperature and diisopropylethylamine (DIPEA) (1.0
mL), dimethylaminopyridine (DMAP) (100 mg), and acetic anhydride
(1.0 mL) were added. Stirring was continued for 1 hour at room
temperature. The polymer was precipitated into diethyl ether and
isolated by filtration. The solid was then dissolved in
dichloromethane and reprecipitated into diethyl ether. The product
was isolated by filtration and dried in vacuo to give 6.5 g (86%
yield) of block copolymer as an off-white powder. .sup.1H NMR (400
MHz, DMSO-d.sub.6, .delta.) 7.9-8.4, 7.35, 5.04, 4.25, 3.10-3.90,
1.75-2.60 ppm.
Example 18
##STR01783##
[0384] Synthesis of
N.sub.3-PEG12K-b-Poly(L-Glu(Bzl).sub.15-co-D-Glu(Bzl).sub.15)-Ac--
[0385]
N.sub.3-PEG12K-b-Poly(L-Glu(Bzl).sub.15-co-D-Glu(Bzl).sub.15) was
synthesized as described in Example 13 from N.sub.3-PEG-NH.sub.3
DFA salt, 12 kDa (5.0 g, 0.42 mmol), L-Glu(Bzl) NCA (1.7 g, 6.3
mmol), and D-Glu(Bzl) NCA (1.7 g, 6.3 mmol). 6.2 g (82% yield) of
block copolymer was isolated as an off-white powder. .sup.1H NMR
(d.sub.6-DMSO) .delta. 8.10, 7.30, 5.03, 4.30, 3.30-3.70, 2.33,
1.75-2.00 ppm.
Example 19
##STR01784##
[0387] Synthesis of
N.sub.3-PEG12K-b-Poly(Asp(But).sub.10)-b-Poly(L-Leu.sub.13-co-L-Tyr(Bzl).-
sub.17)-Ac--
[0388] N.sub.3-PEG-NH.sub.3 DFA salt, 12 kDa (5.0 g, 0.42 mmol) was
weighed into an oven-dried, round-bottom flask, dissolved in
toluene, and dried by azeotropic distillation. Excess toluene was
removed under vacuum. Asp(But) NCA (0.9 g, 4.2 mmol) was added to
the flask, the flask was evacuated under reduced pressure, and
backfilled with nitrogen gas. Dry NMP (29.0 mL) was introduced by
syringe and the solution was heated to 60.degree. C. The reaction
mixture was allowed to stir for 36 hours at 60.degree. C. under
nitrogen gas. In an oven-dried round-bottom flask, L-Leu NCA (0.9
g, 5.4 mmol) and Tyr(Bzl) NCA (2.1 g, 7.1 mmol) were combined and
dissolved in 15 ml of dry NMP under nitrogen gas. This solution was
then transferred to the polymerization by syringe and allowed to
stir for an additional 72 hours at 60.degree. C. under nitrogen
gas. The solution was cooled to room temperature and DIPEA (1.0
mL), DMAP (100 mg), and acetic anhydride (1.0 mL) were added.
Stirring was continued for 1 hour at room temperature. The polymer
was precipitated into diethyl ether and isolated by filtration. The
solid was then dissolved in dichloromethane and reprecipitated into
diethyl ether. The product was isolated by filtration and dried in
vacuo to give 7.6 g (94% yield) of block copolymer as an off-white
powder. 1H NMR (400 MHz, DMSO-d.sub.6, .delta.) 7.80-8.40,
6.60-7.40, 4.95, 4.40, 3.2-3.7, 2.70, 1.36, 0.80 ppm.
Example 20
##STR01785##
[0390] Synthesis of
N.sub.3-PEG12K-b-Poly(Asp(But).sub.10)-b-Poly(D-Leu.sub.13-co-L-Tyr(Bzl).-
sub.17)-Ac
[0391]
N.sub.3-PEG12K-b-Poly(Asp(But)).sub.10-b-Poly(D-Leu.sub.13-co-L-Tyr-
(Bzl).sub.17) was synthesized as described in Example 15 from
N.sub.3-PEG-NH.sub.3 DFA salt, 12 kDa (5.0 g, 0.42 mmol), Asp(But)
NCA (0.9 g, 4.2 mmol), D-Leu NCA (0.9 g, 5.4 mmol), and Tyr(Bzl)
NCA (2.1 g, 7.1 mmol). 7.1 g (88% yield) of block copolymer was
isolated as an off-white powder. .sup.1H NMR (d.sub.6-DMSO) .delta.
7.70-8.40, 7.35, 7.09, 6.82, 4.96, 4.50, 4.00-4.20, 3.20-3.7, 2.90,
2.70, 1.36, 0.40-0.90 ppm.
Example 21
##STR01786##
[0393] Synthesis of
N.sub.3-PEG12K-b-Poly(Asp).sub.10-b-Poly(L-Leu.sub.13-co-L-Tyr.sub.17)-Ac
[0394]
N.sub.3-PEG12K-b-Poly(Asp(But).sub.10)-b-Poly(L-Leu.sub.13-co-L-Tyr-
(Bzl).sub.17) (7.55 g) was dissolved in 80 mL of a 0.5 M solution
of pentamethylbenzene (PMB) in trifluoroacetic acid (TFA). The
reaction was allowed to stir for 2.5 hours at room temperature with
precipitate forming after approximately 1 hour. The polymer was
precipitated into diethyl ether, filtered, dissolved in
dichloromethane, and reprecipitated into diethyl ether. The product
was isolated by filtration and dried in vacuo to 5.3 g (79% yield)
of block copolymer as an off-white powder. .sup.1H NMR
(d.sub.6-DMSO) .delta. 12.35, 9.15, 7.60-8.60, 7.00, 6.60, 4.50,
3.20-3.70, 2.85, 1.40-2.00, 0.82 ppm.
Example 22
##STR01787##
[0396] Synthesis of
N.sub.3-PEG12K-b-Poly(Asp).sub.10-b-Poly(D-Leu.sub.13-co-L-Tyr.sub.17)-Ac
[0397]
N.sub.3-PEG12K-b-Poly(Asp).sub.10-b-Poly(D-Leu.sub.13-co-L-Tyr.sub.-
17) was synthesized as described in Example 21 from N.sub.3-PEG
12K-b-Poly(Asp(But).sub.10)-b-Poly(D-Leu.sub.13-co-L-Tyr(Bzl).sub.17)
(7.05 g) and 80 mL of a 0.5 M solution of pentamethylbenzene (PMB)
in TFA. 5.9 g (94% yield) of block copolymer was isolated as an
off-white powder. 1H NMR (d.sub.6-DMSO) .delta. 12.35, 9.10,
7.60-8.60, 6.96, 6.60, 4.50, 4.40, 4.10-4.25, 3.20-3.70, 2.85,
2.70, 0.40-1.40 ppm.
Example 23
Encapuslation of Fe.sub.3O.sub.4
[0398] A solution consisting of 4 nm Fe.sub.3O.sub.4 nanoparticles
(2.5 mg) (prepared according to Sun, S.; Zeng, H. "Size-Controlled
Synthesis of Magnetite Nanoparticles" J. Am. Chem. Soc. 2002, 124,
8204-8205.) and mPEG-PAsp-(PAsp-co-DBzGlu)-Ac (25 mg) dissolved in
CHCl.sub.3 (1 mL) was added dropwise to a vortexing flask
containing water (20 mL). The mixture was vortexed until a
homogenous solution was formed. The homogenous solution was
analyzed by dynamic light scattering (FIG. 1) then lyophilized and
the dry powder was stored at 4.degree. C. A small portion of the
powder (5 mg) was reconstituted in water (1 mL) and again analyzed
by dynamic light scattering (FIG. 2). Diameter=60+/-8.8 nm
pre-lyophilization, 65+/-9.7 nm post-lyophilization.
Example 24
Encapuslation of Fe.sub.3O.sub.4
[0399] A solution consisting of 4 nm Fe.sub.3O.sub.4 nanoparticles
(1.25 mg) in CHCl.sub.3 (1 mL) was added dropwise to a vortexing
flask containing mPEG-PAsp-(PAsp-co-DBzGlu)-Ac (25 mg) dissolved in
water (20 mL). The mixture was vortexed until a homogenous solution
was formed. The homogenous solution was lyophilized and the dry
powder was stored at 4.degree. C.
Example 25
Encapuslation of Docetaxel
[0400] A solution consisting of Docetaxel (2.5 mg) and
mPEG-PAsp-(PAsp-co-DBzGlu)-Ac (25 mg) dissolved in CHCl.sub.3 (1
mL) was added dropwise to a vortexing flask containing water (20
mL). The mixture was vortexed until a homogenous solution was
formed. The homogenous solution was lyophilized and the dry powder
was stored at 4.degree. C. A small portion of the powder (5 mg) was
reconstituted in water and again analyzed by dynamic light
scattering (FIG. 3). Diameter=39+/-7 nm post-lyophilization.
Example 26
Encapuslation of Docetaxel
[0401] A solution consisting of Docetaxel (1.25 mg) in CHCl.sub.3
was added dropwise to a vortexing flask containing
mPEG-PAsp-(PAsp-co-DBzGlu)-Ac (25 mg) dissolved in water (20 mL).
The mixture was vortexed until a homogenous solution was formed.
The homogenous solution was lyophilized and the dry powder was
stored at 4.degree. C.
Example 27
Encapuslation of Fe.sub.3O.sub.4
[0402] A solution consisting of 4 nm Fe.sub.3O.sub.4 nanoparticles
(1.25 mg) in CHCl.sub.3 was added dropwise to a vortexing flask
containing mPEG-PAsp-(PAsp-co-DBzGlu)-Ac (25 mg) dissolved in
10.sup.-4 ZnCl.sub.2 aqueous solution (20 mL). The mixture was
vortexed until a homogenous solution was formed. The homogenous
solution was lyophilized and the dry powder was stored at 4.degree.
C.
Example 28
Encapuslation of Letrozole
[0403] A solution consisting of Letrozole (1.25 mg) in CHCl.sub.3
was added dropwise to a vortexing flask containing
mPEG-PAsp-(PAsp-co-DBzGlu)-Ac (25 mg) dissolved in water (20 mL).
The mixture was vortexed until a homogenous solution was formed.
The homogenous solution was lyophilized and the dry powder was
stored at 4.degree. C. A small portion of the powder (5 mg) was
reconstituted in water and again analyzed by dynamic light
scattering (FIG. 4). Diameter=63.1+/-9.2 nm
post-lyophilization.
Example 29
Cell Culture
[0404] MCF-7, BT474, LNCaP, amd MG-63 cells were maintained in RPMI
1640 supplemented with 10% FBS, 2 mM L-glutamine, 100 IU
penilcillin/mL and 100 .mu.g/mL streptomycin/mL. MDA-MB-231 and
Saos2 cells were maintained in DMEM with 10% FBS, 2 mM L-glutamine
100 IU penilcillin/mL and 100 .mu.g/mL streptomycin/mL. MCF10A
cells were maintained in a 50:50 mix of DMEM and Ham's F12
supplemented with 5% FBS, 2 mM L-glutamine, 10 ng/mL EGF, 500 ng/mL
hydrocortisone, 0.01 mg/mL insulin, 100 IU penilcillin/mL and 100
.mu.g/mL streptomycin/mL. Cells were maintained at 37 degrees
Celsius with 5% CO2 and were subcultured weekly.
[0405] Polymer cytotoxicity Assay--
[0406] 1.2.times.10.sup.4 MDA-MB-231 cells were plated in 96-well
plates. Twenty-four hours later, media was replaced with micelle
diluted in growth media at a final concentration of 0, 100, 250,
500, 750, 1000, 2500 or 5000 .mu.g/mL
mPEG-PAsp-(PAsp-co-DBzGlu)-Ac. After 72 hours, cell viability was
determined using the Cell-Titer Glo reagent according to the
manufacturer's protocol (Promega, Madison, Wis.). Data were
collected using a plate reader with luminescence detection (BMG
Labtech, Durham, N.C.). Experiments were performed in triplicate
and shown in FIG. 5.
Example 30
CMC Determination
[0407] The CMC of micelles prepared from block copolymers were
determined using the method described by Eisnberg. (Astafieva, I.;
Zhong, X. F.; Eisenberg, A. "Critical Micellization Phenomena in
Block Copolymer Polyelectrolyte Solutions" Macromolecules 1993, 26,
7339-7352.) To perform these experiments, a constant concentration
of pyrene (5.times.10.sup.-7 M) was equilibrated with varying
concentrations of block copolymer (ca.
2.times.10.sup.2-1.times.10.sup.-4 mg/mL) in phosphate buffered
saline at room temperature for 16 hours. Excitation spectra
(recorded on a Perkin Elmer LS-55 spectrophotometer with excitation
between 328 and 342 nm, emission at 390 nm, 2.5 nm slit width, 15
nm/min scan speed) were recorded for each polymer concentration and
the fluorescence intensities recorded at 333 and 338 nm. Eisenberg
has shown that the vibrational fine structure of pyrene is highly
sensitive to the polarity of its environment. Specifically, the
(0,0) excitation band of pyrene will shift from 333 nm in an
aqueous environment to 338.5 nm in a hydrophobic environment. The
ratio of peak intensities (I.sub.338/I.sub.333) reveals the
hydrophobicity of the environment surrounding the pyrene. Values of
.about.2.0 correspond to a hydrophobic environment such as
polystyrene or poly(benzyl glutamate), whereas values of
.about.0.35 correspond to an aqueous environment. Plotting this
ratio vs. log of the block copolymer concentration allows for the
graphical interpretation of the CMC value. A more quantitative
number can be obtained by fitting a logarithmic (y=a ln(x)+b)
regression to the data points between the two plateaus (at .about.2
and .about.0.35). The CMC can be found by setting y=0.35 and
solving for x (concentration in mg/mL). FIG. 6 and FIG. 7 show
exemplary CMC curves for polymers found in Example 17, Example 18,
Example 21, and Example 22. [0408] CMC of
N.sub.3-PEG12K-b-Poly(Asp).sub.10-b-Poly(L-Leu.sub.13-co-L-Tyr.sub.17)-Ac
(Example 21)=0.0061 mg/mL=3.4.times.10.sup.-7M [0409] CMC of
N.sub.3-PEG12K-b-Poly(Asp).sub.10-b-Poly(D-Leu.sub.13-co-L-Tyr.sub.17)-Ac
(Example 22)=0.0207 mg/mL=1.2.times.10.sup.-6M [0410] CMC of
N.sub.3-PEG12K-b-P(L-Glu(Bzl).sub.30)-Ac (Example 17)=0.0054
mg/mL=2.8.times.10.sup.-7 M [0411] CMC of N.sub.3-PEG 1
2K-b-Poly(L-Glu(Bzl).sub.15-co-D-Glu(Bzl).sub.15)-Ac (Example
18)=0.0068 mg/mL=3.6.times.10.sup.-7M
[0412] In addition to CMC data, information regarding the overall
hydrophobicity of the core can be obtained from these pyrene
fluorescence experiments. A higher I.sub.338/I.sub.333 ratio
corresponds to a more hydrophobic micelle core. This data is
represented in Table 12.
Example 31
Core Mobility Determination
[0413] The mobility and rigidity of the micelle core was determined
using the methods described by Yamamoto (J. Cont. Rel., 2007, 123,
11-18). 1,3-bis(1-pyrenyl)propane (dipyrene) is a fluorescent probe
that forms an intramolecular excimer complex when the atmosphere
surrounding the molecule is sufficiently mobile. The ratio between
the excimer complex emission at 480 nm and the pyrene monomer
emission at 398 nm gives information regarding the mobility, where
a very low ratio (0.0-0.2) represents a rigid, low mobility core
and a higher ratio value (0.4-0.7) represents a flexible, mobile
core. Block copolymers were dissolved in phosphate buffered saline
at 5 mg/mL and equilibrated with 5.5.times.10.sup.-6 M dipyrene for
16 hours. The fluorescence emission spectra (recorded on a Perkin
Elmer LS-55 spectrophotometer with emission between 360 and 500 nm,
excitation at 333 nm, 5 nm slit width, 120 nm/min scan speed) were
recorded for each sample and the peak intensities at 398 and 480 nm
were recorded. The mobility can be inferred from the
I.sub.480/I.sub.398 ratio as described above, and is recorded in
Table 12.
Example 32
[0414] Diameters of polymer micelles were determined by dynamic
light scattering. Lyopholyzed polymers were dissolved at 5 mg/mL in
phosphate buffered saline at pH 7.4 and equilibrated overnight.
Each sample was analyzed in a PSS NICOMP 380 with a 690 nm laser at
a 90 degree angle. DLS sizing data was recorded from the volume
weighted Gaussian distribution. Results are summarized in Table
12.
TABLE-US-00013 TABLE 12 Hydrophobicity Micelle CMC Value Mobility
Diameter Polymer (ug/mL) (I338/I333) (I480/I398) (nm) Example 17 -
isotactic 5.4 2.02 0.23 87.3 Example 18 - atactic 6.8 2.08 0.61
42.7 Example 21 - isotactic 6.1 1.83 0.33 40.1 Example 22 - atactic
20.7 1.82 0.51 19.2
[0415] The results summarized in Table 12 show a marked difference
in the physical properties of the micelles formed by isotactic
polymers of all L stereochemistry vs. atactic polymers of mixed
stereochemistry. As expected, the overall hydrophobicity of the
core is similar for both stereoisomers since the chemical
composition remains unchanged. However, there are significant
differences in the CMC values for the triblock copolymers, as well
as differences in both the mobility and in the micelle diameter for
both sets of polymers. It is believed that the random
stereochemistry leads to a random coil conformation, allowing for
greater degrees of freedom, thus increasing the mobility of the
core.
Example 33
[0416] Solution .sup.1H NMR analysis of these polymers was
performed on a Varian VNMRS 400 MHz NMR. Samples were prepared at
40 mg/mL in DMSO-d.sub.6. Example spectra are shown in FIGS. 8-11.
A difference in polymer solution conformation can be observed
between the isotactic and atactic polymers, as the all L configured
isotactic polymers have broad peak shapes, while the atactic
polymers have well defined resonances, again indicating a random
coil conformation in the atactic polymer.
Example 34
Circular Dichroism (CD) Spectroscopy
[0417] Block copolymers were dissolved in phosphate buffered saline
at 0.1 mg/mL. CD/UV spectra were recorded on a AVIV 215
spectrophotometer. .DELTA.A (millidegrees) was recorded in a 1 cm
cuvette at 25.degree. C. from 200-250 nm, and the data was averaged
over three scans, then subtracted from the average of three blank
samples. AA was converted to molar elipticity using the AVIV
software and the number of amino acid residues per polymer chain.
Data is plotted in FIG. 13 and FIG. 14. It was found that the
isotactic polymers found in Example 17 and Example 21 exhibited CD
spectra consistent with a helical secondary structure, while the
actactic, mixed stereochemistry polymers of Example 18 and Example
22 exhibited little to no CD response, consistent with disruption
of any secondary structure.
Example 35
Drug Loading Efficiency
[0418] The drug loading efficiency of Example 17, Example 18,
Example 21, and Example 22 were evaluated for docetaxel,
irinotecan, and SN-38. Target loadings of 10 wt % were attempted
for docetaxel, 15 wt % for irinotecan, and 2 wt % for SN-38. The
drugs were encapsulated with the following general procedure:
[0419] A solution consisting of the desired active (e.g. 10 mg
docetaxel, 15 mg irinotecan, or 2 mg SN-38) and the desired polymer
(ca. 100 mg) in CHCl.sub.3 was added drop-wise to a vortexing flask
containing water (20 mL). The mixture was vortexed until a
homogenous solution was formed, or until the organic phase had
completely evaporated. This solution was filtered through a 0.22
.mu.m filter, then lyophilized and the dry powder stored at
4.degree. C. Actual drug loading was determined by HPLC with the
following methods:
[0420] Docetaxel loading was determined by weighing ca. 10-20 mg of
drug loaded micelle into a 10 mL volumetric flask and filling to
volume with 0.5% acetic acid in methanol. 10 .mu.L of this solution
was injected onto a Waters 2695 HPLC with a 996 photodiode array
detector and ES Industries Chromegabond Alkyl-Phenyl column (300
mm) eluting with 35% acetonitrile in water at 1 mL/min. Docetaxel
eluted at 20.5 minutes under these conditions. Quantitation was
performed from a calibration curve constructed from known
concentrations of docetaxel standard injections from chromatograms
extracted at 227 nm. Area under the curve (AUC) can be converted to
concentration with the following equation:
g 10 L = AUC 1100928 = mg 10 mL ##EQU00001##
[0421] Irinotecan loading was determined by weighing ca. 10-20 mg
of drug loaded micelle into a 10 mL volumetric flask and filling to
volume with 5 mL of 100 mM sodium acetate buffer at pH 3.1 and 5 mL
acetonitrile. 10 L of this solution was injected onto a Waters 2695
HPLC with a 996 photodiode array detector and ES Industries
Chromegabond Alkyl-Phenyl column (300 mm) eluting with 40% 100 mM
sodium acetate buffer (pH .about.3.1) and 60% acetonitrile at 1
mL/min. Irinotecan eluted at 6.5 minutes under these conditions.
Quantitation was performed from a calibration curve constructed
from known concentrations of irinotecan standard injections from
chromatograms extracted at 227 nm. Area under the curve (AUC) can
be converted to concentration with the following equation:
g 10 L = AUC 3110806 = mg 10 mL ##EQU00002##
[0422] SN-38 loading was determined by weighing ca. 10-20 mg of
drug loaded micelle into a 10 mL volumetric flask and filling to
volume with 2 mL of DMSO and 8 mL of acetonitrile. 10 .mu.L of this
solution was injected onto a Waters 2695 HPLC with a 996 photodiode
array detector and ES Industries Chromegabond Alkyl-Phenyl column
(300 mm) eluting with 50% 25 mM monobasic sodium phosphate buffer
(pH .about.3.1) and 50% acetonitrile at 1 mL/min. SN-38 eluted at
4.0 minutes under these conditions. Quantitation was performed from
a calibration curve constructed from known concentrations of SN-38
standard injections from chromatograms extracted at 265 nm. Area
under the curve (AUC) can be converted to concentration with the
following equation:
g 10 L = AUC 3936855 = mg 10 mL ##EQU00003##
[0423] Drug loadings and drug loading efficiencies are reported in
Table 13.
TABLE-US-00014 TABLE 13 Polymer Feed % Final % % Efficiency
Docetaxel Example 17 - isotactic 9.2 8.4 91.8 Example 18 - atactic
9.2 8.5 92.2 Example 21 - isotactic 8.8 7.9 89.5 Example 22 -
atactic 8.9 8.3 94.0 Irinotecan Example 17 - isotactic 13.1 1.6
12.2 Example 18 - atactic 13.5 13.2 97.8 Example 21 - isotactic
13.1 8.0 61.1 Example 22 - atactic 12.9 12.6 97.7 SN-38 Example 17
- isotactic 2.3 0.02 0.7 Example 18 - atactic 2.1 0.02 0.8 Example
21 - isotactic 2.5 0.03 1.2 Example 22 - atactic 2.0 0.03 1.2
[0424] While we have described a number of embodiments of this
invention, it is apparent that our basic examples may be altered to
provide other embodiments that utilize the compounds and methods of
this invention. Therefore, it will be appreciated that the scope of
this invention is to be defined by the appended claims rather than
by the specific embodiments that have been represented by way of
example.
* * * * *